id	sid	tid	token	lemma	pos
cord-286132-ag2l1xa7	1	1	key	key	NNP
cord-286132-ag2l1xa7	1	2	:	:	:
cord-286132-ag2l1xa7	1	3	cord-286132-ag2l1xa7	cord-286132-ag2l1xa7	NNS
cord-286132-ag2l1xa7	1	4	authors	author	NNS
cord-286132-ag2l1xa7	1	5	:	:	:
cord-286132-ag2l1xa7	1	6	Akiyama	Akiyama	NNP
cord-286132-ag2l1xa7	1	7	,	,	,
cord-286132-ag2l1xa7	1	8	Shintaro	Shintaro	NNP
cord-286132-ag2l1xa7	1	9	;	;	:
cord-286132-ag2l1xa7	1	10	Yamada	Yamada	NNP
cord-286132-ag2l1xa7	1	11	,	,	,
cord-286132-ag2l1xa7	1	12	Akihiro	Akihiro	NNP
cord-286132-ag2l1xa7	1	13	;	;	:
cord-286132-ag2l1xa7	1	14	Micic	Micic	NNP
cord-286132-ag2l1xa7	1	15	,	,	,
cord-286132-ag2l1xa7	1	16	Dejan	Dejan	NNP
cord-286132-ag2l1xa7	1	17	;	;	:
cord-286132-ag2l1xa7	1	18	Sakuraba	Sakuraba	NNP
cord-286132-ag2l1xa7	1	19	,	,	,
cord-286132-ag2l1xa7	2	1	Atsushi	Atsushi	NNP
cord-286132-ag2l1xa7	2	2	title	title	NN
cord-286132-ag2l1xa7	2	3	:	:	:
cord-286132-ag2l1xa7	3	1	The	the	DT
cord-286132-ag2l1xa7	3	2	risk	risk	NN
cord-286132-ag2l1xa7	3	3	of	of	IN
cord-286132-ag2l1xa7	3	4	respiratory	respiratory	JJ
cord-286132-ag2l1xa7	3	5	tract	tract	NN
cord-286132-ag2l1xa7	3	6	infections	infection	NNS
cord-286132-ag2l1xa7	3	7	and	and	CC
cord-286132-ag2l1xa7	3	8	interstitial	interstitial	JJ
cord-286132-ag2l1xa7	3	9	lung	lung	NN
cord-286132-ag2l1xa7	3	10	disease	disease	NN
cord-286132-ag2l1xa7	3	11	with	with	IN
cord-286132-ag2l1xa7	3	12	IL-12/23	IL-12/23	NNP
cord-286132-ag2l1xa7	3	13	and	and	CC
cord-286132-ag2l1xa7	3	14	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	3	15	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	3	16	in	in	IN
cord-286132-ag2l1xa7	3	17	patients	patient	NNS
cord-286132-ag2l1xa7	3	18	with	with	IN
cord-286132-ag2l1xa7	3	19	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	3	20	diseases	disease	NNS
cord-286132-ag2l1xa7	3	21	:	:	:
cord-286132-ag2l1xa7	3	22	a	a	DT
cord-286132-ag2l1xa7	3	23	systematic	systematic	JJ
cord-286132-ag2l1xa7	3	24	review	review	NN
cord-286132-ag2l1xa7	3	25	and	and	CC
cord-286132-ag2l1xa7	3	26	meta	meta	NN
cord-286132-ag2l1xa7	3	27	-	-	HYPH
cord-286132-ag2l1xa7	3	28	analysis	analysis	NN
cord-286132-ag2l1xa7	3	29	date	date	NN
cord-286132-ag2l1xa7	3	30	:	:	:
cord-286132-ag2l1xa7	3	31	2020	2020	CD
cord-286132-ag2l1xa7	3	32	-	-	HYPH
cord-286132-ag2l1xa7	3	33	08	08	CD
cord-286132-ag2l1xa7	3	34	-	-	HYPH
cord-286132-ag2l1xa7	3	35	11	11	CD
cord-286132-ag2l1xa7	3	36	journal	journal	NN
cord-286132-ag2l1xa7	3	37	:	:	:
cord-286132-ag2l1xa7	3	38	J	J	NNP
cord-286132-ag2l1xa7	3	39	Am	Am	NNP
cord-286132-ag2l1xa7	3	40	Acad	Acad	NNP
cord-286132-ag2l1xa7	3	41	Dermatol	Dermatol	NNP
cord-286132-ag2l1xa7	4	1	DOI	DOI	NNP
cord-286132-ag2l1xa7	4	2	:	:	:
cord-286132-ag2l1xa7	5	1	10.1016	10.1016	CD
cord-286132-ag2l1xa7	5	2	/	/	SYM
cord-286132-ag2l1xa7	5	3	j.jaad.2020.08.026	j.jaad.2020.08.026	NNP
cord-286132-ag2l1xa7	5	4	sha	sha	NNP
cord-286132-ag2l1xa7	5	5	:	:	:
cord-286132-ag2l1xa7	6	1	83897f590cb4747442ca2dbc4274f37425dbd352	83897f590cb4747442ca2dbc4274f37425dbd352	NFP
cord-286132-ag2l1xa7	6	2	doc_id	doc_id	CD
cord-286132-ag2l1xa7	6	3	:	:	:
cord-286132-ag2l1xa7	6	4	286132	286132	CD
cord-286132-ag2l1xa7	6	5	cord_uid	cord_uid	NNS
cord-286132-ag2l1xa7	6	6	:	:	:
cord-286132-ag2l1xa7	7	1	ag2l1xa7	ag2l1xa7	UH
cord-286132-ag2l1xa7	7	2	Abstract	Abstract	NNP
cord-286132-ag2l1xa7	7	3	Background	Background	NNP
cord-286132-ag2l1xa7	7	4	Respiratory	respiratory	JJ
cord-286132-ag2l1xa7	7	5	tract	tract	NN
cord-286132-ag2l1xa7	7	6	infections	infection	NNS
cord-286132-ag2l1xa7	7	7	(	(	-LRB-
cord-286132-ag2l1xa7	7	8	RTIs	rti	NNS
cord-286132-ag2l1xa7	7	9	)	)	-RRB-
cord-286132-ag2l1xa7	7	10	and	and	CC
cord-286132-ag2l1xa7	7	11	interstitial	interstitial	JJ
cord-286132-ag2l1xa7	7	12	lung	lung	NN
cord-286132-ag2l1xa7	7	13	disease	disease	NN
cord-286132-ag2l1xa7	7	14	(	(	-LRB-
cord-286132-ag2l1xa7	7	15	ILD	ILD	NNP
cord-286132-ag2l1xa7	7	16	)	)	-RRB-
cord-286132-ag2l1xa7	7	17	secondary	secondary	JJ
cord-286132-ag2l1xa7	7	18	to	to	IN
cord-286132-ag2l1xa7	7	19	interleukin	interleukin	NN
cord-286132-ag2l1xa7	7	20	(	(	-LRB-
cord-286132-ag2l1xa7	7	21	IL)-12/23	IL)-12/23	NNP
cord-286132-ag2l1xa7	7	22	or	or	CC
cord-286132-ag2l1xa7	7	23	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	7	24	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	7	25	have	have	VBP
cord-286132-ag2l1xa7	7	26	been	be	VBN
cord-286132-ag2l1xa7	7	27	reported	report	VBN
cord-286132-ag2l1xa7	7	28	in	in	IN
cord-286132-ag2l1xa7	7	29	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	7	30	diseases	disease	NNS
cord-286132-ag2l1xa7	7	31	.	.	.
cord-286132-ag2l1xa7	8	1	Objective	objective	JJ
cord-286132-ag2l1xa7	9	1	To	to	TO
cord-286132-ag2l1xa7	9	2	assess	assess	VB
cord-286132-ag2l1xa7	9	3	the	the	DT
cord-286132-ag2l1xa7	9	4	risk	risk	NN
cord-286132-ag2l1xa7	9	5	of	of	IN
cord-286132-ag2l1xa7	9	6	RTIs	rti	NNS
cord-286132-ag2l1xa7	9	7	and	and	CC
cord-286132-ag2l1xa7	9	8	non	non	JJ
cord-286132-ag2l1xa7	9	9	-	-	JJ
cord-286132-ag2l1xa7	9	10	infectious	infectious	JJ
cord-286132-ag2l1xa7	9	11	ILD	ild	NN
cord-286132-ag2l1xa7	9	12	with	with	IN
cord-286132-ag2l1xa7	9	13	these	these	DT
cord-286132-ag2l1xa7	9	14	drugs	drug	NNS
cord-286132-ag2l1xa7	9	15	.	.	.
cord-286132-ag2l1xa7	10	1	Methods	method	NNS
cord-286132-ag2l1xa7	11	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	11	2	conducted	conduct	VBD
cord-286132-ag2l1xa7	11	3	a	a	DT
cord-286132-ag2l1xa7	11	4	systematic	systematic	JJ
cord-286132-ag2l1xa7	11	5	review	review	NN
cord-286132-ag2l1xa7	11	6	and	and	CC
cord-286132-ag2l1xa7	11	7	meta	meta	NNP
cord-286132-ag2l1xa7	11	8	-	-	HYPH
cord-286132-ag2l1xa7	11	9	analysis	analysis	NN
cord-286132-ag2l1xa7	11	10	of	of	IN
cord-286132-ag2l1xa7	11	11	randomized	randomized	JJ
cord-286132-ag2l1xa7	11	12	controlled	control	VBN
cord-286132-ag2l1xa7	11	13	trials	trial	NNS
cord-286132-ag2l1xa7	11	14	(	(	-LRB-
cord-286132-ag2l1xa7	11	15	RCTs	RCTs	NNP
cord-286132-ag2l1xa7	11	16	)	)	-RRB-
cord-286132-ag2l1xa7	11	17	.	.	.
cord-286132-ag2l1xa7	12	1	Risk	risk	NN
cord-286132-ag2l1xa7	12	2	of	of	IN
cord-286132-ag2l1xa7	12	3	RTIs	rti	NNS
cord-286132-ag2l1xa7	12	4	and	and	CC
cord-286132-ag2l1xa7	12	5	non	non	JJ
cord-286132-ag2l1xa7	12	6	-	-	JJ
cord-286132-ag2l1xa7	12	7	infectious	infectious	JJ
cord-286132-ag2l1xa7	12	8	ILD	ILD	NNP
cord-286132-ag2l1xa7	12	9	was	be	VBD
cord-286132-ag2l1xa7	12	10	compared	compare	VBN
cord-286132-ag2l1xa7	12	11	to	to	IN
cord-286132-ag2l1xa7	12	12	placebo	placebo	NN
cord-286132-ag2l1xa7	12	13	by	by	IN
cord-286132-ag2l1xa7	12	14	Mantel	Mantel	NNP
cord-286132-ag2l1xa7	12	15	-	-	HYPH
cord-286132-ag2l1xa7	12	16	Haenszel	Haenszel	NNP
cord-286132-ag2l1xa7	12	17	(	(	-LRB-
cord-286132-ag2l1xa7	12	18	MH	MH	NNP
cord-286132-ag2l1xa7	12	19	)	)	-RRB-
cord-286132-ag2l1xa7	12	20	risk	risk	NN
cord-286132-ag2l1xa7	12	21	difference	difference	NN
cord-286132-ag2l1xa7	12	22	(	(	-LRB-
cord-286132-ag2l1xa7	12	23	RD	RD	NNP
cord-286132-ag2l1xa7	12	24	)	)	-RRB-
cord-286132-ag2l1xa7	12	25	.	.	.
cord-286132-ag2l1xa7	13	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	13	2	divided	divide	VBD
cord-286132-ag2l1xa7	13	3	RTIs	rti	NNS
cord-286132-ag2l1xa7	13	4	into	into	IN
cord-286132-ag2l1xa7	13	5	upper	upper	JJ
cord-286132-ag2l1xa7	13	6	RTIs	rti	NNS
cord-286132-ag2l1xa7	13	7	(	(	-LRB-
cord-286132-ag2l1xa7	13	8	URTI	URTI	NNP
cord-286132-ag2l1xa7	13	9	)	)	-RRB-
cord-286132-ag2l1xa7	13	10	,	,	,
cord-286132-ag2l1xa7	13	11	viral	viral	JJ
cord-286132-ag2l1xa7	13	12	URTIs	urti	NNS
cord-286132-ag2l1xa7	13	13	,	,	,
cord-286132-ag2l1xa7	13	14	and	and	CC
cord-286132-ag2l1xa7	13	15	lower	low	JJR
cord-286132-ag2l1xa7	13	16	RTIs	rti	NNS
cord-286132-ag2l1xa7	13	17	(	(	-LRB-
cord-286132-ag2l1xa7	13	18	LRTIs	LRTIs	NNP
cord-286132-ag2l1xa7	13	19	)	)	-RRB-
cord-286132-ag2l1xa7	13	20	including	include	VBG
cord-286132-ag2l1xa7	13	21	infectious	infectious	JJ
cord-286132-ag2l1xa7	13	22	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	13	23	.	.	.
cord-286132-ag2l1xa7	14	1	Non	non	JJ
cord-286132-ag2l1xa7	14	2	-	-	JJ
cord-286132-ag2l1xa7	14	3	infectious	infectious	JJ
cord-286132-ag2l1xa7	14	4	ILD	ILD	NNP
cord-286132-ag2l1xa7	14	5	included	include	VBD
cord-286132-ag2l1xa7	14	6	ILD	ILD	NNP
cord-286132-ag2l1xa7	14	7	,	,	,
cord-286132-ag2l1xa7	14	8	eosinophilic	eosinophilic	JJ
cord-286132-ag2l1xa7	14	9	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	14	10	,	,	,
cord-286132-ag2l1xa7	14	11	and	and	CC
cord-286132-ag2l1xa7	14	12	pneumonitis	pneumonitis	NN
cord-286132-ag2l1xa7	14	13	.	.	.
cord-286132-ag2l1xa7	15	1	Results	result	NNS
cord-286132-ag2l1xa7	16	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	16	2	identified	identify	VBD
cord-286132-ag2l1xa7	16	3	54	54	CD
cord-286132-ag2l1xa7	16	4	RCTs	rct	NNS
cord-286132-ag2l1xa7	16	5	including	include	VBG
cord-286132-ag2l1xa7	16	6	10,907	10,907	CD
cord-286132-ag2l1xa7	16	7	patients	patient	NNS
cord-286132-ag2l1xa7	16	8	with	with	IN
cord-286132-ag2l1xa7	16	9	six	six	CD
cord-286132-ag2l1xa7	16	10	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	16	11	or	or	CC
cord-286132-ag2l1xa7	16	12	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	16	13	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	16	14	and	and	CC
cord-286132-ag2l1xa7	16	15	5,175	5,175	CD
cord-286132-ag2l1xa7	16	16	patients	patient	NNS
cord-286132-ag2l1xa7	16	17	with	with	IN
cord-286132-ag2l1xa7	16	18	placebo	placebo	NN
cord-286132-ag2l1xa7	16	19	.	.	.
cord-286132-ag2l1xa7	17	1	These	these	DT
cord-286132-ag2l1xa7	17	2	drugs	drug	NNS
cord-286132-ag2l1xa7	17	3	significantly	significantly	RB
cord-286132-ag2l1xa7	17	4	increased	increase	VBD
cord-286132-ag2l1xa7	17	5	the	the	DT
cord-286132-ag2l1xa7	17	6	risk	risk	NN
cord-286132-ag2l1xa7	17	7	of	of	IN
cord-286132-ag2l1xa7	17	8	RTIs	rti	NNS
cord-286132-ag2l1xa7	17	9	(	(	-LRB-
cord-286132-ag2l1xa7	17	10	MH	MH	NNP
cord-286132-ag2l1xa7	17	11	RD	RD	NNP
cord-286132-ag2l1xa7	17	12	0.019	0.019	CD
cord-286132-ag2l1xa7	17	13	,	,	,
cord-286132-ag2l1xa7	17	14	95	95	CD
cord-286132-ag2l1xa7	17	15	%	%	NN
cord-286132-ag2l1xa7	17	16	confidence	confidence	NN
cord-286132-ag2l1xa7	17	17	interval	interval	NN
cord-286132-ag2l1xa7	17	18	0.005	0.005	CD
cord-286132-ag2l1xa7	17	19	-	-	HYPH
cord-286132-ag2l1xa7	17	20	0.033	0.033	CD
cord-286132-ag2l1xa7	17	21	,	,	,
cord-286132-ag2l1xa7	17	22	P	p	NN
cord-286132-ag2l1xa7	17	23	=	=	SYM
cord-286132-ag2l1xa7	17	24	0.007	0.007	CD
cord-286132-ag2l1xa7	17	25	)	)	-RRB-
cord-286132-ag2l1xa7	17	26	which	which	WDT
cord-286132-ag2l1xa7	17	27	was	be	VBD
cord-286132-ag2l1xa7	17	28	attributed	attribute	VBN
cord-286132-ag2l1xa7	17	29	to	to	IN
cord-286132-ag2l1xa7	17	30	URTIs	urti	NNS
cord-286132-ag2l1xa7	17	31	,	,	,
cord-286132-ag2l1xa7	17	32	but	but	CC
cord-286132-ag2l1xa7	17	33	not	not	RB
cord-286132-ag2l1xa7	17	34	viral	viral	JJ
cord-286132-ag2l1xa7	17	35	URTIs	urti	NNS
cord-286132-ag2l1xa7	17	36	or	or	CC
cord-286132-ag2l1xa7	17	37	LRTIs	lrti	NNS
cord-286132-ag2l1xa7	17	38	.	.	.
cord-286132-ag2l1xa7	18	1	There	there	EX
cord-286132-ag2l1xa7	18	2	was	be	VBD
cord-286132-ag2l1xa7	18	3	no	no	DT
cord-286132-ag2l1xa7	18	4	significant	significant	JJ
cord-286132-ag2l1xa7	18	5	difference	difference	NN
cord-286132-ag2l1xa7	18	6	in	in	IN
cord-286132-ag2l1xa7	18	7	infectious	infectious	JJ
cord-286132-ag2l1xa7	18	8	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	18	9	and	and	CC
cord-286132-ag2l1xa7	18	10	non	non	JJ
cord-286132-ag2l1xa7	18	11	-	-	JJ
cord-286132-ag2l1xa7	18	12	infectious	infectious	JJ
cord-286132-ag2l1xa7	18	13	ILD	ild	NN
cord-286132-ag2l1xa7	18	14	between	between	IN
cord-286132-ag2l1xa7	18	15	two	two	CD
cord-286132-ag2l1xa7	18	16	groups	group	NNS
cord-286132-ag2l1xa7	18	17	.	.	.
cord-286132-ag2l1xa7	19	1	Limitations	limitation	NNS
cord-286132-ag2l1xa7	20	1	Due	due	IN
cord-286132-ag2l1xa7	20	2	to	to	IN
cord-286132-ag2l1xa7	20	3	the	the	DT
cord-286132-ag2l1xa7	20	4	rarity	rarity	NN
cord-286132-ag2l1xa7	20	5	of	of	IN
cord-286132-ag2l1xa7	20	6	infectious	infectious	JJ
cord-286132-ag2l1xa7	20	7	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	20	8	and	and	CC
cord-286132-ag2l1xa7	20	9	ILD	ILD	NNP
cord-286132-ag2l1xa7	20	10	,	,	,
cord-286132-ag2l1xa7	20	11	sensitivity	sensitivity	NN
cord-286132-ag2l1xa7	20	12	analysis	analysis	NN
cord-286132-ag2l1xa7	20	13	was	be	VBD
cord-286132-ag2l1xa7	20	14	required	require	VBN
cord-286132-ag2l1xa7	20	15	.	.	.
cord-286132-ag2l1xa7	21	1	Conclusion	conclusion	NN
cord-286132-ag2l1xa7	22	1	The	the	DT
cord-286132-ag2l1xa7	22	2	use	use	NN
cord-286132-ag2l1xa7	22	3	of	of	IN
cord-286132-ag2l1xa7	22	4	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	22	5	or	or	CC
cord-286132-ag2l1xa7	22	6	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	22	7	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	22	8	for	for	IN
cord-286132-ag2l1xa7	22	9	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	22	10	diseases	disease	NNS
cord-286132-ag2l1xa7	22	11	increased	increase	VBD
cord-286132-ag2l1xa7	22	12	the	the	DT
cord-286132-ag2l1xa7	22	13	risk	risk	NN
cord-286132-ag2l1xa7	22	14	of	of	IN
cord-286132-ag2l1xa7	22	15	URTIs	urti	NNS
cord-286132-ag2l1xa7	22	16	,	,	,
cord-286132-ag2l1xa7	22	17	but	but	CC
cord-286132-ag2l1xa7	22	18	not	not	RB
cord-286132-ag2l1xa7	22	19	viral	viral	JJ
cord-286132-ag2l1xa7	22	20	URTIs	urti	NNS
cord-286132-ag2l1xa7	22	21	,	,	,
cord-286132-ag2l1xa7	22	22	LRTIs	lrti	NNS
cord-286132-ag2l1xa7	22	23	,	,	,
cord-286132-ag2l1xa7	22	24	and	and	CC
cord-286132-ag2l1xa7	22	25	non	non	JJ
cord-286132-ag2l1xa7	22	26	-	-	JJ
cord-286132-ag2l1xa7	22	27	infectious	infectious	JJ
cord-286132-ag2l1xa7	22	28	ILD	ILD	NNP
cord-286132-ag2l1xa7	22	29	.	.	.
cord-286132-ag2l1xa7	23	1	The	the	DT
cord-286132-ag2l1xa7	23	2	clinical	clinical	JJ
cord-286132-ag2l1xa7	23	3	benefit	benefit	NN
cord-286132-ag2l1xa7	23	4	of	of	IN
cord-286132-ag2l1xa7	23	5	interleukin	interleukin	NN
cord-286132-ag2l1xa7	23	6	(	(	-LRB-
cord-286132-ag2l1xa7	23	7	IL)-12	il)-12	NN
cord-286132-ag2l1xa7	23	8	and	and	CC
cord-286132-ag2l1xa7	23	9	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	23	10	inhibition	inhibition	NN
cord-286132-ag2l1xa7	23	11	has	have	VBZ
cord-286132-ag2l1xa7	23	12	been	be	VBN
cord-286132-ag2l1xa7	23	13	demonstrated	demonstrate	VBN
cord-286132-ag2l1xa7	23	14	in	in	IN
cord-286132-ag2l1xa7	23	15	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	23	16	2	2	CD
cord-286132-ag2l1xa7	23	17	and	and	CC
cord-286132-ag2l1xa7	23	18	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	23	19	's	's	POS
cord-286132-ag2l1xa7	23	20	disease	disease	NN
cord-286132-ag2l1xa7	23	21	(	(	-LRB-
cord-286132-ag2l1xa7	23	22	CD	CD	NNP
cord-286132-ag2l1xa7	23	23	)	)	-RRB-
cord-286132-ag2l1xa7	23	24	by	by	IN
cord-286132-ag2l1xa7	23	25	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	23	26	1	1	CD
cord-286132-ag2l1xa7	23	27	,	,	,
cord-286132-ag2l1xa7	23	28	2	2	CD
cord-286132-ag2l1xa7	23	29	or	or	CC
cord-286132-ag2l1xa7	23	30	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	23	31	.	.	.
cord-286132-ag2l1xa7	24	1	3	3	CD
cord-286132-ag2l1xa7	24	2	,	,	,
cord-286132-ag2l1xa7	24	3	4	4	CD
cord-286132-ag2l1xa7	25	1	Furthermore	furthermore	RB
cord-286132-ag2l1xa7	25	2	,	,	,
cord-286132-ag2l1xa7	25	3	IL-23-specific	IL-23-specific	NNP
cord-286132-ag2l1xa7	25	4	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	25	5	,	,	,
cord-286132-ag2l1xa7	25	6	such	such	JJ
cord-286132-ag2l1xa7	25	7	3	3	CD
cord-286132-ag2l1xa7	25	8	as	as	IN
cord-286132-ag2l1xa7	25	9	tildrakizumab	tildrakizumab	NNP
cord-286132-ag2l1xa7	25	10	,	,	,
cord-286132-ag2l1xa7	25	11	5	5	CD
cord-286132-ag2l1xa7	25	12	,	,	,
cord-286132-ag2l1xa7	25	13	6	6	CD
cord-286132-ag2l1xa7	25	14	risankizumab	risankizumab	NNS
cord-286132-ag2l1xa7	25	15	,	,	,
cord-286132-ag2l1xa7	25	16	7	7	CD
cord-286132-ag2l1xa7	25	17	,	,	,
cord-286132-ag2l1xa7	25	18	8	8	CD
cord-286132-ag2l1xa7	25	19	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	25	20	,	,	,
cord-286132-ag2l1xa7	25	21	9	9	CD
cord-286132-ag2l1xa7	25	22	,	,	,
cord-286132-ag2l1xa7	25	23	10	10	CD
cord-286132-ag2l1xa7	25	24	and	and	CC
cord-286132-ag2l1xa7	25	25	brazikumab	brazikumab	NNP
cord-286132-ag2l1xa7	25	26	,	,	,
cord-286132-ag2l1xa7	25	27	11	11	CD
cord-286132-ag2l1xa7	25	28	have	have	VBP
cord-286132-ag2l1xa7	25	29	completed	complete	VBN
cord-286132-ag2l1xa7	25	30	phase	phase	NN
cord-286132-ag2l1xa7	25	31	2	2	CD
cord-286132-ag2l1xa7	25	32	or	or	CC
cord-286132-ag2l1xa7	25	33	3	3	CD
cord-286132-ag2l1xa7	25	34	trials	trial	NNS
cord-286132-ag2l1xa7	25	35	.	.	.
cord-286132-ag2l1xa7	26	1	4	4	LS
cord-286132-ag2l1xa7	27	1	Currently	currently	RB
cord-286132-ag2l1xa7	27	2	,	,	,
cord-286132-ag2l1xa7	27	3	IL-12/23	IL-12/23	NNP
cord-286132-ag2l1xa7	27	4	or	or	CC
cord-286132-ag2l1xa7	27	5	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	27	6	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	27	7	are	be	VBP
cord-286132-ag2l1xa7	27	8	the	the	DT
cord-286132-ag2l1xa7	27	9	second	second	JJ
cord-286132-ag2l1xa7	27	10	most	most	RBS
cord-286132-ag2l1xa7	27	11	commonly	commonly	RB
cord-286132-ag2l1xa7	27	12	prescribed	prescribe	VBN
cord-286132-ag2l1xa7	27	13	category	category	NN
cord-286132-ag2l1xa7	27	14	of	of	IN
cord-286132-ag2l1xa7	27	15	biologics	biologic	NNS
cord-286132-ag2l1xa7	27	16	for	for	IN
cord-286132-ag2l1xa7	27	17	5	5	CD
cord-286132-ag2l1xa7	27	18	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	27	19	and	and	CC
cord-286132-ag2l1xa7	27	20	CD	CD	NNP
cord-286132-ag2l1xa7	27	21	,	,	,
cord-286132-ag2l1xa7	27	22	behind	behind	IN
cord-286132-ag2l1xa7	27	23	anti	anti	JJ
cord-286132-ag2l1xa7	27	24	-	-	JJ
cord-286132-ag2l1xa7	27	25	tumor	tumor	JJ
cord-286132-ag2l1xa7	27	26	necrosis	necrosis	NN
cord-286132-ag2l1xa7	27	27	factor	factor	NN
cord-286132-ag2l1xa7	27	28	agents	agent	NNS
cord-286132-ag2l1xa7	27	29	.	.	.
cord-286132-ag2l1xa7	28	1	12	12	CD
cord-286132-ag2l1xa7	28	2	6	6	CD
cord-286132-ag2l1xa7	28	3	However	however	RB
cord-286132-ag2l1xa7	28	4	,	,	,
cord-286132-ag2l1xa7	28	5	randomized	randomized	JJ
cord-286132-ag2l1xa7	28	6	controlled	control	VBN
cord-286132-ag2l1xa7	28	7	trials	trial	NNS
cord-286132-ag2l1xa7	28	8	(	(	-LRB-
cord-286132-ag2l1xa7	28	9	RCTs	RCTs	NNP
cord-286132-ag2l1xa7	28	10	)	)	-RRB-
cord-286132-ag2l1xa7	28	11	of	of	IN
cord-286132-ag2l1xa7	28	12	these	these	DT
cord-286132-ag2l1xa7	28	13	drugs	drug	NNS
cord-286132-ag2l1xa7	28	14	reported	report	VBD
cord-286132-ag2l1xa7	28	15	respiratory	respiratory	JJ
cord-286132-ag2l1xa7	28	16	tract	tract	NN
cord-286132-ag2l1xa7	28	17	infections	infection	NNS
cord-286132-ag2l1xa7	28	18	7	7	CD
cord-286132-ag2l1xa7	29	1	(	(	-LRB-
cord-286132-ag2l1xa7	29	2	RTIs	RTIs	NNP
cord-286132-ag2l1xa7	29	3	)	)	-RRB-
cord-286132-ag2l1xa7	29	4	as	as	IN
cord-286132-ag2l1xa7	29	5	the	the	DT
cord-286132-ag2l1xa7	29	6	most	most	RBS
cord-286132-ag2l1xa7	29	7	common	common	JJ
cord-286132-ag2l1xa7	29	8	adverse	adverse	JJ
cord-286132-ag2l1xa7	29	9	events	event	NNS
cord-286132-ag2l1xa7	29	10	.	.	.
cord-286132-ag2l1xa7	30	1	13	13	CD
cord-286132-ag2l1xa7	31	1	Furthermore	furthermore	RB
cord-286132-ag2l1xa7	31	2	,	,	,
cord-286132-ag2l1xa7	31	3	the	the	DT
cord-286132-ag2l1xa7	31	4	surveillance	surveillance	NN
cord-286132-ag2l1xa7	31	5	conducted	conduct	VBN
cord-286132-ag2l1xa7	31	6	by	by	IN
cord-286132-ag2l1xa7	31	7	Food	Food	NNP
cord-286132-ag2l1xa7	31	8	and	and	CC
cord-286132-ag2l1xa7	31	9	Drug	Drug	NNP
cord-286132-ag2l1xa7	31	10	8	8	NNP
cord-286132-ag2l1xa7	31	11	Administration	Administration	NNP
cord-286132-ag2l1xa7	31	12	(	(	-LRB-
cord-286132-ag2l1xa7	31	13	FDA	FDA	NNP
cord-286132-ag2l1xa7	31	14	)	)	-RRB-
cord-286132-ag2l1xa7	31	15	reported	report	VBD
cord-286132-ag2l1xa7	31	16	the	the	DT
cord-286132-ag2l1xa7	31	17	development	development	NN
cord-286132-ag2l1xa7	31	18	of	of	IN
cord-286132-ag2l1xa7	31	19	non	non	JJ
cord-286132-ag2l1xa7	31	20	-	-	JJ
cord-286132-ag2l1xa7	31	21	infectious	infectious	JJ
cord-286132-ag2l1xa7	31	22	interstitial	interstitial	JJ
cord-286132-ag2l1xa7	31	23	lung	lung	NN
cord-286132-ag2l1xa7	31	24	disease	disease	NN
cord-286132-ag2l1xa7	31	25	(	(	-LRB-
cord-286132-ag2l1xa7	31	26	ILD	ILD	NNP
cord-286132-ag2l1xa7	31	27	)	)	-RRB-
cord-286132-ag2l1xa7	31	28	following	follow	VBG
cord-286132-ag2l1xa7	31	29	9	9	CD
cord-286132-ag2l1xa7	31	30	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	31	31	.	.	.
cord-286132-ag2l1xa7	32	1	14	14	CD
cord-286132-ag2l1xa7	33	1	Hence	hence	RB
cord-286132-ag2l1xa7	33	2	,	,	,
cord-286132-ag2l1xa7	33	3	physicians	physician	NNS
cord-286132-ag2l1xa7	33	4	need	need	VBP
cord-286132-ag2l1xa7	33	5	evidences	evidence	NNS
cord-286132-ag2l1xa7	33	6	to	to	TO
cord-286132-ag2l1xa7	33	7	decide	decide	VB
cord-286132-ag2l1xa7	33	8	whether	whether	IN
cord-286132-ag2l1xa7	33	9	to	to	TO
cord-286132-ag2l1xa7	33	10	continue	continue	VB
cord-286132-ag2l1xa7	33	11	or	or	CC
cord-286132-ag2l1xa7	33	12	hold	hold	VB
cord-286132-ag2l1xa7	33	13	these	these	DT
cord-286132-ag2l1xa7	33	14	drugs	drug	NNS
cord-286132-ag2l1xa7	33	15	10	10	CD
cord-286132-ag2l1xa7	33	16	particularly	particularly	RB
cord-286132-ag2l1xa7	33	17	during	during	IN
cord-286132-ag2l1xa7	33	18	the	the	DT
cord-286132-ag2l1xa7	33	19	current	current	JJ
cord-286132-ag2l1xa7	33	20	COVID-19	COVID-19	NNP
cord-286132-ag2l1xa7	33	21	pandemic	pandemic	NN
cord-286132-ag2l1xa7	33	22	.	.	.
cord-286132-ag2l1xa7	34	1	15	15	CD
cord-286132-ag2l1xa7	34	2	-	-	SYM
cord-286132-ag2l1xa7	34	3	17	17	CD
cord-286132-ag2l1xa7	34	4	11	11	CD
cord-286132-ag2l1xa7	34	5	This	this	DT
cord-286132-ag2l1xa7	34	6	systematic	systematic	JJ
cord-286132-ag2l1xa7	34	7	review	review	NN
cord-286132-ag2l1xa7	34	8	and	and	CC
cord-286132-ag2l1xa7	34	9	meta	meta	NNP
cord-286132-ag2l1xa7	34	10	-	-	HYPH
cord-286132-ag2l1xa7	34	11	analysis	analysis	NN
cord-286132-ag2l1xa7	34	12	aimed	aim	VBN
cord-286132-ag2l1xa7	34	13	to	to	TO
cord-286132-ag2l1xa7	34	14	determine	determine	VB
cord-286132-ag2l1xa7	34	15	the	the	DT
cord-286132-ag2l1xa7	34	16	risk	risk	NN
cord-286132-ag2l1xa7	34	17	of	of	IN
cord-286132-ag2l1xa7	34	18	RTIs	rti	NNS
cord-286132-ag2l1xa7	34	19	and	and	CC
cord-286132-ag2l1xa7	34	20	non	non	JJ
cord-286132-ag2l1xa7	34	21	-	-	JJ
cord-286132-ag2l1xa7	34	22	infectious	infectious	JJ
cord-286132-ag2l1xa7	34	23	12	12	CD
cord-286132-ag2l1xa7	35	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	35	2	evaluated	evaluate	VBD
cord-286132-ag2l1xa7	35	3	the	the	DT
cord-286132-ag2l1xa7	35	4	presence	presence	NN
cord-286132-ag2l1xa7	35	5	of	of	IN
cord-286132-ag2l1xa7	35	6	heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	35	7	across	across	IN
cord-286132-ag2l1xa7	35	8	trials	trial	NNS
cord-286132-ag2l1xa7	35	9	by	by	IN
cord-286132-ag2l1xa7	35	10	using	use	VBG
cord-286132-ag2l1xa7	35	11	the	the	DT
cord-286132-ag2l1xa7	35	12	I	I	NNP
cord-286132-ag2l1xa7	35	13	2	2	CD
cord-286132-ag2l1xa7	35	14	statistic	statistic	NN
cord-286132-ag2l1xa7	35	15	.	.	.
cord-286132-ag2l1xa7	36	1	An	an	DT
cord-286132-ag2l1xa7	36	2	I	i	NN
cord-286132-ag2l1xa7	36	3	2	2	CD
cord-286132-ag2l1xa7	36	4	value	value	NN
cord-286132-ag2l1xa7	36	5	of	of	IN
cord-286132-ag2l1xa7	36	6	<	<	$
cord-286132-ag2l1xa7	36	7	25	25	CD
cord-286132-ag2l1xa7	36	8	%	%	NN
cord-286132-ag2l1xa7	36	9	1	1	CD
cord-286132-ag2l1xa7	36	10	indicated	indicate	VBD
cord-286132-ag2l1xa7	36	11	low	low	JJ
cord-286132-ag2l1xa7	36	12	heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	36	13	,	,	,
cord-286132-ag2l1xa7	36	14	25	25	CD
cord-286132-ag2l1xa7	36	15	-	-	SYM
cord-286132-ag2l1xa7	36	16	75	75	CD
cord-286132-ag2l1xa7	36	17	%	%	NN
cord-286132-ag2l1xa7	36	18	as	as	IN
cord-286132-ag2l1xa7	36	19	moderate	moderate	JJ
cord-286132-ag2l1xa7	36	20	heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	36	21	and	and	CC
cord-286132-ag2l1xa7	36	22	>	>	XX
cord-286132-ag2l1xa7	36	23	75	75	CD
cord-286132-ag2l1xa7	36	24	%	%	NN
cord-286132-ag2l1xa7	36	25	as	as	IN
cord-286132-ag2l1xa7	36	26	considerable	considerable	JJ
cord-286132-ag2l1xa7	36	27	heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	36	28	,	,	,
cord-286132-ag2l1xa7	36	29	2	2	CD
cord-286132-ag2l1xa7	36	30	respectively	respectively	RB
cord-286132-ag2l1xa7	36	31	.	.	.
cord-286132-ag2l1xa7	37	1	29	29	CD
cord-286132-ag2l1xa7	37	2	Heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	37	3	was	be	VBD
cord-286132-ag2l1xa7	37	4	evaluated	evaluate	VBN
cord-286132-ag2l1xa7	37	5	by	by	IN
cord-286132-ag2l1xa7	37	6	using	use	VBG
cord-286132-ag2l1xa7	37	7	Cochran	Cochran	NNP
cord-286132-ag2l1xa7	37	8	's	's	POS
cord-286132-ag2l1xa7	37	9	Q	q	NN
cord-286132-ag2l1xa7	37	10	-	-	HYPH
cord-286132-ag2l1xa7	37	11	statistics	statistic	NNS
cord-286132-ag2l1xa7	37	12	with	with	IN
cord-286132-ag2l1xa7	37	13	a	a	DT
cord-286132-ag2l1xa7	37	14	significance	significance	NN
cord-286132-ag2l1xa7	37	15	level	level	NN
cord-286132-ag2l1xa7	37	16	of	of	IN
cord-286132-ag2l1xa7	37	17	3	3	CD
cord-286132-ag2l1xa7	37	18	P<0	P<0	NNP
cord-286132-ag2l1xa7	37	19	.	.	.
cord-286132-ag2l1xa7	38	1	10	10	CD
cord-286132-ag2l1xa7	38	2	.	.	.
cord-286132-ag2l1xa7	38	3	30	30	CD
cord-286132-ag2l1xa7	39	1	Begg	Begg	NNP
cord-286132-ag2l1xa7	39	2	's	's	POS
cord-286132-ag2l1xa7	39	3	and	and	CC
cord-286132-ag2l1xa7	39	4	Egger	Egger	NNP
cord-286132-ag2l1xa7	39	5	's	's	POS
cord-286132-ag2l1xa7	39	6	tests	test	NNS
cord-286132-ag2l1xa7	39	7	were	be	VBD
cord-286132-ag2l1xa7	39	8	performed	perform	VBN
cord-286132-ag2l1xa7	39	9	to	to	TO
cord-286132-ag2l1xa7	39	10	access	access	VB
cord-286132-ag2l1xa7	39	11	publication	publication	NN
cord-286132-ag2l1xa7	39	12	bias	bias	NN
cord-286132-ag2l1xa7	39	13	and	and	CC
cord-286132-ag2l1xa7	39	14	funnel	funnel	VB
cord-286132-ag2l1xa7	39	15	plots	plot	NNS
cord-286132-ag2l1xa7	39	16	were	be	VBD
cord-286132-ag2l1xa7	39	17	4	4	CD
cord-286132-ag2l1xa7	39	18	constructed	construct	VBN
cord-286132-ag2l1xa7	39	19	to	to	TO
cord-286132-ag2l1xa7	39	20	visualize	visualize	VB
cord-286132-ag2l1xa7	39	21	possible	possible	JJ
cord-286132-ag2l1xa7	39	22	asymmetry	asymmetry	NN
cord-286132-ag2l1xa7	39	23	when	when	WRB
cord-286132-ag2l1xa7	39	24	three	three	CD
cord-286132-ag2l1xa7	39	25	or	or	CC
cord-286132-ag2l1xa7	39	26	more	more	JJR
cord-286132-ag2l1xa7	39	27	studies	study	NNS
cord-286132-ag2l1xa7	39	28	were	be	VBD
cord-286132-ag2l1xa7	39	29	available	available	JJ
cord-286132-ag2l1xa7	39	30	.	.	.
cord-286132-ag2l1xa7	40	1	31	31	CD
cord-286132-ag2l1xa7	40	2	,	,	,
cord-286132-ag2l1xa7	40	3	32	32	CD
cord-286132-ag2l1xa7	40	4	5	5	CD
cord-286132-ag2l1xa7	40	5	Statistical	statistical	JJ
cord-286132-ag2l1xa7	40	6	analyses	analysis	NNS
cord-286132-ag2l1xa7	40	7	were	be	VBD
cord-286132-ag2l1xa7	40	8	performed	perform	VBN
cord-286132-ag2l1xa7	40	9	using	use	VBG
cord-286132-ag2l1xa7	40	10	the	the	DT
cord-286132-ag2l1xa7	40	11	Comprehensive	Comprehensive	NNP
cord-286132-ag2l1xa7	40	12	Meta	Meta	NNP
cord-286132-ag2l1xa7	40	13	-	-	HYPH
cord-286132-ag2l1xa7	40	14	Analysis	Analysis	NNP
cord-286132-ag2l1xa7	40	15	Software	Software	NNP
cord-286132-ag2l1xa7	40	16	(	(	-LRB-
cord-286132-ag2l1xa7	40	17	version	version	NN
cord-286132-ag2l1xa7	40	18	2.0	2.0	CD
cord-286132-ag2l1xa7	40	19	;	;	:
cord-286132-ag2l1xa7	40	20	6	6	CD
cord-286132-ag2l1xa7	40	21	Biostat	Biostat	NNP
cord-286132-ag2l1xa7	40	22	,	,	,
cord-286132-ag2l1xa7	40	23	Englewood	Englewood	NNP
cord-286132-ag2l1xa7	40	24	,	,	,
cord-286132-ag2l1xa7	40	25	NJ	NJ	NNP
cord-286132-ag2l1xa7	40	26	,	,	,
cord-286132-ag2l1xa7	40	27	USA	USA	NNP
cord-286132-ag2l1xa7	40	28	)	)	-RRB-
cord-286132-ag2l1xa7	40	29	.	.	.
cord-286132-ag2l1xa7	41	1	All	all	DT
cord-286132-ag2l1xa7	41	2	statistical	statistical	JJ
cord-286132-ag2l1xa7	41	3	tests	test	NNS
cord-286132-ag2l1xa7	41	4	used	use	VBD
cord-286132-ag2l1xa7	41	5	a	a	DT
cord-286132-ag2l1xa7	41	6	two	two	CD
cord-286132-ag2l1xa7	41	7	-	-	HYPH
cord-286132-ag2l1xa7	41	8	sided	sided	JJ
cord-286132-ag2l1xa7	41	9	a	a	DT
cord-286132-ag2l1xa7	41	10	value	value	NN
cord-286132-ag2l1xa7	41	11	of	of	IN
cord-286132-ag2l1xa7	41	12	0.05	0.05	CD
cord-286132-ag2l1xa7	41	13	for	for	IN
cord-286132-ag2l1xa7	41	14	significance	significance	NN
cord-286132-ag2l1xa7	41	15	.	.	.
cord-286132-ag2l1xa7	42	1	characteristics	characteristic	NNS
cord-286132-ag2l1xa7	42	2	and	and	CC
cord-286132-ag2l1xa7	42	3	outcomes	outcome	NNS
cord-286132-ag2l1xa7	42	4	of	of	IN
cord-286132-ag2l1xa7	42	5	the	the	DT
cord-286132-ag2l1xa7	42	6	included	include	VBN
cord-286132-ag2l1xa7	42	7	studies	study	NNS
cord-286132-ag2l1xa7	42	8	are	be	VBP
cord-286132-ag2l1xa7	42	9	summarized	summarize	VBN
cord-286132-ag2l1xa7	42	10	in	in	IN
cord-286132-ag2l1xa7	42	11	Table	Table	NNP
cord-286132-ag2l1xa7	42	12	1	1	CD
cord-286132-ag2l1xa7	42	13	The	the	DT
cord-286132-ag2l1xa7	42	14	percentage	percentage	NN
cord-286132-ag2l1xa7	42	15	of	of	IN
cord-286132-ag2l1xa7	42	16	studies	study	NNS
cord-286132-ag2l1xa7	42	17	which	which	WDT
cord-286132-ag2l1xa7	42	18	permitted	permit	VBD
cord-286132-ag2l1xa7	42	19	to	to	TO
cord-286132-ag2l1xa7	42	20	use	use	VB
cord-286132-ag2l1xa7	42	21	concomitant	concomitant	JJ
cord-286132-ag2l1xa7	42	22	drugs	drug	NNS
cord-286132-ag2l1xa7	42	23	(	(	-LRB-
cord-286132-ag2l1xa7	42	24	e.g.	e.g.	IN
cord-286132-ag2l1xa7	42	25	corticosteroids	corticosteroid	NNS
cord-286132-ag2l1xa7	42	26	,	,	,
cord-286132-ag2l1xa7	42	27	budesonide	budesonide	NN
cord-286132-ag2l1xa7	42	28	,	,	,
cord-286132-ag2l1xa7	42	29	13	13	CD
cord-286132-ag2l1xa7	42	30	thiopurines	thiopurine	NNS
cord-286132-ag2l1xa7	42	31	,	,	,
cord-286132-ag2l1xa7	42	32	methotrexate	methotrexate	NNP
cord-286132-ag2l1xa7	42	33	,	,	,
cord-286132-ag2l1xa7	42	34	calcineurin	calcineurin	NNP
cord-286132-ag2l1xa7	42	35	inhibitors	inhibitor	NNS
cord-286132-ag2l1xa7	42	36	,	,	,
cord-286132-ag2l1xa7	42	37	or	or	CC
cord-286132-ag2l1xa7	42	38	aminosalicylates	aminosalicylates	NNP
cord-286132-ag2l1xa7	42	39	)	)	-RRB-
cord-286132-ag2l1xa7	42	40	during	during	IN
cord-286132-ag2l1xa7	42	41	the	the	DT
cord-286132-ag2l1xa7	42	42	trials	trial	NNS
cord-286132-ag2l1xa7	42	43	was	be	VBD
cord-286132-ag2l1xa7	42	44	40.0	40.0	CD
cord-286132-ag2l1xa7	42	45	%	%	NN
cord-286132-ag2l1xa7	42	46	for	for	IN
cord-286132-ag2l1xa7	42	47	14	14	CD
cord-286132-ag2l1xa7	42	48	risankizumab	risankizumab	NNS
cord-286132-ag2l1xa7	42	49	,	,	,
cord-286132-ag2l1xa7	42	50	38.5	38.5	CD
cord-286132-ag2l1xa7	42	51	%	%	NN
cord-286132-ag2l1xa7	42	52	for	for	IN
cord-286132-ag2l1xa7	42	53	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	42	54	,	,	,
cord-286132-ag2l1xa7	42	55	37.5	37.5	CD
cord-286132-ag2l1xa7	42	56	%	%	NN
cord-286132-ag2l1xa7	42	57	for	for	IN
cord-286132-ag2l1xa7	42	58	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	42	59	,	,	,
cord-286132-ag2l1xa7	42	60	0	0	CD
cord-286132-ag2l1xa7	42	61	%	%	NN
cord-286132-ag2l1xa7	42	62	for	for	IN
cord-286132-ag2l1xa7	42	63	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	42	64	,	,	,
cord-286132-ag2l1xa7	42	65	and	and	CC
cord-286132-ag2l1xa7	42	66	0	0	CD
cord-286132-ag2l1xa7	42	67	%	%	NN
cord-286132-ag2l1xa7	42	68	for	for	IN
cord-286132-ag2l1xa7	42	69	tildrakizumab	tildrakizumab	NNS
cord-286132-ag2l1xa7	42	70	.	.	.
cord-286132-ag2l1xa7	43	1	15	15	CD
cord-286132-ag2l1xa7	44	1	As	as	IN
cord-286132-ag2l1xa7	44	2	for	for	IN
cord-286132-ag2l1xa7	44	3	brazikumab	brazikumab	NNP
cord-286132-ag2l1xa7	44	4	,	,	,
cord-286132-ag2l1xa7	44	5	one	one	CD
cord-286132-ag2l1xa7	44	6	study	study	NN
cord-286132-ag2l1xa7	44	7	for	for	IN
cord-286132-ag2l1xa7	44	8	CD	CD	NNP
cord-286132-ag2l1xa7	44	9	was	be	VBD
cord-286132-ag2l1xa7	44	10	included	include	VBN
cord-286132-ag2l1xa7	44	11	in	in	IN
cord-286132-ag2l1xa7	44	12	this	this	DT
cord-286132-ag2l1xa7	44	13	analysis	analysis	NN
cord-286132-ag2l1xa7	44	14	and	and	CC
cord-286132-ag2l1xa7	44	15	permitted	permit	VBD
cord-286132-ag2l1xa7	44	16	concomitant	concomitant	JJ
cord-286132-ag2l1xa7	44	17	drugs	drug	NNS
cord-286132-ag2l1xa7	44	18	(	(	-LRB-
cord-286132-ag2l1xa7	44	19	Table	table	NN
cord-286132-ag2l1xa7	44	20	1	1	CD
cord-286132-ag2l1xa7	44	21	)	)	-RRB-
cord-286132-ag2l1xa7	44	22	.	.	.
cord-286132-ag2l1xa7	45	1	16	16	CD
cord-286132-ag2l1xa7	45	2	Meta	Meta	NNP
cord-286132-ag2l1xa7	45	3	-	-	HYPH
cord-286132-ag2l1xa7	45	4	analysis	analysis	NN
cord-286132-ag2l1xa7	45	5	with	with	IN
cord-286132-ag2l1xa7	45	6	a	a	DT
cord-286132-ag2l1xa7	45	7	random	random	JJ
cord-286132-ag2l1xa7	45	8	-	-	HYPH
cord-286132-ag2l1xa7	45	9	effects	effect	NNS
cord-286132-ag2l1xa7	45	10	model	model	NN
cord-286132-ag2l1xa7	45	11	showed	show	VBD
cord-286132-ag2l1xa7	45	12	that	that	IN
cord-286132-ag2l1xa7	45	13	the	the	DT
cord-286132-ag2l1xa7	45	14	overall	overall	JJ
cord-286132-ag2l1xa7	45	15	risk	risk	NN
cord-286132-ag2l1xa7	45	16	of	of	IN
cord-286132-ag2l1xa7	45	17	RTIs	rti	NNS
cord-286132-ag2l1xa7	45	18	with	with	IN
cord-286132-ag2l1xa7	45	19	1	1	CD
cord-286132-ag2l1xa7	45	20	anti	anti	JJ
cord-286132-ag2l1xa7	45	21	-	-	JJ
cord-286132-ag2l1xa7	45	22	IL-12	IL-12	NNP
cord-286132-ag2l1xa7	45	23	/	/	SYM
cord-286132-ag2l1xa7	45	24	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	45	25	or	or	CC
cord-286132-ag2l1xa7	45	26	anti	anti	NNP
cord-286132-ag2l1xa7	45	27	-	-	JJ
cord-286132-ag2l1xa7	45	28	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	45	29	agents	agent	NNS
cord-286132-ag2l1xa7	45	30	was	be	VBD
cord-286132-ag2l1xa7	45	31	significantly	significantly	RB
cord-286132-ag2l1xa7	45	32	higher	high	JJR
cord-286132-ag2l1xa7	45	33	than	than	IN
cord-286132-ag2l1xa7	45	34	that	that	DT
cord-286132-ag2l1xa7	45	35	of	of	IN
cord-286132-ag2l1xa7	45	36	placebo	placebo	NN
cord-286132-ag2l1xa7	45	37	(	(	-LRB-
cord-286132-ag2l1xa7	45	38	MH	MH	NNP
cord-286132-ag2l1xa7	45	39	RD	RD	NNP
cord-286132-ag2l1xa7	45	40	0.019	0.019	CD
cord-286132-ag2l1xa7	45	41	,	,	,
cord-286132-ag2l1xa7	45	42	95	95	CD
cord-286132-ag2l1xa7	45	43	%	%	NN
cord-286132-ag2l1xa7	45	44	2	2	CD
cord-286132-ag2l1xa7	45	45	confidence	confidence	NN
cord-286132-ag2l1xa7	45	46	interval	interval	NN
cord-286132-ag2l1xa7	45	47	[	[	-LRB-
cord-286132-ag2l1xa7	45	48	CI	CI	NNP
cord-286132-ag2l1xa7	45	49	]	]	-RRB-
cord-286132-ag2l1xa7	45	50	0.005	0.005	CD
cord-286132-ag2l1xa7	45	51	-	-	HYPH
cord-286132-ag2l1xa7	45	52	0.033	0.033	CD
cord-286132-ag2l1xa7	45	53	,	,	,
cord-286132-ag2l1xa7	45	54	P	p	NN
cord-286132-ag2l1xa7	45	55	=	=	SYM
cord-286132-ag2l1xa7	45	56	0.007	0.007	CD
cord-286132-ag2l1xa7	45	57	)	)	-RRB-
cord-286132-ag2l1xa7	46	1	(	(	-LRB-
cord-286132-ag2l1xa7	46	2	Figure	figure	NN
cord-286132-ag2l1xa7	46	3	2	2	CD
cord-286132-ag2l1xa7	46	4	)	)	-RRB-
cord-286132-ag2l1xa7	46	5	.	.	.
cord-286132-ag2l1xa7	47	1	The	the	DT
cord-286132-ag2l1xa7	47	2	number	number	NN
cord-286132-ag2l1xa7	47	3	needed	need	VBN
cord-286132-ag2l1xa7	47	4	to	to	TO
cord-286132-ag2l1xa7	47	5	harm	harm	NN
cord-286132-ag2l1xa7	47	6	of	of	IN
cord-286132-ag2l1xa7	47	7	RTIs	rti	NNS
cord-286132-ag2l1xa7	47	8	was	be	VBD
cord-286132-ag2l1xa7	47	9	58.8	58.8	CD
cord-286132-ag2l1xa7	47	10	.	.	.
cord-286132-ag2l1xa7	48	1	3	3	LS
cord-286132-ag2l1xa7	49	1	Subgroup	Subgroup	NNP
cord-286132-ag2l1xa7	49	2	analysis	analysis	NN
cord-286132-ag2l1xa7	49	3	revealed	reveal	VBD
cord-286132-ag2l1xa7	49	4	a	a	DT
cord-286132-ag2l1xa7	49	5	significantly	significantly	RB
cord-286132-ag2l1xa7	49	6	increased	increase	VBN
cord-286132-ag2l1xa7	49	7	risk	risk	NN
cord-286132-ag2l1xa7	49	8	of	of	IN
cord-286132-ag2l1xa7	49	9	RTIs	rti	NNS
cord-286132-ag2l1xa7	49	10	with	with	IN
cord-286132-ag2l1xa7	49	11	briakinumab	briakinumab	NNP
cord-286132-ag2l1xa7	49	12	(	(	-LRB-
cord-286132-ag2l1xa7	49	13	MH	MH	NNP
cord-286132-ag2l1xa7	49	14	RD	RD	NNP
cord-286132-ag2l1xa7	49	15	0.021	0.021	CD
cord-286132-ag2l1xa7	49	16	,	,	,
cord-286132-ag2l1xa7	49	17	95	95	CD
cord-286132-ag2l1xa7	49	18	%	%	NN
cord-286132-ag2l1xa7	49	19	CI	CI	NNP
cord-286132-ag2l1xa7	49	20	4	4	CD
cord-286132-ag2l1xa7	49	21	0.001	0.001	CD
cord-286132-ag2l1xa7	49	22	-	-	HYPH
cord-286132-ag2l1xa7	49	23	0.041	0.041	CD
cord-286132-ag2l1xa7	49	24	,	,	,
cord-286132-ag2l1xa7	49	25	P	p	NN
cord-286132-ag2l1xa7	49	26	=	=	SYM
cord-286132-ag2l1xa7	49	27	0.036	0.036	CD
cord-286132-ag2l1xa7	49	28	)	)	-RRB-
cord-286132-ag2l1xa7	49	29	and	and	CC
cord-286132-ag2l1xa7	49	30	risankizumab	risankizumab	NNP
cord-286132-ag2l1xa7	49	31	(	(	-LRB-
cord-286132-ag2l1xa7	49	32	MH	MH	NNP
cord-286132-ag2l1xa7	49	33	RD	RD	NNP
cord-286132-ag2l1xa7	49	34	0.040	0.040	CD
cord-286132-ag2l1xa7	49	35	,	,	,
cord-286132-ag2l1xa7	49	36	95	95	CD
cord-286132-ag2l1xa7	49	37	%	%	NN
cord-286132-ag2l1xa7	49	38	CI	CI	NNP
cord-286132-ag2l1xa7	49	39	0.005	0.005	CD
cord-286132-ag2l1xa7	49	40	-	-	HYPH
cord-286132-ag2l1xa7	49	41	0.076	0.076	CD
cord-286132-ag2l1xa7	49	42	,	,	,
cord-286132-ag2l1xa7	49	43	P	p	NN
cord-286132-ag2l1xa7	49	44	=	=	SYM
cord-286132-ag2l1xa7	49	45	0.026	0.026	CD
cord-286132-ag2l1xa7	49	46	)	)	-RRB-
cord-286132-ag2l1xa7	49	47	.	.	.
cord-286132-ag2l1xa7	50	1	Heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	50	2	5	5	CD
cord-286132-ag2l1xa7	50	3	was	be	VBD
cord-286132-ag2l1xa7	50	4	absent	absent	JJ
cord-286132-ag2l1xa7	51	1	(	(	-LRB-
cord-286132-ag2l1xa7	51	2	I	i	NN
cord-286132-ag2l1xa7	51	3	2	2	CD
cord-286132-ag2l1xa7	51	4	=	=	SYM
cord-286132-ag2l1xa7	51	5	0	0	CD
cord-286132-ag2l1xa7	51	6	%	%	NN
cord-286132-ag2l1xa7	51	7	)	)	-RRB-
cord-286132-ag2l1xa7	51	8	in	in	IN
cord-286132-ag2l1xa7	51	9	overall	overall	JJ
cord-286132-ag2l1xa7	51	10	and	and	CC
cord-286132-ag2l1xa7	51	11	subgroup	subgroup	NN
cord-286132-ag2l1xa7	51	12	analyses	analysis	NNS
cord-286132-ag2l1xa7	51	13	except	except	IN
cord-286132-ag2l1xa7	51	14	for	for	IN
cord-286132-ag2l1xa7	51	15	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	51	16	(	(	-LRB-
cord-286132-ag2l1xa7	51	17	I	i	NN
cord-286132-ag2l1xa7	51	18	2	2	CD
cord-286132-ag2l1xa7	51	19	=	=	SYM
cord-286132-ag2l1xa7	51	20	31	31	CD
cord-286132-ag2l1xa7	51	21	%	%	NN
cord-286132-ag2l1xa7	51	22	)	)	-RRB-
cord-286132-ag2l1xa7	51	23	.	.	.
cord-286132-ag2l1xa7	52	1	Funnel	funnel	VB
cord-286132-ag2l1xa7	52	2	plot	plot	NN
cord-286132-ag2l1xa7	52	3	6	6	CD
cord-286132-ag2l1xa7	52	4	demonstrated	demonstrate	VBD
cord-286132-ag2l1xa7	52	5	no	no	DT
cord-286132-ag2l1xa7	52	6	asymmetry	asymmetry	NN
cord-286132-ag2l1xa7	52	7	,	,	,
cord-286132-ag2l1xa7	52	8	therefore	therefore	RB
cord-286132-ag2l1xa7	52	9	suggesting	suggest	VBG
cord-286132-ag2l1xa7	52	10	there	there	EX
cord-286132-ag2l1xa7	52	11	was	be	VBD
cord-286132-ag2l1xa7	52	12	no	no	DT
cord-286132-ag2l1xa7	52	13	small	small	JJ
cord-286132-ag2l1xa7	52	14	-	-	HYPH
cord-286132-ag2l1xa7	52	15	study	study	NN
cord-286132-ag2l1xa7	52	16	effects	effect	NNS
cord-286132-ag2l1xa7	52	17	or	or	CC
cord-286132-ag2l1xa7	52	18	publication	publication	NN
cord-286132-ag2l1xa7	52	19	bias	bias	NN
cord-286132-ag2l1xa7	52	20	,	,	,
cord-286132-ag2l1xa7	52	21	which	which	WDT
cord-286132-ag2l1xa7	52	22	7	7	CD
cord-286132-ag2l1xa7	52	23	was	be	VBD
cord-286132-ag2l1xa7	52	24	supported	support	VBN
cord-286132-ag2l1xa7	52	25	by	by	IN
cord-286132-ag2l1xa7	52	26	Begg	Begg	NNP
cord-286132-ag2l1xa7	52	27	's	's	POS
cord-286132-ag2l1xa7	52	28	and	and	CC
cord-286132-ag2l1xa7	52	29	Egger	Egger	NNP
cord-286132-ag2l1xa7	52	30	's	's	POS
cord-286132-ag2l1xa7	52	31	tests	test	NNS
cord-286132-ag2l1xa7	52	32	(	(	-LRB-
cord-286132-ag2l1xa7	52	33	Figure	Figure	NNP
cord-286132-ag2l1xa7	52	34	S1	S1	NNP
cord-286132-ag2l1xa7	52	35	)	)	-RRB-
cord-286132-ag2l1xa7	52	36	.	.	.
cord-286132-ag2l1xa7	53	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	53	2	also	also	RB
cord-286132-ag2l1xa7	53	3	assessed	assess	VBD
cord-286132-ag2l1xa7	53	4	the	the	DT
cord-286132-ag2l1xa7	53	5	differential	differential	JJ
cord-286132-ag2l1xa7	53	6	risk	risk	NN
cord-286132-ag2l1xa7	53	7	of	of	IN
cord-286132-ag2l1xa7	53	8	RTIs	rti	NNS
cord-286132-ag2l1xa7	53	9	by	by	IN
cord-286132-ag2l1xa7	53	10	8	8	CD
cord-286132-ag2l1xa7	53	11	underlying	underlie	VBG
cord-286132-ag2l1xa7	53	12	disease	disease	NN
cord-286132-ag2l1xa7	53	13	and	and	CC
cord-286132-ag2l1xa7	53	14	showed	show	VBD
cord-286132-ag2l1xa7	53	15	a	a	DT
cord-286132-ag2l1xa7	53	16	significantly	significantly	RB
cord-286132-ag2l1xa7	53	17	increased	increase	VBN
cord-286132-ag2l1xa7	53	18	risk	risk	NN
cord-286132-ag2l1xa7	53	19	of	of	IN
cord-286132-ag2l1xa7	53	20	RTIs	rti	NNS
cord-286132-ag2l1xa7	53	21	in	in	IN
cord-286132-ag2l1xa7	53	22	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	53	23	(	(	-LRB-
cord-286132-ag2l1xa7	53	24	MH	MH	NNP
cord-286132-ag2l1xa7	53	25	RD	RD	NNP
cord-286132-ag2l1xa7	53	26	0.023	0.023	CD
cord-286132-ag2l1xa7	53	27	,	,	,
cord-286132-ag2l1xa7	53	28	95	95	CD
cord-286132-ag2l1xa7	53	29	%	%	NN
cord-286132-ag2l1xa7	54	1	CI	CI	NNP
cord-286132-ag2l1xa7	54	2	We	-PRON-	PRP
cord-286132-ag2l1xa7	54	3	divided	divide	VBD
cord-286132-ag2l1xa7	54	4	RTIs	rti	NNS
cord-286132-ag2l1xa7	54	5	into	into	IN
cord-286132-ag2l1xa7	54	6	URTIs	urti	NNS
cord-286132-ag2l1xa7	54	7	,	,	,
cord-286132-ag2l1xa7	54	8	viral	viral	JJ
cord-286132-ag2l1xa7	54	9	URTIs	urti	NNS
cord-286132-ag2l1xa7	54	10	,	,	,
cord-286132-ag2l1xa7	54	11	and	and	CC
cord-286132-ag2l1xa7	54	12	LRTIs	lrti	NNS
cord-286132-ag2l1xa7	54	13	and	and	CC
cord-286132-ag2l1xa7	54	14	investigated	investigate	VBD
cord-286132-ag2l1xa7	54	15	each	each	DT
cord-286132-ag2l1xa7	54	16	risk	risk	NN
cord-286132-ag2l1xa7	54	17	with	with	IN
cord-286132-ag2l1xa7	54	18	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	54	19	or	or	CC
cord-286132-ag2l1xa7	54	20	12	12	CD
cord-286132-ag2l1xa7	54	21	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	54	22	inhibitors	inhibitor	NNS
cord-286132-ag2l1xa7	54	23	.	.	.
cord-286132-ag2l1xa7	55	1	The	the	DT
cord-286132-ag2l1xa7	55	2	overall	overall	JJ
cord-286132-ag2l1xa7	55	3	risk	risk	NN
cord-286132-ag2l1xa7	55	4	of	of	IN
cord-286132-ag2l1xa7	55	5	URTIs	urti	NNS
cord-286132-ag2l1xa7	55	6	was	be	VBD
cord-286132-ag2l1xa7	55	7	significantly	significantly	RB
cord-286132-ag2l1xa7	55	8	higher	high	JJR
cord-286132-ag2l1xa7	55	9	in	in	IN
cord-286132-ag2l1xa7	55	10	the	the	DT
cord-286132-ag2l1xa7	55	11	treatment	treatment	NN
cord-286132-ag2l1xa7	55	12	group	group	NN
cord-286132-ag2l1xa7	55	13	compared	compare	VBN
cord-286132-ag2l1xa7	55	14	to	to	IN
cord-286132-ag2l1xa7	55	15	Anti	Anti	NNP
cord-286132-ag2l1xa7	55	16	-	-	JJ
cord-286132-ag2l1xa7	55	17	IL-12	IL-12	NNP
cord-286132-ag2l1xa7	55	18	/	/	SYM
cord-286132-ag2l1xa7	55	19	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	55	20	or	or	CC
cord-286132-ag2l1xa7	55	21	anti	anti	NNP
cord-286132-ag2l1xa7	55	22	-	-	JJ
cord-286132-ag2l1xa7	55	23	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	55	24	agents	agent	NNS
cord-286132-ag2l1xa7	55	25	did	do	VBD
cord-286132-ag2l1xa7	55	26	not	not	RB
cord-286132-ag2l1xa7	55	27	increase	increase	VB
cord-286132-ag2l1xa7	55	28	the	the	DT
cord-286132-ag2l1xa7	55	29	overall	overall	JJ
cord-286132-ag2l1xa7	55	30	risks	risk	NNS
cord-286132-ag2l1xa7	55	31	of	of	IN
cord-286132-ag2l1xa7	55	32	viral	viral	JJ
cord-286132-ag2l1xa7	55	33	URTIs	urti	NNS
cord-286132-ag2l1xa7	55	34	(	(	-LRB-
cord-286132-ag2l1xa7	55	35	MH	MH	NNP
cord-286132-ag2l1xa7	55	36	RD	RD	NNP
cord-286132-ag2l1xa7	55	37	17	17	CD
cord-286132-ag2l1xa7	55	38	0.001	0.001	CD
cord-286132-ag2l1xa7	55	39	,	,	,
cord-286132-ag2l1xa7	55	40	95	95	CD
cord-286132-ag2l1xa7	55	41	%	%	NN
cord-286132-ag2l1xa7	56	1	CI	CI	NNP
cord-286132-ag2l1xa7	56	2	-0.002	-0.002	NNP
cord-286132-ag2l1xa7	56	3	-	-	HYPH
cord-286132-ag2l1xa7	56	4	0.003	0.003	CD
cord-286132-ag2l1xa7	56	5	,	,	,
cord-286132-ag2l1xa7	56	6	P	p	NN
cord-286132-ag2l1xa7	56	7	=	=	SYM
cord-286132-ag2l1xa7	56	8	0.60	0.60	CD
cord-286132-ag2l1xa7	56	9	)	)	-RRB-
cord-286132-ag2l1xa7	56	10	and	and	CC
cord-286132-ag2l1xa7	56	11	LRTIs	LRTIs	NNP
cord-286132-ag2l1xa7	56	12	(	(	-LRB-
cord-286132-ag2l1xa7	56	13	MH	MH	NNP
cord-286132-ag2l1xa7	56	14	RD	RD	NNP
cord-286132-ag2l1xa7	56	15	0	0	CD
cord-286132-ag2l1xa7	56	16	,	,	,
cord-286132-ag2l1xa7	56	17	95	95	CD
cord-286132-ag2l1xa7	56	18	%	%	NN
cord-286132-ag2l1xa7	57	1	CI	CI	NNP
cord-286132-ag2l1xa7	57	2	-0.002	-0.002	NNP
cord-286132-ag2l1xa7	57	3	-	-	HYPH
cord-286132-ag2l1xa7	57	4	0.002	0.002	NNP
cord-286132-ag2l1xa7	57	5	,	,	,
cord-286132-ag2l1xa7	57	6	P	p	NN
cord-286132-ag2l1xa7	57	7	=	=	SYM
cord-286132-ag2l1xa7	57	8	0.71	0.71	CD
cord-286132-ag2l1xa7	57	9	)	)	-RRB-
cord-286132-ag2l1xa7	58	1	(	(	-LRB-
cord-286132-ag2l1xa7	58	2	Figure	figure	NN
cord-286132-ag2l1xa7	58	3	S4A	s4a	NN
cord-286132-ag2l1xa7	58	4	,	,	,
cord-286132-ag2l1xa7	58	5	18	18	CD
cord-286132-ag2l1xa7	58	6	S5A	s5a	CD
cord-286132-ag2l1xa7	58	7	)	)	-RRB-
cord-286132-ag2l1xa7	58	8	.	.	.
cord-286132-ag2l1xa7	59	1	Heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	59	2	was	be	VBD
cord-286132-ag2l1xa7	59	3	absent	absent	JJ
cord-286132-ag2l1xa7	60	1	(	(	-LRB-
cord-286132-ag2l1xa7	60	2	I	i	NN
cord-286132-ag2l1xa7	60	3	2	2	CD
cord-286132-ag2l1xa7	60	4	=	=	SYM
cord-286132-ag2l1xa7	60	5	0	0	CD
cord-286132-ag2l1xa7	60	6	%	%	NN
cord-286132-ag2l1xa7	60	7	)	)	-RRB-
cord-286132-ag2l1xa7	60	8	in	in	IN
cord-286132-ag2l1xa7	60	9	these	these	DT
cord-286132-ag2l1xa7	60	10	analyses	analysis	NNS
cord-286132-ag2l1xa7	60	11	.	.	.
cord-286132-ag2l1xa7	61	1	Publication	publication	NN
cord-286132-ag2l1xa7	61	2	bias	bias	NN
cord-286132-ag2l1xa7	61	3	was	be	VBD
cord-286132-ag2l1xa7	61	4	indicated	indicate	VBN
cord-286132-ag2l1xa7	61	5	in	in	IN
cord-286132-ag2l1xa7	61	6	the	the	DT
cord-286132-ag2l1xa7	61	7	analysis	analysis	NN
cord-286132-ag2l1xa7	61	8	of	of	IN
cord-286132-ag2l1xa7	61	9	19	19	CD
cord-286132-ag2l1xa7	61	10	viral	viral	JJ
cord-286132-ag2l1xa7	61	11	URTIs	urti	NNS
cord-286132-ag2l1xa7	61	12	(	(	-LRB-
cord-286132-ag2l1xa7	61	13	Begg	Begg	NNP
cord-286132-ag2l1xa7	61	14	:	:	:
cord-286132-ag2l1xa7	61	15	P	p	NN
cord-286132-ag2l1xa7	61	16	<	<	XX
cord-286132-ag2l1xa7	61	17	0.001	0.001	CD
cord-286132-ag2l1xa7	61	18	,	,	,
cord-286132-ag2l1xa7	61	19	Egger	Egger	NNP
cord-286132-ag2l1xa7	61	20	:	:	:
cord-286132-ag2l1xa7	61	21	P	p	NN
cord-286132-ag2l1xa7	61	22	=	=	SYM
cord-286132-ag2l1xa7	61	23	0.019	0.019	CD
cord-286132-ag2l1xa7	61	24	)	)	-RRB-
cord-286132-ag2l1xa7	62	1	(	(	-LRB-
cord-286132-ag2l1xa7	62	2	Figure	figure	NN
cord-286132-ag2l1xa7	62	3	S4B	s4b	CD
cord-286132-ag2l1xa7	62	4	)	)	-RRB-
cord-286132-ag2l1xa7	62	5	and	and	CC
cord-286132-ag2l1xa7	62	6	LRTIs	lrtis	ADD
cord-286132-ag2l1xa7	63	1	(	(	-LRB-
cord-286132-ag2l1xa7	63	2	Begg	Begg	NNP
cord-286132-ag2l1xa7	63	3	:	:	:
cord-286132-ag2l1xa7	63	4	P	p	NN
cord-286132-ag2l1xa7	63	5	<	<	XX
cord-286132-ag2l1xa7	63	6	0.001	0.001	CD
cord-286132-ag2l1xa7	63	7	,	,	,
cord-286132-ag2l1xa7	63	8	Egger	Egger	NNP
cord-286132-ag2l1xa7	63	9	:	:	:
cord-286132-ag2l1xa7	63	10	P	p	NN
cord-286132-ag2l1xa7	63	11	=	=	SYM
cord-286132-ag2l1xa7	63	12	0.55	0.55	CD
cord-286132-ag2l1xa7	63	13	)	)	-RRB-
cord-286132-ag2l1xa7	63	14	1	1	CD
cord-286132-ag2l1xa7	64	1	(	(	-LRB-
cord-286132-ag2l1xa7	64	2	Figure	figure	NN
cord-286132-ag2l1xa7	64	3	S5B	S5B	NNP
cord-286132-ag2l1xa7	64	4	)	)	-RRB-
cord-286132-ag2l1xa7	64	5	,	,	.
cord-286132-ag2l1xa7	65	1	but	but	CC
cord-286132-ag2l1xa7	65	2	the	the	DT
cord-286132-ag2l1xa7	65	3	funnel	funnel	NN
cord-286132-ag2l1xa7	65	4	plots	plot	NNS
cord-286132-ag2l1xa7	65	5	did	do	VBD
cord-286132-ag2l1xa7	65	6	not	not	RB
cord-286132-ag2l1xa7	65	7	appear	appear	VB
cord-286132-ag2l1xa7	65	8	asymmetric	asymmetric	JJ
cord-286132-ag2l1xa7	65	9	on	on	IN
cord-286132-ag2l1xa7	65	10	visual	visual	JJ
cord-286132-ag2l1xa7	65	11	inspection	inspection	NN
cord-286132-ag2l1xa7	65	12	.	.	.
cord-286132-ag2l1xa7	66	1	2	2	LS
cord-286132-ag2l1xa7	66	2	3	3	CD
cord-286132-ag2l1xa7	66	3	The	the	DT
cord-286132-ag2l1xa7	66	4	total	total	JJ
cord-286132-ag2l1xa7	66	5	numbers	number	NNS
cord-286132-ag2l1xa7	66	6	of	of	IN
cord-286132-ag2l1xa7	66	7	infectious	infectious	JJ
cord-286132-ag2l1xa7	66	8	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	66	9	were	be	VBD
cord-286132-ag2l1xa7	66	10	9	9	CD
cord-286132-ag2l1xa7	66	11	and	and	CC
cord-286132-ag2l1xa7	66	12	4	4	CD
cord-286132-ag2l1xa7	66	13	cases	case	NNS
cord-286132-ag2l1xa7	66	14	in	in	IN
cord-286132-ag2l1xa7	66	15	the	the	DT
cord-286132-ag2l1xa7	66	16	treatment	treatment	NN
cord-286132-ag2l1xa7	66	17	group	group	NN
cord-286132-ag2l1xa7	66	18	and	and	CC
cord-286132-ag2l1xa7	66	19	placebo	placebo	NN
cord-286132-ag2l1xa7	66	20	,	,	,
cord-286132-ag2l1xa7	66	21	5	5	CD
cord-286132-ag2l1xa7	66	22	respectively	respectively	RB
cord-286132-ag2l1xa7	66	23	.	.	.
cord-286132-ag2l1xa7	67	1	Mycobacterium	Mycobacterium	NNP
cord-286132-ag2l1xa7	67	2	tuberculosis	tuberculosis	NN
cord-286132-ag2l1xa7	67	3	and	and	CC
cord-286132-ag2l1xa7	67	4	viral	viral	JJ
cord-286132-ag2l1xa7	67	5	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	67	6	were	be	VBD
cord-286132-ag2l1xa7	67	7	not	not	RB
cord-286132-ag2l1xa7	67	8	reported	report	VBN
cord-286132-ag2l1xa7	67	9	.	.	.
cord-286132-ag2l1xa7	68	1	The	the	DT
cord-286132-ag2l1xa7	68	2	overall	overall	JJ
cord-286132-ag2l1xa7	68	3	risk	risk	NN
cord-286132-ag2l1xa7	68	4	of	of	IN
cord-286132-ag2l1xa7	68	5	6	6	CD
cord-286132-ag2l1xa7	68	6	infectious	infectious	JJ
cord-286132-ag2l1xa7	68	7	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	68	8	was	be	VBD
cord-286132-ag2l1xa7	68	9	not	not	RB
cord-286132-ag2l1xa7	68	10	significantly	significantly	RB
cord-286132-ag2l1xa7	68	11	increased	increase	VBN
cord-286132-ag2l1xa7	68	12	in	in	IN
cord-286132-ag2l1xa7	68	13	the	the	DT
cord-286132-ag2l1xa7	68	14	treatment	treatment	NN
cord-286132-ag2l1xa7	68	15	group	group	NN
cord-286132-ag2l1xa7	68	16	compared	compare	VBN
cord-286132-ag2l1xa7	68	17	to	to	IN
cord-286132-ag2l1xa7	68	18	placebo	placebo	NN
cord-286132-ag2l1xa7	68	19	(	(	-LRB-
cord-286132-ag2l1xa7	68	20	MH	MH	NNP
cord-286132-ag2l1xa7	68	21	RD	RD	NNP
cord-286132-ag2l1xa7	68	22	0	0	CD
cord-286132-ag2l1xa7	68	23	,	,	,
cord-286132-ag2l1xa7	68	24	7	7	CD
cord-286132-ag2l1xa7	68	25	95	95	CD
cord-286132-ag2l1xa7	68	26	%	%	NN
cord-286132-ag2l1xa7	68	27	CI	CI	NNP
cord-286132-ag2l1xa7	68	28	-0.002	-0.002	NNP
cord-286132-ag2l1xa7	68	29	-	-	HYPH
cord-286132-ag2l1xa7	68	30	0.002	0.002	NNP
cord-286132-ag2l1xa7	68	31	,	,	,
cord-286132-ag2l1xa7	68	32	P	p	NN
cord-286132-ag2l1xa7	68	33	=	=	SYM
cord-286132-ag2l1xa7	68	34	0.87	0.87	CD
cord-286132-ag2l1xa7	68	35	)	)	-RRB-
cord-286132-ag2l1xa7	69	1	(	(	-LRB-
cord-286132-ag2l1xa7	69	2	Figure	figure	NN
cord-286132-ag2l1xa7	69	3	3	3	CD
cord-286132-ag2l1xa7	69	4	)	)	-RRB-
cord-286132-ag2l1xa7	69	5	.	.	.
cord-286132-ag2l1xa7	70	1	Heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	70	2	was	be	VBD
cord-286132-ag2l1xa7	70	3	absent	absent	JJ
cord-286132-ag2l1xa7	71	1	(	(	-LRB-
cord-286132-ag2l1xa7	71	2	I	i	NN
cord-286132-ag2l1xa7	71	3	2	2	CD
cord-286132-ag2l1xa7	71	4	=	=	SYM
cord-286132-ag2l1xa7	71	5	0	0	CD
cord-286132-ag2l1xa7	71	6	%	%	NN
cord-286132-ag2l1xa7	71	7	)	)	-RRB-
cord-286132-ag2l1xa7	71	8	.	.	.
cord-286132-ag2l1xa7	72	1	The	the	DT
cord-286132-ag2l1xa7	72	2	funnel	funnel	NN
cord-286132-ag2l1xa7	72	3	plot	plot	NN
cord-286132-ag2l1xa7	72	4	was	be	VBD
cord-286132-ag2l1xa7	72	5	not	not	RB
cord-286132-ag2l1xa7	72	6	8	8	CD
cord-286132-ag2l1xa7	72	7	asymmetric	asymmetric	JJ
cord-286132-ag2l1xa7	72	8	,	,	,
cord-286132-ag2l1xa7	72	9	indicating	indicate	VBG
cord-286132-ag2l1xa7	72	10	no	no	DT
cord-286132-ag2l1xa7	72	11	publication	publication	NN
cord-286132-ag2l1xa7	72	12	bias	bias	NN
cord-286132-ag2l1xa7	72	13	,	,	,
cord-286132-ag2l1xa7	72	14	which	which	WDT
cord-286132-ag2l1xa7	72	15	was	be	VBD
cord-286132-ag2l1xa7	72	16	supported	support	VBN
cord-286132-ag2l1xa7	72	17	by	by	IN
cord-286132-ag2l1xa7	72	18	Egger	Egger	NNP
cord-286132-ag2l1xa7	72	19	's	's	POS
cord-286132-ag2l1xa7	72	20	test	test	NN
cord-286132-ag2l1xa7	72	21	(	(	-LRB-
cord-286132-ag2l1xa7	72	22	P	p	NN
cord-286132-ag2l1xa7	72	23	=	=	SYM
cord-286132-ag2l1xa7	72	24	0.93	0.93	CD
cord-286132-ag2l1xa7	72	25	)	)	-RRB-
cord-286132-ag2l1xa7	72	26	but	but	CC
cord-286132-ag2l1xa7	72	27	not	not	RB
cord-286132-ag2l1xa7	72	28	Begg	Begg	NNP
cord-286132-ag2l1xa7	72	29	's	's	POS
cord-286132-ag2l1xa7	72	30	test	test	NN
cord-286132-ag2l1xa7	72	31	9	9	CD
cord-286132-ag2l1xa7	72	32	(	(	-LRB-
cord-286132-ag2l1xa7	72	33	P	p	NN
cord-286132-ag2l1xa7	72	34	<	<	XX
cord-286132-ag2l1xa7	72	35	0.001	0.001	CD
cord-286132-ag2l1xa7	72	36	)	)	-RRB-
cord-286132-ag2l1xa7	72	37	(	(	-LRB-
cord-286132-ag2l1xa7	72	38	Figure	figure	NN
cord-286132-ag2l1xa7	72	39	S6	S6	NNP
cord-286132-ag2l1xa7	72	40	)	)	-RRB-
cord-286132-ag2l1xa7	72	41	.	.	.
cord-286132-ag2l1xa7	73	1	10	10	CD
cord-286132-ag2l1xa7	74	1	In	in	IN
cord-286132-ag2l1xa7	74	2	terms	term	NNS
cord-286132-ag2l1xa7	74	3	of	of	IN
cord-286132-ag2l1xa7	74	4	non	non	JJ
cord-286132-ag2l1xa7	74	5	-	-	JJ
cord-286132-ag2l1xa7	74	6	infectious	infectious	JJ
cord-286132-ag2l1xa7	74	7	ILD	ILD	NNP
cord-286132-ag2l1xa7	74	8	,	,	,
cord-286132-ag2l1xa7	74	9	2	2	CD
cord-286132-ag2l1xa7	74	10	and	and	CC
cord-286132-ag2l1xa7	74	11	1	1	CD
cord-286132-ag2l1xa7	74	12	cases	case	NNS
cord-286132-ag2l1xa7	74	13	were	be	VBD
cord-286132-ag2l1xa7	74	14	identified	identify	VBN
cord-286132-ag2l1xa7	74	15	in	in	IN
cord-286132-ag2l1xa7	74	16	the	the	DT
cord-286132-ag2l1xa7	74	17	treatment	treatment	NN
cord-286132-ag2l1xa7	74	18	group	group	NN
cord-286132-ag2l1xa7	74	19	and	and	CC
cord-286132-ag2l1xa7	74	20	placebo	placebo	NN
cord-286132-ag2l1xa7	74	21	,	,	,
cord-286132-ag2l1xa7	74	22	11	11	CD
cord-286132-ag2l1xa7	74	23	respectively	respectively	RB
cord-286132-ag2l1xa7	74	24	.	.	.
cord-286132-ag2l1xa7	75	1	All	all	DT
cord-286132-ag2l1xa7	75	2	3	3	CD
cord-286132-ag2l1xa7	75	3	cases	case	NNS
cord-286132-ag2l1xa7	75	4	were	be	VBD
cord-286132-ag2l1xa7	75	5	reported	report	VBN
cord-286132-ag2l1xa7	75	6	in	in	IN
cord-286132-ag2l1xa7	75	7	the	the	DT
cord-286132-ag2l1xa7	75	8	trials	trial	NNS
cord-286132-ag2l1xa7	75	9	of	of	IN
cord-286132-ag2l1xa7	75	10	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	75	11	and	and	CC
cord-286132-ag2l1xa7	75	12	occurred	occur	VBD
cord-286132-ag2l1xa7	75	13	within	within	IN
cord-286132-ag2l1xa7	75	14	16	16	CD
cord-286132-ag2l1xa7	75	15	weeks	week	NNS
cord-286132-ag2l1xa7	75	16	after	after	IN
cord-286132-ag2l1xa7	75	17	12	12	CD
cord-286132-ag2l1xa7	75	18	initiation	initiation	NN
cord-286132-ag2l1xa7	75	19	of	of	IN
cord-286132-ag2l1xa7	75	20	the	the	DT
cord-286132-ag2l1xa7	75	21	trial	trial	NN
cord-286132-ag2l1xa7	75	22	.	.	.
cord-286132-ag2l1xa7	76	1	[	[	-LRB-
cord-286132-ag2l1xa7	76	2	33	33	CD
cord-286132-ag2l1xa7	76	3	]	]	-RRB-
cord-286132-ag2l1xa7	76	4	[	[	-LRB-
cord-286132-ag2l1xa7	76	5	34	34	CD
cord-286132-ag2l1xa7	76	6	]	]	-RRB-
cord-286132-ag2l1xa7	76	7	[	[	-LRB-
cord-286132-ag2l1xa7	76	8	35	35	CD
cord-286132-ag2l1xa7	76	9	]	]	-RRB-
cord-286132-ag2l1xa7	77	1	The	the	DT
cord-286132-ag2l1xa7	77	2	overall	overall	JJ
cord-286132-ag2l1xa7	77	3	risk	risk	NN
cord-286132-ag2l1xa7	77	4	of	of	IN
cord-286132-ag2l1xa7	77	5	ILD	ILD	NNP
cord-286132-ag2l1xa7	77	6	was	be	VBD
cord-286132-ag2l1xa7	77	7	not	not	RB
cord-286132-ag2l1xa7	77	8	significantly	significantly	RB
cord-286132-ag2l1xa7	77	9	increased	increase	VBN
cord-286132-ag2l1xa7	77	10	in	in	IN
cord-286132-ag2l1xa7	77	11	the	the	DT
cord-286132-ag2l1xa7	77	12	treatment	treatment	NN
cord-286132-ag2l1xa7	77	13	group	group	NN
cord-286132-ag2l1xa7	77	14	(	(	-LRB-
cord-286132-ag2l1xa7	77	15	MH	MH	NNP
cord-286132-ag2l1xa7	77	16	13	13	CD
cord-286132-ag2l1xa7	77	17	RD	RD	NNP
cord-286132-ag2l1xa7	77	18	0	0	CD
cord-286132-ag2l1xa7	77	19	,	,	,
cord-286132-ag2l1xa7	77	20	95	95	CD
cord-286132-ag2l1xa7	77	21	%	%	NN
cord-286132-ag2l1xa7	78	1	CI	CI	NNP
cord-286132-ag2l1xa7	78	2	-0.002	-0.002	NNP
cord-286132-ag2l1xa7	78	3	-	-	HYPH
cord-286132-ag2l1xa7	78	4	0.002	0.002	NNP
cord-286132-ag2l1xa7	78	5	,	,	,
cord-286132-ag2l1xa7	78	6	P	p	NN
cord-286132-ag2l1xa7	78	7	=	=	SYM
cord-286132-ag2l1xa7	78	8	0.99	0.99	CD
cord-286132-ag2l1xa7	78	9	)	)	-RRB-
cord-286132-ag2l1xa7	79	1	(	(	-LRB-
cord-286132-ag2l1xa7	79	2	Figure	figure	NN
cord-286132-ag2l1xa7	79	3	4	4	CD
cord-286132-ag2l1xa7	79	4	)	)	-RRB-
cord-286132-ag2l1xa7	79	5	.	.	.
cord-286132-ag2l1xa7	80	1	Heterogeneity	heterogeneity	NN
cord-286132-ag2l1xa7	80	2	was	be	VBD
cord-286132-ag2l1xa7	80	3	absent	absent	JJ
cord-286132-ag2l1xa7	81	1	(	(	-LRB-
cord-286132-ag2l1xa7	81	2	I	i	NN
cord-286132-ag2l1xa7	81	3	2	2	CD
cord-286132-ag2l1xa7	81	4	=	=	SYM
cord-286132-ag2l1xa7	81	5	0	0	CD
cord-286132-ag2l1xa7	81	6	%	%	NN
cord-286132-ag2l1xa7	81	7	)	)	-RRB-
cord-286132-ag2l1xa7	81	8	.	.	.
cord-286132-ag2l1xa7	82	1	Begg	Begg	NNP
cord-286132-ag2l1xa7	82	2	's	's	POS
cord-286132-ag2l1xa7	82	3	(	(	-LRB-
cord-286132-ag2l1xa7	82	4	P	p	NN
cord-286132-ag2l1xa7	82	5	<	<	XX
cord-286132-ag2l1xa7	82	6	0.001	0.001	CD
cord-286132-ag2l1xa7	82	7	)	)	-RRB-
cord-286132-ag2l1xa7	82	8	,	,	,
cord-286132-ag2l1xa7	82	9	but	but	CC
cord-286132-ag2l1xa7	82	10	14	14	CD
cord-286132-ag2l1xa7	82	11	not	not	RB
cord-286132-ag2l1xa7	82	12	Egger	Egger	NNP
cord-286132-ag2l1xa7	82	13	's	's	POS
cord-286132-ag2l1xa7	82	14	(	(	-LRB-
cord-286132-ag2l1xa7	82	15	P	p	NN
cord-286132-ag2l1xa7	82	16	=	=	SYM
cord-286132-ag2l1xa7	82	17	0.69	0.69	CD
cord-286132-ag2l1xa7	82	18	)	)	-RRB-
cord-286132-ag2l1xa7	82	19	,	,	,
cord-286132-ag2l1xa7	82	20	test	test	NN
cord-286132-ag2l1xa7	82	21	was	be	VBD
cord-286132-ag2l1xa7	82	22	suggestive	suggestive	JJ
cord-286132-ag2l1xa7	82	23	of	of	IN
cord-286132-ag2l1xa7	82	24	publication	publication	NN
cord-286132-ag2l1xa7	82	25	bias	bias	NN
cord-286132-ag2l1xa7	82	26	,	,	,
cord-286132-ag2l1xa7	82	27	but	but	CC
cord-286132-ag2l1xa7	82	28	the	the	DT
cord-286132-ag2l1xa7	82	29	funnel	funnel	NN
cord-286132-ag2l1xa7	82	30	plot	plot	NN
cord-286132-ag2l1xa7	82	31	was	be	VBD
cord-286132-ag2l1xa7	82	32	not	not	RB
cord-286132-ag2l1xa7	82	33	asymmetric	asymmetric	JJ
cord-286132-ag2l1xa7	83	1	(	(	-LRB-
cord-286132-ag2l1xa7	83	2	The	the	DT
cord-286132-ag2l1xa7	83	3	sensitivity	sensitivity	NN
cord-286132-ag2l1xa7	83	4	analysis	analysis	NN
cord-286132-ag2l1xa7	83	5	revealed	reveal	VBD
cord-286132-ag2l1xa7	83	6	consistent	consistent	JJ
cord-286132-ag2l1xa7	83	7	results	result	NNS
cord-286132-ag2l1xa7	83	8	(	(	-LRB-
cord-286132-ag2l1xa7	83	9	Table	Table	NNP
cord-286132-ag2l1xa7	83	10	S1	S1	NNP
cord-286132-ag2l1xa7	83	11	-	-	HYPH
cord-286132-ag2l1xa7	83	12	2	2	CD
cord-286132-ag2l1xa7	83	13	,	,	,
cord-286132-ag2l1xa7	83	14	S4	S4	NNP
cord-286132-ag2l1xa7	83	15	-	-	HYPH
cord-286132-ag2l1xa7	83	16	5	5	CD
cord-286132-ag2l1xa7	83	17	,	,	,
cord-286132-ag2l1xa7	83	18	S6	S6	NNP
cord-286132-ag2l1xa7	83	19	,	,	,
cord-286132-ag2l1xa7	83	20	S8	S8	NNP
cord-286132-ag2l1xa7	83	21	)	)	-RRB-
cord-286132-ag2l1xa7	83	22	except	except	IN
cord-286132-ag2l1xa7	83	23	the	the	DT
cord-286132-ag2l1xa7	83	24	analysis	analysis	NN
cord-286132-ag2l1xa7	83	25	17	17	CD
cord-286132-ag2l1xa7	83	26	with	with	IN
cord-286132-ag2l1xa7	83	27	0.5	0.5	CD
cord-286132-ag2l1xa7	83	28	constant	constant	JJ
cord-286132-ag2l1xa7	83	29	correction	correction	NN
cord-286132-ag2l1xa7	83	30	of	of	IN
cord-286132-ag2l1xa7	83	31	zero	zero	CD
cord-286132-ag2l1xa7	83	32	-	-	HYPH
cord-286132-ag2l1xa7	83	33	event	event	NN
cord-286132-ag2l1xa7	83	34	studies	study	NNS
cord-286132-ag2l1xa7	83	35	showed	show	VBD
cord-286132-ag2l1xa7	83	36	a	a	DT
cord-286132-ag2l1xa7	83	37	lower	low	JJR
cord-286132-ag2l1xa7	83	38	risk	risk	NN
cord-286132-ag2l1xa7	83	39	of	of	IN
cord-286132-ag2l1xa7	83	40	infectious	infectious	JJ
cord-286132-ag2l1xa7	83	41	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	83	42	(	(	-LRB-
cord-286132-ag2l1xa7	83	43	Table	Table	NNP
cord-286132-ag2l1xa7	83	44	S3	S3	NNP
cord-286132-ag2l1xa7	83	45	)	)	-RRB-
cord-286132-ag2l1xa7	83	46	and	and	CC
cord-286132-ag2l1xa7	83	47	Based	base	VBN
cord-286132-ag2l1xa7	83	48	on	on	IN
cord-286132-ag2l1xa7	83	49	the	the	DT
cord-286132-ag2l1xa7	83	50	GRADE	grade	NN
cord-286132-ag2l1xa7	83	51	,	,	,
cord-286132-ag2l1xa7	83	52	an	an	DT
cord-286132-ag2l1xa7	83	53	overall	overall	JJ
cord-286132-ag2l1xa7	83	54	quality	quality	NN
cord-286132-ag2l1xa7	83	55	of	of	IN
cord-286132-ag2l1xa7	83	56	evidence	evidence	NN
cord-286132-ag2l1xa7	83	57	for	for	IN
cord-286132-ag2l1xa7	83	58	this	this	DT
cord-286132-ag2l1xa7	83	59	analysis	analysis	NN
cord-286132-ag2l1xa7	83	60	was	be	VBD
cord-286132-ag2l1xa7	83	61	moderate	moderate	JJ
cord-286132-ag2l1xa7	83	62	as	as	RB
cord-286132-ag2l1xa7	83	63	infectious	infectious	JJ
cord-286132-ag2l1xa7	83	64	3	3	CD
cord-286132-ag2l1xa7	83	65	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	83	66	and	and	CC
cord-286132-ag2l1xa7	83	67	ILD	ILD	NNP
cord-286132-ag2l1xa7	83	68	were	be	VBD
cord-286132-ag2l1xa7	83	69	rare	rare	JJ
cord-286132-ag2l1xa7	83	70	events	event	NNS
cord-286132-ag2l1xa7	83	71	(	(	-LRB-
cord-286132-ag2l1xa7	84	1	Tables	Tables	NNPS
cord-286132-ag2l1xa7	84	2	S9	S9	NNP
cord-286132-ag2l1xa7	84	3	and	and	CC
cord-286132-ag2l1xa7	84	4	S10	S10	NNP
cord-286132-ag2l1xa7	84	5	)	)	-RRB-
cord-286132-ag2l1xa7	84	6	.	.	.
cord-286132-ag2l1xa7	85	1	4	4	LS
cord-286132-ag2l1xa7	86	1	Our	-PRON-	PRP$
cord-286132-ag2l1xa7	86	2	meta	meta	JJ
cord-286132-ag2l1xa7	86	3	-	-	HYPH
cord-286132-ag2l1xa7	86	4	analysis	analysis	NN
cord-286132-ag2l1xa7	86	5	showed	show	VBD
cord-286132-ag2l1xa7	86	6	that	that	IN
cord-286132-ag2l1xa7	86	7	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	86	8	or	or	CC
cord-286132-ag2l1xa7	86	9	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	86	10	inhibitors	inhibitor	NNS
cord-286132-ag2l1xa7	86	11	increased	increase	VBD
cord-286132-ag2l1xa7	86	12	the	the	DT
cord-286132-ag2l1xa7	86	13	risk	risk	NN
cord-286132-ag2l1xa7	86	14	of	of	IN
cord-286132-ag2l1xa7	86	15	RTIs	rti	NNS
cord-286132-ag2l1xa7	86	16	,	,	,
cord-286132-ag2l1xa7	86	17	especially	especially	RB
cord-286132-ag2l1xa7	86	18	2	2	CD
cord-286132-ag2l1xa7	86	19	URTIs	urti	NNS
cord-286132-ag2l1xa7	86	20	,	,	,
cord-286132-ag2l1xa7	86	21	but	but	CC
cord-286132-ag2l1xa7	86	22	not	not	RB
cord-286132-ag2l1xa7	86	23	viral	viral	JJ
cord-286132-ag2l1xa7	86	24	URTIs	urti	NNS
cord-286132-ag2l1xa7	86	25	and	and	CC
cord-286132-ag2l1xa7	86	26	LRTIs	lrti	NNS
cord-286132-ag2l1xa7	86	27	,	,	,
cord-286132-ag2l1xa7	86	28	and	and	CC
cord-286132-ag2l1xa7	86	29	non	non	JJ
cord-286132-ag2l1xa7	86	30	-	-	JJ
cord-286132-ag2l1xa7	86	31	infectious	infectious	JJ
cord-286132-ag2l1xa7	86	32	ILD	ILD	NNP
cord-286132-ag2l1xa7	86	33	in	in	IN
cord-286132-ag2l1xa7	86	34	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	86	35	diseases	disease	NNS
cord-286132-ag2l1xa7	86	36	.	.	.
cord-286132-ag2l1xa7	87	1	3	3	LS
cord-286132-ag2l1xa7	88	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	88	2	found	find	VBD
cord-286132-ag2l1xa7	88	3	that	that	IN
cord-286132-ag2l1xa7	88	4	risankizumab	risankizumab	NN
cord-286132-ag2l1xa7	88	5	and	and	CC
cord-286132-ag2l1xa7	88	6	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	88	7	particularly	particularly	RB
cord-286132-ag2l1xa7	88	8	enhanced	enhance	VBD
cord-286132-ag2l1xa7	88	9	the	the	DT
cord-286132-ag2l1xa7	88	10	risk	risk	NN
cord-286132-ag2l1xa7	88	11	of	of	IN
cord-286132-ag2l1xa7	88	12	RTIs	rti	NNS
cord-286132-ag2l1xa7	88	13	and	and	CC
cord-286132-ag2l1xa7	88	14	4	4	CD
cord-286132-ag2l1xa7	88	15	hypothesized	hypothesize	VBD
cord-286132-ag2l1xa7	88	16	that	that	IN
cord-286132-ag2l1xa7	88	17	concomitant	concomitant	JJ
cord-286132-ag2l1xa7	88	18	therapies	therapy	NNS
cord-286132-ag2l1xa7	88	19	during	during	IN
cord-286132-ag2l1xa7	88	20	the	the	DT
cord-286132-ag2l1xa7	88	21	trials	trial	NNS
cord-286132-ag2l1xa7	88	22	might	may	MD
cord-286132-ag2l1xa7	88	23	differentiate	differentiate	VB
cord-286132-ag2l1xa7	88	24	the	the	DT
cord-286132-ag2l1xa7	88	25	risk	risk	NN
cord-286132-ag2l1xa7	88	26	of	of	IN
cord-286132-ag2l1xa7	88	27	RTIs	rti	NNS
cord-286132-ag2l1xa7	88	28	.	.	.
cord-286132-ag2l1xa7	89	1	In	in	IN
cord-286132-ag2l1xa7	89	2	terms	term	NNS
cord-286132-ag2l1xa7	89	3	of	of	IN
cord-286132-ag2l1xa7	89	4	5	5	CD
cord-286132-ag2l1xa7	89	5	anti	anti	NNP
cord-286132-ag2l1xa7	89	6	-	-	JJ
cord-286132-ag2l1xa7	89	7	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	89	8	agents	agent	NNS
cord-286132-ag2l1xa7	89	9	,	,	,
cord-286132-ag2l1xa7	89	10	risankizumab	risankizumab	NNS
cord-286132-ag2l1xa7	89	11	showed	show	VBD
cord-286132-ag2l1xa7	89	12	a	a	DT
cord-286132-ag2l1xa7	89	13	higher	high	JJR
cord-286132-ag2l1xa7	89	14	rate	rate	NN
cord-286132-ag2l1xa7	89	15	of	of	IN
cord-286132-ag2l1xa7	89	16	RCTs	rct	NNS
cord-286132-ag2l1xa7	89	17	which	which	WDT
cord-286132-ag2l1xa7	89	18	permitted	permit	VBD
cord-286132-ag2l1xa7	89	19	concomitant	concomitant	JJ
cord-286132-ag2l1xa7	89	20	therapies	therapy	NNS
cord-286132-ag2l1xa7	89	21	(	(	-LRB-
cord-286132-ag2l1xa7	89	22	40.0	40.0	CD
cord-286132-ag2l1xa7	89	23	%	%	NN
cord-286132-ag2l1xa7	89	24	)	)	-RRB-
cord-286132-ag2l1xa7	89	25	6	6	CD
cord-286132-ag2l1xa7	89	26	compared	compare	VBN
cord-286132-ag2l1xa7	89	27	with	with	IN
cord-286132-ag2l1xa7	89	28	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	89	29	(	(	-LRB-
cord-286132-ag2l1xa7	89	30	0	0	CD
cord-286132-ag2l1xa7	89	31	%	%	NN
cord-286132-ag2l1xa7	89	32	)	)	-RRB-
cord-286132-ag2l1xa7	89	33	and	and	CC
cord-286132-ag2l1xa7	89	34	tildrakizumab	tildrakizumab	NNP
cord-286132-ag2l1xa7	89	35	(	(	-LRB-
cord-286132-ag2l1xa7	89	36	0	0	CD
cord-286132-ag2l1xa7	89	37	%	%	NN
cord-286132-ag2l1xa7	89	38	)	)	-RRB-
cord-286132-ag2l1xa7	89	39	.	.	.
cord-286132-ag2l1xa7	90	1	Among	among	IN
cord-286132-ag2l1xa7	90	2	RCTs	rct	NNS
cord-286132-ag2l1xa7	90	3	of	of	IN
cord-286132-ag2l1xa7	90	4	risankizumab	risankizumab	NNP
cord-286132-ag2l1xa7	90	5	,	,	,
cord-286132-ag2l1xa7	90	6	the	the	DT
cord-286132-ag2l1xa7	90	7	only	only	JJ
cord-286132-ag2l1xa7	90	8	study	study	NN
cord-286132-ag2l1xa7	90	9	7	7	CD
cord-286132-ag2l1xa7	90	10	reporting	report	VBG
cord-286132-ag2l1xa7	90	11	an	an	DT
cord-286132-ag2l1xa7	90	12	increased	increase	VBN
cord-286132-ag2l1xa7	90	13	risk	risk	NN
cord-286132-ag2l1xa7	90	14	of	of	IN
cord-286132-ag2l1xa7	90	15	RTIs	rti	NNS
cord-286132-ag2l1xa7	90	16	was	be	VBD
cord-286132-ag2l1xa7	90	17	performed	perform	VBN
cord-286132-ag2l1xa7	90	18	in	in	IN
cord-286132-ag2l1xa7	90	19	patients	patient	NNS
cord-286132-ag2l1xa7	90	20	with	with	IN
cord-286132-ag2l1xa7	90	21	ankylosing	ankylosing	NNP
cord-286132-ag2l1xa7	90	22	spondylitis	spondylitis	NN
cord-286132-ag2l1xa7	90	23	who	who	WP
cord-286132-ag2l1xa7	90	24	were	be	VBD
cord-286132-ag2l1xa7	90	25	permitted	permit	VBN
cord-286132-ag2l1xa7	90	26	8	8	CD
cord-286132-ag2l1xa7	90	27	to	to	TO
cord-286132-ag2l1xa7	90	28	use	use	VB
cord-286132-ag2l1xa7	90	29	conventional	conventional	JJ
cord-286132-ag2l1xa7	90	30	disease	disease	NN
cord-286132-ag2l1xa7	90	31	-	-	HYPH
cord-286132-ag2l1xa7	90	32	modifying	modify	VBG
cord-286132-ag2l1xa7	90	33	antirheumatic	antirheumatic	JJ
cord-286132-ag2l1xa7	90	34	drugs	drug	NNS
cord-286132-ag2l1xa7	90	35	or	or	CC
cord-286132-ag2l1xa7	90	36	low	low	JJ
cord-286132-ag2l1xa7	90	37	-	-	HYPH
cord-286132-ag2l1xa7	90	38	dose	dose	NN
cord-286132-ag2l1xa7	90	39	systemic	systemic	JJ
cord-286132-ag2l1xa7	90	40	steroids	steroid	NNS
cord-286132-ag2l1xa7	90	41	.	.	.
cord-286132-ag2l1xa7	91	1	36	36	CD
cord-286132-ag2l1xa7	92	1	This	this	DT
cord-286132-ag2l1xa7	92	2	suggests	suggest	VBZ
cord-286132-ag2l1xa7	92	3	that	that	IN
cord-286132-ag2l1xa7	92	4	9	9	CD
cord-286132-ag2l1xa7	92	5	combination	combination	NN
cord-286132-ag2l1xa7	92	6	therapy	therapy	NN
cord-286132-ag2l1xa7	92	7	of	of	IN
cord-286132-ag2l1xa7	92	8	anti	anti	NNP
cord-286132-ag2l1xa7	92	9	-	-	JJ
cord-286132-ag2l1xa7	92	10	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	92	11	agents	agent	NNS
cord-286132-ag2l1xa7	92	12	with	with	IN
cord-286132-ag2l1xa7	92	13	immunosuppressants	immunosuppressant	NNS
cord-286132-ag2l1xa7	92	14	might	may	MD
cord-286132-ag2l1xa7	92	15	work	work	VB
cord-286132-ag2l1xa7	92	16	synergistically	synergistically	RB
cord-286132-ag2l1xa7	92	17	to	to	TO
cord-286132-ag2l1xa7	92	18	surface	surface	VB
cord-286132-ag2l1xa7	92	19	the	the	DT
cord-286132-ag2l1xa7	92	20	10	10	CD
cord-286132-ag2l1xa7	92	21	risk	risk	NN
cord-286132-ag2l1xa7	92	22	of	of	IN
cord-286132-ag2l1xa7	92	23	RTIs	rti	NNS
cord-286132-ag2l1xa7	92	24	.	.	.
cord-286132-ag2l1xa7	93	1	As	as	IN
cord-286132-ag2l1xa7	93	2	for	for	IN
cord-286132-ag2l1xa7	93	3	anti	anti	JJ
cord-286132-ag2l1xa7	93	4	-	-	JJ
cord-286132-ag2l1xa7	93	5	IL-12	IL-12	NNP
cord-286132-ag2l1xa7	93	6	/	/	SYM
cord-286132-ag2l1xa7	93	7	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	93	8	agents	agent	NNS
cord-286132-ag2l1xa7	93	9	,	,	,
cord-286132-ag2l1xa7	93	10	each	each	DT
cord-286132-ag2l1xa7	93	11	of	of	IN
cord-286132-ag2l1xa7	93	12	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	93	13	and	and	CC
cord-286132-ag2l1xa7	93	14	ustekinumab	ustekinumab	NNP
cord-286132-ag2l1xa7	93	15	has	have	VBZ
cord-286132-ag2l1xa7	93	16	a	a	DT
cord-286132-ag2l1xa7	93	17	similar	similar	JJ
cord-286132-ag2l1xa7	93	18	percentage	percentage	NN
cord-286132-ag2l1xa7	93	19	of	of	IN
cord-286132-ag2l1xa7	93	20	11	11	CD
cord-286132-ag2l1xa7	93	21	RCTs	rct	NNS
cord-286132-ag2l1xa7	93	22	which	which	WDT
cord-286132-ag2l1xa7	93	23	permitted	permit	VBD
cord-286132-ag2l1xa7	93	24	concomitant	concomitant	JJ
cord-286132-ag2l1xa7	93	25	drugs	drug	NNS
cord-286132-ag2l1xa7	93	26	(	(	-LRB-
cord-286132-ag2l1xa7	93	27	37.5	37.5	CD
cord-286132-ag2l1xa7	93	28	%	%	NN
cord-286132-ag2l1xa7	93	29	for	for	IN
cord-286132-ag2l1xa7	93	30	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	93	31	and	and	CC
cord-286132-ag2l1xa7	93	32	38.5	38.5	CD
cord-286132-ag2l1xa7	93	33	%	%	NN
cord-286132-ag2l1xa7	93	34	for	for	IN
cord-286132-ag2l1xa7	93	35	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	93	36	)	)	-RRB-
cord-286132-ag2l1xa7	93	37	.	.	.
cord-286132-ag2l1xa7	94	1	Other	other	JJ
cord-286132-ag2l1xa7	94	2	12	12	CD
cord-286132-ag2l1xa7	94	3	potential	potential	JJ
cord-286132-ag2l1xa7	94	4	risk	risk	NN
cord-286132-ag2l1xa7	94	5	factors	factor	NNS
cord-286132-ag2l1xa7	94	6	such	such	JJ
cord-286132-ag2l1xa7	94	7	as	as	IN
cord-286132-ag2l1xa7	94	8	age	age	NN
cord-286132-ag2l1xa7	94	9	and	and	CC
cord-286132-ag2l1xa7	94	10	sex	sex	NN
cord-286132-ag2l1xa7	94	11	were	be	VBD
cord-286132-ag2l1xa7	94	12	not	not	RB
cord-286132-ag2l1xa7	94	13	different	different	JJ
cord-286132-ag2l1xa7	94	14	among	among	IN
cord-286132-ag2l1xa7	94	15	the	the	DT
cord-286132-ag2l1xa7	94	16	drugs	drug	NNS
cord-286132-ag2l1xa7	94	17	.	.	.
cord-286132-ag2l1xa7	95	1	Given	give	VBN
cord-286132-ag2l1xa7	95	2	that	that	DT
cord-286132-ag2l1xa7	95	3	briakinumab	briakinumab	NN
cord-286132-ag2l1xa7	95	4	has	have	VBZ
cord-286132-ag2l1xa7	95	5	13	13	CD
cord-286132-ag2l1xa7	95	6	been	be	VBN
cord-286132-ag2l1xa7	95	7	withdrawn	withdraw	VBN
cord-286132-ag2l1xa7	95	8	from	from	IN
cord-286132-ag2l1xa7	95	9	the	the	DT
cord-286132-ag2l1xa7	95	10	application	application	NN
cord-286132-ag2l1xa7	95	11	with	with	IN
cord-286132-ag2l1xa7	95	12	FDA	FDA	NNP
cord-286132-ag2l1xa7	95	13	due	due	JJ
cord-286132-ag2l1xa7	95	14	to	to	IN
cord-286132-ag2l1xa7	95	15	severe	severe	JJ
cord-286132-ag2l1xa7	95	16	adverse	adverse	JJ
cord-286132-ag2l1xa7	95	17	events	event	NNS
cord-286132-ag2l1xa7	95	18	,	,	,
cord-286132-ag2l1xa7	95	19	1	1	CD
cord-286132-ag2l1xa7	95	20	the	the	DT
cord-286132-ag2l1xa7	95	21	difference	difference	NN
cord-286132-ag2l1xa7	95	22	in	in	IN
cord-286132-ag2l1xa7	95	23	risk	risk	NN
cord-286132-ag2l1xa7	95	24	of	of	IN
cord-286132-ag2l1xa7	95	25	RTIs	rti	NNS
cord-286132-ag2l1xa7	95	26	14	14	CD
cord-286132-ag2l1xa7	95	27	among	among	IN
cord-286132-ag2l1xa7	95	28	two	two	CD
cord-286132-ag2l1xa7	95	29	drugs	drug	NNS
cord-286132-ag2l1xa7	95	30	would	would	MD
cord-286132-ag2l1xa7	95	31	be	be	VB
cord-286132-ag2l1xa7	95	32	explained	explain	VBN
cord-286132-ag2l1xa7	95	33	by	by	IN
cord-286132-ag2l1xa7	95	34	different	different	JJ
cord-286132-ag2l1xa7	95	35	properties	property	NNS
cord-286132-ag2l1xa7	95	36	of	of	IN
cord-286132-ag2l1xa7	95	37	these	these	DT
cord-286132-ag2l1xa7	95	38	drugs	drug	NNS
cord-286132-ag2l1xa7	95	39	.	.	.
cord-286132-ag2l1xa7	96	1	15	15	CD
cord-286132-ag2l1xa7	97	1	Our	-PRON-	PRP$
cord-286132-ag2l1xa7	97	2	study	study	NN
cord-286132-ag2l1xa7	97	3	might	may	MD
cord-286132-ag2l1xa7	97	4	support	support	VB
cord-286132-ag2l1xa7	97	5	that	that	IN
cord-286132-ag2l1xa7	97	6	anti	anti	NNS
cord-286132-ag2l1xa7	97	7	-	-	JJ
cord-286132-ag2l1xa7	97	8	IL-12/23	il-12/23	JJ
cord-286132-ag2l1xa7	97	9	and	and	CC
cord-286132-ag2l1xa7	97	10	anti	anti	JJ
cord-286132-ag2l1xa7	97	11	-	-	JJ
cord-286132-ag2l1xa7	97	12	IL-23	il-23	JJ
cord-286132-ag2l1xa7	97	13	therapies	therapy	NNS
cord-286132-ag2l1xa7	97	14	can	can	MD
cord-286132-ag2l1xa7	97	15	be	be	VB
cord-286132-ag2l1xa7	97	16	safely	safely	RB
cord-286132-ag2l1xa7	97	17	used	use	VBN
cord-286132-ag2l1xa7	97	18	for	for	IN
cord-286132-ag2l1xa7	97	19	16	16	CD
cord-286132-ag2l1xa7	97	20	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	97	21	diseases	disease	NNS
cord-286132-ag2l1xa7	97	22	even	even	RB
cord-286132-ag2l1xa7	97	23	during	during	IN
cord-286132-ag2l1xa7	97	24	the	the	DT
cord-286132-ag2l1xa7	97	25	current	current	JJ
cord-286132-ag2l1xa7	97	26	COVID-19	COVID-19	NNP
cord-286132-ag2l1xa7	97	27	pandemic	pandemic	NN
cord-286132-ag2l1xa7	97	28	.	.	.
cord-286132-ag2l1xa7	98	1	However	however	RB
cord-286132-ag2l1xa7	98	2	,	,	,
cord-286132-ag2l1xa7	98	3	given	give	VBN
cord-286132-ag2l1xa7	98	4	that	that	IN
cord-286132-ag2l1xa7	98	5	influenza	influenza	NN
cord-286132-ag2l1xa7	98	6	Respiratory	Respiratory	NNP
cord-286132-ag2l1xa7	98	7	Syndrome	Syndrome	NNP
cord-286132-ag2l1xa7	98	8	coronavirus	coronavirus	NN
cord-286132-ag2l1xa7	98	9	showed	show	VBD
cord-286132-ag2l1xa7	98	10	that	that	IN
cord-286132-ag2l1xa7	98	11	a	a	DT
cord-286132-ag2l1xa7	98	12	patient	patient	NN
cord-286132-ag2l1xa7	98	13	with	with	IN
cord-286132-ag2l1xa7	98	14	a	a	DT
cord-286132-ag2l1xa7	98	15	poor	poor	JJ
cord-286132-ag2l1xa7	98	16	outcome	outcome	NN
cord-286132-ag2l1xa7	98	17	had	have	VBD
cord-286132-ag2l1xa7	98	18	an	an	DT
cord-286132-ag2l1xa7	98	19	increased	increase	VBN
cord-286132-ag2l1xa7	98	20	level	level	NN
cord-286132-ag2l1xa7	98	21	of	of	IN
cord-286132-ag2l1xa7	98	22	IL-	il-	CD
cord-286132-ag2l1xa7	98	23	17	17	CD
cord-286132-ag2l1xa7	98	24	15	15	CD
cord-286132-ag2l1xa7	98	25	expression	expression	NN
cord-286132-ag2l1xa7	98	26	in	in	IN
cord-286132-ag2l1xa7	98	27	the	the	DT
cord-286132-ag2l1xa7	98	28	lung	lung	NN
cord-286132-ag2l1xa7	98	29	.	.	.
cord-286132-ag2l1xa7	99	1	41	41	CD
cord-286132-ag2l1xa7	100	1	These	these	DT
cord-286132-ag2l1xa7	100	2	data	datum	NNS
cord-286132-ag2l1xa7	100	3	suggest	suggest	VBP
cord-286132-ag2l1xa7	100	4	that	that	IN
cord-286132-ag2l1xa7	100	5	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	100	6	or	or	CC
cord-286132-ag2l1xa7	100	7	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	100	8	inhibitors	inhibitor	NNS
cord-286132-ag2l1xa7	100	9	might	may	MD
cord-286132-ag2l1xa7	100	10	theoretically	theoretically	RB
cord-286132-ag2l1xa7	100	11	be	be	VB
cord-286132-ag2l1xa7	100	12	preventive	preventive	JJ
cord-286132-ag2l1xa7	100	13	16	16	CD
cord-286132-ag2l1xa7	100	14	for	for	IN
cord-286132-ag2l1xa7	100	15	SARS	SARS	NNP
cord-286132-ag2l1xa7	100	16	-	-	HYPH
cord-286132-ag2l1xa7	100	17	CoV-2-induced	cov-2-induce	VBN
cord-286132-ag2l1xa7	100	18	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	100	19	rather	rather	RB
cord-286132-ag2l1xa7	100	20	than	than	IN
cord-286132-ag2l1xa7	100	21	detrimental	detrimental	JJ
cord-286132-ag2l1xa7	100	22	in	in	IN
cord-286132-ag2l1xa7	100	23	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	100	24	diseases	disease	NNS
cord-286132-ag2l1xa7	100	25	during	during	IN
cord-286132-ag2l1xa7	100	26	the	the	DT
cord-286132-ag2l1xa7	100	27	COVID-	covid-	NN
cord-286132-ag2l1xa7	100	28	19	19	CD
cord-286132-ag2l1xa7	100	29	17	17	CD
cord-286132-ag2l1xa7	100	30	pandemic	pandemic	NN
cord-286132-ag2l1xa7	100	31	.	.	.
cord-286132-ag2l1xa7	101	1	18	18	CD
cord-286132-ag2l1xa7	102	1	First	first	RB
cord-286132-ag2l1xa7	102	2	,	,	,
cord-286132-ag2l1xa7	102	3	this	this	DT
cord-286132-ag2l1xa7	102	4	study	study	NN
cord-286132-ag2l1xa7	102	5	did	do	VBD
cord-286132-ag2l1xa7	102	6	not	not	RB
cord-286132-ag2l1xa7	102	7	assess	assess	VB
cord-286132-ag2l1xa7	102	8	the	the	DT
cord-286132-ag2l1xa7	102	9	long	long	JJ
cord-286132-ag2l1xa7	102	10	-	-	HYPH
cord-286132-ag2l1xa7	102	11	term	term	NN
cord-286132-ag2l1xa7	102	12	effect	effect	NN
cord-286132-ag2l1xa7	102	13	of	of	IN
cord-286132-ag2l1xa7	102	14	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	102	15	or	or	CC
cord-286132-ag2l1xa7	102	16	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	102	17	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	102	18	on	on	IN
cord-286132-ag2l1xa7	102	19	RTIs	rti	NNS
cord-286132-ag2l1xa7	102	20	and	and	CC
cord-286132-ag2l1xa7	102	21	2	2	CD
cord-286132-ag2l1xa7	102	22	ILD	ILD	NNP
cord-286132-ag2l1xa7	102	23	.	.	.
cord-286132-ag2l1xa7	103	1	However	however	RB
cord-286132-ag2l1xa7	103	2	,	,	,
cord-286132-ag2l1xa7	103	3	92.6	92.6	CD
cord-286132-ag2l1xa7	103	4	%	%	NN
cord-286132-ag2l1xa7	103	5	(	(	-LRB-
cord-286132-ag2l1xa7	103	6	50/54	50/54	CD
cord-286132-ag2l1xa7	103	7	)	)	-RRB-
cord-286132-ag2l1xa7	103	8	of	of	IN
cord-286132-ag2l1xa7	103	9	included	include	VBN
cord-286132-ag2l1xa7	103	10	studies	study	NNS
cord-286132-ag2l1xa7	103	11	reported	report	VBD
cord-286132-ag2l1xa7	103	12	RTIs	rti	NNS
cord-286132-ag2l1xa7	103	13	during	during	IN
cord-286132-ag2l1xa7	103	14	placebo	placebo	NN
cord-286132-ag2l1xa7	103	15	-	-	HYPH
cord-286132-ag2l1xa7	103	16	controlled	control	VBN
cord-286132-ag2l1xa7	103	17	phases	phase	NNS
cord-286132-ag2l1xa7	103	18	.	.	.
cord-286132-ag2l1xa7	104	1	FDA	FDA	NNP
cord-286132-ag2l1xa7	104	2	3	3	CD
cord-286132-ag2l1xa7	104	3	reported	report	VBD
cord-286132-ag2l1xa7	104	4	the	the	DT
cord-286132-ag2l1xa7	104	5	onset	onset	NN
cord-286132-ag2l1xa7	104	6	of	of	IN
cord-286132-ag2l1xa7	104	7	ILD	ILD	NNP
cord-286132-ag2l1xa7	104	8	was	be	VBD
cord-286132-ag2l1xa7	104	9	acute	acute	JJ
cord-286132-ag2l1xa7	104	10	or	or	CC
cord-286132-ag2l1xa7	104	11	subacute	subacute	JJ
cord-286132-ag2l1xa7	104	12	,	,	,
cord-286132-ag2l1xa7	105	1	14	14	CD
cord-286132-ag2l1xa7	105	2	so	so	RB
cord-286132-ag2l1xa7	105	3	our	-PRON-	PRP$
cord-286132-ag2l1xa7	105	4	data	datum	NNS
cord-286132-ag2l1xa7	105	5	would	would	MD
cord-286132-ag2l1xa7	105	6	most	most	RBS
cord-286132-ag2l1xa7	105	7	likely	likely	RB
cord-286132-ag2l1xa7	105	8	include	include	VB
cord-286132-ag2l1xa7	105	9	the	the	DT
cord-286132-ag2l1xa7	105	10	incidence	incidence	NN
cord-286132-ag2l1xa7	105	11	of	of	IN
cord-286132-ag2l1xa7	105	12	these	these	DT
cord-286132-ag2l1xa7	105	13	4	4	CD
cord-286132-ag2l1xa7	105	14	events	event	NNS
cord-286132-ag2l1xa7	105	15	.	.	.
cord-286132-ag2l1xa7	106	1	Second	second	RB
cord-286132-ag2l1xa7	106	2	,	,	,
cord-286132-ag2l1xa7	106	3	regarding	regard	VBG
cord-286132-ag2l1xa7	106	4	infectious	infectious	JJ
cord-286132-ag2l1xa7	106	5	pneumonia	pneumonia	NN
cord-286132-ag2l1xa7	106	6	and	and	CC
cord-286132-ag2l1xa7	106	7	ILD	ILD	NNP
cord-286132-ag2l1xa7	106	8	,	,	,
cord-286132-ag2l1xa7	106	9	many	many	JJ
cord-286132-ag2l1xa7	106	10	studies	study	NNS
cord-286132-ag2l1xa7	106	11	had	have	VBD
cord-286132-ag2l1xa7	106	12	both	both	DT
cord-286132-ag2l1xa7	106	13	-	-	HYPH
cord-286132-ag2l1xa7	106	14	armed	armed	JJ
cord-286132-ag2l1xa7	106	15	zero	zero	CD
cord-286132-ag2l1xa7	106	16	-	-	HYPH
cord-286132-ag2l1xa7	106	17	event	event	NN
cord-286132-ag2l1xa7	106	18	(	(	-LRB-
cord-286132-ag2l1xa7	106	19	87	87	CD
cord-286132-ag2l1xa7	106	20	%	%	NN
cord-286132-ag2l1xa7	106	21	5	5	CD
cord-286132-ag2l1xa7	106	22	(	(	-LRB-
cord-286132-ag2l1xa7	106	23	47/54	47/54	CD
cord-286132-ag2l1xa7	106	24	)	)	-RRB-
cord-286132-ag2l1xa7	106	25	and	and	CC
cord-286132-ag2l1xa7	106	26	94	94	CD
cord-286132-ag2l1xa7	106	27	%	%	NN
cord-286132-ag2l1xa7	106	28	(	(	-LRB-
cord-286132-ag2l1xa7	106	29	51/54	51/54	CD
cord-286132-ag2l1xa7	106	30	)	)	-RRB-
cord-286132-ag2l1xa7	106	31	,	,	,
cord-286132-ag2l1xa7	106	32	respectively	respectively	RB
cord-286132-ag2l1xa7	106	33	)	)	-RRB-
cord-286132-ag2l1xa7	106	34	.	.	.
cord-286132-ag2l1xa7	107	1	Thus	thus	RB
cord-286132-ag2l1xa7	107	2	,	,	,
cord-286132-ag2l1xa7	107	3	we	-PRON-	PRP
cord-286132-ag2l1xa7	107	4	undertook	undertake	VBD
cord-286132-ag2l1xa7	107	5	comprehensive	comprehensive	JJ
cord-286132-ag2l1xa7	107	6	analyses	analysis	NNS
cord-286132-ag2l1xa7	107	7	that	that	WDT
cord-286132-ag2l1xa7	107	8	either	either	CC
cord-286132-ag2l1xa7	107	9	included	include	VBD
cord-286132-ag2l1xa7	107	10	or	or	CC
cord-286132-ag2l1xa7	107	11	6	6	CD
cord-286132-ag2l1xa7	107	12	excluded	exclude	VBN
cord-286132-ag2l1xa7	107	13	double	double	JJ
cord-286132-ag2l1xa7	107	14	-	-	HYPH
cord-286132-ag2l1xa7	107	15	zero	zero	CD
cord-286132-ag2l1xa7	107	16	-	-	HYPH
cord-286132-ag2l1xa7	107	17	event	event	NN
cord-286132-ag2l1xa7	107	18	studies	study	NNS
cord-286132-ag2l1xa7	107	19	.	.	.
cord-286132-ag2l1xa7	108	1	The	the	DT
cord-286132-ag2l1xa7	108	2	analysis	analysis	NN
cord-286132-ag2l1xa7	108	3	with	with	IN
cord-286132-ag2l1xa7	108	4	0.5	0.5	CD
cord-286132-ag2l1xa7	108	5	constant	constant	JJ
cord-286132-ag2l1xa7	108	6	correction	correction	NN
cord-286132-ag2l1xa7	108	7	showed	show	VBD
cord-286132-ag2l1xa7	108	8	a	a	DT
cord-286132-ag2l1xa7	108	9	lower	low	JJR
cord-286132-ag2l1xa7	108	10	risk	risk	NN
cord-286132-ag2l1xa7	108	11	of	of	IN
cord-286132-ag2l1xa7	108	12	these	these	DT
cord-286132-ag2l1xa7	108	13	7	7	CD
cord-286132-ag2l1xa7	108	14	events	event	NNS
cord-286132-ag2l1xa7	108	15	in	in	IN
cord-286132-ag2l1xa7	108	16	the	the	DT
cord-286132-ag2l1xa7	108	17	treatment	treatment	NN
cord-286132-ag2l1xa7	108	18	group	group	NN
cord-286132-ag2l1xa7	108	19	.	.	.
cord-286132-ag2l1xa7	109	1	We	-PRON-	PRP
cord-286132-ag2l1xa7	109	2	also	also	RB
cord-286132-ag2l1xa7	109	3	used	use	VBD
cord-286132-ag2l1xa7	109	4	treatment	treatment	NN
cord-286132-ag2l1xa7	109	5	arm	arm	NN
cord-286132-ag2l1xa7	109	6	correction	correction	NN
cord-286132-ag2l1xa7	109	7	because	because	IN
cord-286132-ag2l1xa7	109	8	this	this	DT
cord-286132-ag2l1xa7	109	9	method	method	NN
cord-286132-ag2l1xa7	109	10	performed	perform	VBN
cord-286132-ag2l1xa7	109	11	better	well	JJR
cord-286132-ag2l1xa7	109	12	8	8	CD
cord-286132-ag2l1xa7	109	13	than	than	IN
cord-286132-ag2l1xa7	109	14	0.5	0.5	CD
cord-286132-ag2l1xa7	109	15	constant	constant	JJ
cord-286132-ag2l1xa7	109	16	correction	correction	NN
cord-286132-ag2l1xa7	109	17	to	to	TO
cord-286132-ag2l1xa7	109	18	examine	examine	VB
cord-286132-ag2l1xa7	109	19	rare	rare	JJ
cord-286132-ag2l1xa7	109	20	events	event	NNS
cord-286132-ag2l1xa7	109	21	.	.	.
cord-286132-ag2l1xa7	110	1	46	46	CD
cord-286132-ag2l1xa7	110	2	Third	Third	NNP
cord-286132-ag2l1xa7	110	3	,	,	,
cord-286132-ag2l1xa7	110	4	our	-PRON-	PRP$
cord-286132-ag2l1xa7	110	5	study	study	NN
cord-286132-ag2l1xa7	110	6	may	may	MD
cord-286132-ag2l1xa7	110	7	not	not	RB
cord-286132-ag2l1xa7	110	8	reflect	reflect	VB
cord-286132-ag2l1xa7	110	9	the	the	DT
cord-286132-ag2l1xa7	110	10	risk	risk	NN
cord-286132-ag2l1xa7	110	11	in	in	IN
cord-286132-ag2l1xa7	110	12	patients	patient	NNS
cord-286132-ag2l1xa7	110	13	at	at	IN
cord-286132-ag2l1xa7	110	14	9	9	CD
cord-286132-ag2l1xa7	110	15	high	high	JJ
cord-286132-ag2l1xa7	110	16	risk	risk	NN
cord-286132-ag2l1xa7	110	17	for	for	IN
cord-286132-ag2l1xa7	110	18	RTIs	rti	NNS
cord-286132-ag2l1xa7	110	19	due	due	IN
cord-286132-ag2l1xa7	110	20	to	to	IN
cord-286132-ag2l1xa7	110	21	the	the	DT
cord-286132-ag2l1xa7	110	22	possible	possible	JJ
cord-286132-ag2l1xa7	110	23	exclusion	exclusion	NN
cord-286132-ag2l1xa7	110	24	of	of	IN
cord-286132-ag2l1xa7	110	25	patients	patient	NNS
cord-286132-ag2l1xa7	110	26	with	with	IN
cord-286132-ag2l1xa7	110	27	recent	recent	JJ
cord-286132-ag2l1xa7	110	28	RTIs	rti	NNS
cord-286132-ag2l1xa7	110	29	or	or	CC
cord-286132-ag2l1xa7	110	30	chronic	chronic	JJ
cord-286132-ag2l1xa7	110	31	lung	lung	NN
cord-286132-ag2l1xa7	110	32	disease	disease	NN
cord-286132-ag2l1xa7	110	33	in	in	IN
cord-286132-ag2l1xa7	110	34	clinical	clinical	JJ
cord-286132-ag2l1xa7	110	35	10	10	CD
cord-286132-ag2l1xa7	110	36	trials	trial	NNS
cord-286132-ag2l1xa7	110	37	.	.	.
cord-286132-ag2l1xa7	111	1	Fourth	fourth	RB
cord-286132-ag2l1xa7	111	2	,	,	,
cord-286132-ag2l1xa7	111	3	we	-PRON-	PRP
cord-286132-ag2l1xa7	111	4	categorized	categorize	VBD
cord-286132-ag2l1xa7	111	5	RTIs	rti	NNS
cord-286132-ag2l1xa7	111	6	into	into	IN
cord-286132-ag2l1xa7	111	7	URTIs	urti	NNS
cord-286132-ag2l1xa7	111	8	,	,	,
cord-286132-ag2l1xa7	111	9	viral	viral	JJ
cord-286132-ag2l1xa7	111	10	URTIs	urti	NNS
cord-286132-ag2l1xa7	111	11	,	,	,
cord-286132-ag2l1xa7	111	12	and	and	CC
cord-286132-ag2l1xa7	111	13	LRTIs	LRTIs	NNP
cord-286132-ag2l1xa7	111	14	based	base	VBN
cord-286132-ag2l1xa7	111	15	on	on	IN
cord-286132-ag2l1xa7	111	16	MedDRA	MedDRA	NNS
cord-286132-ag2l1xa7	111	17	which	which	WDT
cord-286132-ag2l1xa7	111	18	is	be	VBZ
cord-286132-ag2l1xa7	111	19	widely	widely	RB
cord-286132-ag2l1xa7	111	20	11	11	CD
cord-286132-ag2l1xa7	111	21	used	use	VBN
cord-286132-ag2l1xa7	111	22	in	in	IN
cord-286132-ag2l1xa7	111	23	clinical	clinical	JJ
cord-286132-ag2l1xa7	111	24	trials	trial	NNS
cord-286132-ag2l1xa7	111	25	,	,	,
cord-286132-ag2l1xa7	111	26	but	but	CC
cord-286132-ag2l1xa7	111	27	not	not	RB
cord-286132-ag2l1xa7	111	28	so	so	RB
cord-286132-ag2l1xa7	111	29	much	much	RB
cord-286132-ag2l1xa7	111	30	in	in	IN
cord-286132-ag2l1xa7	111	31	clinical	clinical	JJ
cord-286132-ag2l1xa7	111	32	research	research	NN
cord-286132-ag2l1xa7	111	33	.	.	.
cord-286132-ag2l1xa7	112	1	Furthermore	furthermore	RB
cord-286132-ag2l1xa7	112	2	,	,	,
cord-286132-ag2l1xa7	112	3	the	the	DT
cord-286132-ag2l1xa7	112	4	included	include	VBN
cord-286132-ag2l1xa7	112	5	studies	study	NNS
cord-286132-ag2l1xa7	112	6	have	have	VBP
cord-286132-ag2l1xa7	112	7	been	be	VBN
cord-286132-ag2l1xa7	112	8	12	12	CD
cord-286132-ag2l1xa7	112	9	conducted	conduct	VBN
cord-286132-ag2l1xa7	112	10	before	before	IN
cord-286132-ag2l1xa7	112	11	the	the	DT
cord-286132-ag2l1xa7	112	12	pandemic	pandemic	NN
cord-286132-ag2l1xa7	112	13	.	.	.
cord-286132-ag2l1xa7	113	1	Hence	hence	RB
cord-286132-ag2l1xa7	113	2	,	,	,
cord-286132-ag2l1xa7	113	3	it	-PRON-	PRP
cord-286132-ag2l1xa7	113	4	does	do	VBZ
cord-286132-ag2l1xa7	113	5	not	not	RB
cord-286132-ag2l1xa7	113	6	provide	provide	VB
cord-286132-ag2l1xa7	113	7	evidences	evidence	NNS
cord-286132-ag2l1xa7	113	8	whether	whether	IN
cord-286132-ag2l1xa7	113	9	there	there	EX
cord-286132-ag2l1xa7	113	10	is	be	VBZ
cord-286132-ag2l1xa7	113	11	an	an	DT
cord-286132-ag2l1xa7	113	12	increase	increase	NN
cord-286132-ag2l1xa7	113	13	in	in	IN
cord-286132-ag2l1xa7	113	14	RTIs	rti	NNS
cord-286132-ag2l1xa7	113	15	or	or	CC
cord-286132-ag2l1xa7	113	16	13	13	CD
cord-286132-ag2l1xa7	113	17	ILD	ILD	NNP
cord-286132-ag2l1xa7	113	18	during	during	IN
cord-286132-ag2l1xa7	113	19	the	the	DT
cord-286132-ag2l1xa7	113	20	pandemic	pandemic	NN
cord-286132-ag2l1xa7	113	21	in	in	IN
cord-286132-ag2l1xa7	113	22	patients	patient	NNS
cord-286132-ag2l1xa7	113	23	receiving	receive	VBG
cord-286132-ag2l1xa7	113	24	IL-12/23	il-12/23	NN
cord-286132-ag2l1xa7	113	25	or	or	CC
cord-286132-ag2l1xa7	113	26	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	113	27	antagonists	antagonist	NNS
cord-286132-ag2l1xa7	113	28	,	,	,
cord-286132-ag2l1xa7	113	29	nor	nor	CC
cord-286132-ag2l1xa7	113	30	whether	whether	IN
cord-286132-ag2l1xa7	113	31	these	these	DT
cord-286132-ag2l1xa7	113	32	agents	agent	NNS
cord-286132-ag2l1xa7	113	33	can	can	MD
cord-286132-ag2l1xa7	113	34	be	be	VB
cord-286132-ag2l1xa7	113	35	14	14	CD
cord-286132-ag2l1xa7	113	36	autoimmune	autoimmune	JJ
cord-286132-ag2l1xa7	113	37	diseases	disease	NNS
cord-286132-ag2l1xa7	113	38	is	be	VBZ
cord-286132-ag2l1xa7	113	39	needed	need	VBN
cord-286132-ag2l1xa7	113	40	.	.	.
cord-286132-ag2l1xa7	114	1	20	20	CD
cord-286132-ag2l1xa7	115	1	Nemoto	Nemoto	NNP
cord-286132-ag2l1xa7	115	2	et	et	NNP
cord-286132-ag2l1xa7	115	3	al	al	NNP
cord-286132-ag2l1xa7	115	4	2018	2018	CD
cord-286132-ag2l1xa7	115	5	48	48	CD
cord-286132-ag2l1xa7	115	6	Blauvelt	Blauvelt	NNP
cord-286132-ag2l1xa7	115	7	et	et	NNP
cord-286132-ag2l1xa7	115	8	al	al	NNP
cord-286132-ag2l1xa7	115	9	2017	2017	CD
cord-286132-ag2l1xa7	115	10	49	49	CD
cord-286132-ag2l1xa7	115	11	Reich	Reich	NNP
cord-286132-ag2l1xa7	115	12	et	et	NNP
cord-286132-ag2l1xa7	115	13	al	al	NNP
cord-286132-ag2l1xa7	115	14	2017	2017	CD
cord-286132-ag2l1xa7	115	15	10	10	CD
cord-286132-ag2l1xa7	115	16	Gordon	Gordon	NNP
cord-286132-ag2l1xa7	115	17	et	et	NNP
cord-286132-ag2l1xa7	115	18	al	al	NNP
cord-286132-ag2l1xa7	115	19	2015	2015	CD
cord-286132-ag2l1xa7	115	20	9	9	CD
cord-286132-ag2l1xa7	115	21	Sofen	Sofen	NNP
cord-286132-ag2l1xa7	115	22	et	et	FW
cord-286132-ag2l1xa7	115	23	al	al	NNP
cord-286132-ag2l1xa7	116	1	2014	2014	CD
cord-286132-ag2l1xa7	116	2	50	50	CD
cord-286132-ag2l1xa7	116	3	Terui	Terui	NNP
cord-286132-ag2l1xa7	116	4	et	et	NNP
cord-286132-ag2l1xa7	116	5	al	al	NNP
cord-286132-ag2l1xa7	116	6	2018	2018	CD
cord-286132-ag2l1xa7	116	7	51	51	CD
cord-286132-ag2l1xa7	116	8	[	[	-LRB-
cord-286132-ag2l1xa7	116	9	wt>100	wt>100	NNP
cord-286132-ag2l1xa7	116	10	kg	kg	NNP
cord-286132-ag2l1xa7	116	11	]	]	-RRB-
cord-286132-ag2l1xa7	117	1	at	at	IN
cord-286132-ag2l1xa7	117	2	wk	wk	NN
cord-286132-ag2l1xa7	117	3	0,4	0,4	CD
cord-286132-ag2l1xa7	117	4	45	45	CD
cord-286132-ag2l1xa7	117	5	s.c.at	s.c.at	NN
cord-286132-ag2l1xa7	117	6	wk	wk	XX
cord-286132-ag2l1xa7	117	7	0,4	0,4	CD
cord-286132-ag2l1xa7	118	1	33	33	CD
cord-286132-ag2l1xa7	118	2	Tsai	Tsai	NNP
cord-286132-ag2l1xa7	118	3	et	et	NNP
cord-286132-ag2l1xa7	118	4	al	al	NNP
cord-286132-ag2l1xa7	118	5	2011	2011	CD
cord-286132-ag2l1xa7	119	1	63	63	CD
cord-286132-ag2l1xa7	119	2	Papp	Papp	NNP
cord-286132-ag2l1xa7	119	3	et	et	NNP
cord-286132-ag2l1xa7	119	4	al	al	NNP
cord-286132-ag2l1xa7	119	5	2008	2008	CD
cord-286132-ag2l1xa7	119	6	3	3	CD
cord-286132-ag2l1xa7	119	7	Leonardi	Leonardi	NNP
cord-286132-ag2l1xa7	119	8	et	et	NNP
cord-286132-ag2l1xa7	119	9	al	al	NNP
cord-286132-ag2l1xa7	119	10	2008	2008	CD
cord-286132-ag2l1xa7	119	11	64	64	CD
cord-286132-ag2l1xa7	119	12	Krueger	Krueger	NNP
cord-286132-ag2l1xa7	119	13	et	et	NNP
cord-286132-ag2l1xa7	119	14	al	al	NNP
cord-286132-ag2l1xa7	119	15	2007	2007	CD
cord-286132-ag2l1xa7	120	1	65	65	CD
cord-286132-ag2l1xa7	120	2	Ritchlin	Ritchlin	NNP
cord-286132-ag2l1xa7	120	3	et	et	NNP
cord-286132-ag2l1xa7	120	4	al	al	NNP
cord-286132-ag2l1xa7	120	5	2014	2014	CD
cord-286132-ag2l1xa7	121	1	34	34	CD
cord-286132-ag2l1xa7	121	2	Mclnne	Mclnne	NNP
cord-286132-ag2l1xa7	121	3	et	et	NNP
cord-286132-ag2l1xa7	121	4	al	al	NNP
cord-286132-ag2l1xa7	121	5	2013	2013	CD
cord-286132-ag2l1xa7	121	6	66	66	CD
cord-286132-ag2l1xa7	121	7	Gottlieb	Gottlieb	NNP
cord-286132-ag2l1xa7	121	8	et	et	NNP
cord-286132-ag2l1xa7	121	9	al	al	NNP
cord-286132-ag2l1xa7	121	10	2009	2009	CD
cord-286132-ag2l1xa7	121	11	67	67	CD
cord-286132-ag2l1xa7	122	1	Feagan	Feagan	NNP
cord-286132-ag2l1xa7	122	2	et	et	FW
cord-286132-ag2l1xa7	122	3	al	al	NNP
cord-286132-ag2l1xa7	122	4	2016	2016	CD
cord-286132-ag2l1xa7	123	1	68	68	CD
cord-286132-ag2l1xa7	123	2	Feagan	Feagan	NNP
cord-286132-ag2l1xa7	123	3	et	et	NNP
cord-286132-ag2l1xa7	123	4	al	al	NNP
cord-286132-ag2l1xa7	123	5	2016	2016	CD
cord-286132-ag2l1xa7	124	1	68	68	CD
cord-286132-ag2l1xa7	124	2	Sandborn	Sandborn	NNP
cord-286132-ag2l1xa7	124	3	et	et	NNP
cord-286132-ag2l1xa7	124	4	al	al	NNP
cord-286132-ag2l1xa7	124	5	2012	2012	CD
cord-286132-ag2l1xa7	124	6	4	4	CD
cord-286132-ag2l1xa7	124	7	Sandborn	Sandborn	NNP
cord-286132-ag2l1xa7	124	8	et	et	NNP
cord-286132-ag2l1xa7	124	9	al	al	NNP
cord-286132-ag2l1xa7	124	10	2008	2008	CD
cord-286132-ag2l1xa7	124	11	69	69	CD
cord-286132-ag2l1xa7	124	12	Khattri	Khattri	NNP
cord-286132-ag2l1xa7	124	13	et	et	FW
cord-286132-ag2l1xa7	124	14	al	al	NNP
cord-286132-ag2l1xa7	125	1	2017	2017	CD
cord-286132-ag2l1xa7	125	2	70	70	CD
cord-286132-ag2l1xa7	125	3	Saeki	Saeki	NNP
cord-286132-ag2l1xa7	125	4	 	 	_SP
cord-286132-ag2l1xa7	125	5	(	(	-LRB-
cord-286132-ag2l1xa7	125	6	s	s	NN
cord-286132-ag2l1xa7	125	7	)	)	-RRB-
cord-286132-ag2l1xa7	125	8	130	130	CD
cord-286132-ag2l1xa7	125	9	,	,	,
cord-286132-ag2l1xa7	126	1	6mg	6mg	NN
cord-286132-ag2l1xa7	126	2	/	/	SYM
cord-286132-ag2l1xa7	126	3	kg	kg	NNP
cord-286132-ag2l1xa7	126	4	i.v	i.v	NNP
cord-286132-ag2l1xa7	126	5	.	.	.
cord-286132-ag2l1xa7	127	1	(	(	-LRB-
cord-286132-ag2l1xa7	127	2	s	s	NN
cord-286132-ag2l1xa7	127	3	)	)	-RRB-
cord-286132-ag2l1xa7	127	4	1	1	CD
cord-286132-ag2l1xa7	127	5	,	,	,
cord-286132-ag2l1xa7	127	6	3	3	CD
cord-286132-ag2l1xa7	127	7	,	,	,
cord-286132-ag2l1xa7	128	1	6mg	6mg	NN
cord-286132-ag2l1xa7	128	2	/	/	SYM
cord-286132-ag2l1xa7	128	3	kg	kg	NNP
cord-286132-ag2l1xa7	128	4	i.v	i.v	NNP
cord-286132-ag2l1xa7	128	5	.	.	.
cord-286132-ag2l1xa7	129	1	(	(	-LRB-
cord-286132-ag2l1xa7	129	2	s	s	NN
cord-286132-ag2l1xa7	129	3	)	)	-RRB-
cord-286132-ag2l1xa7	130	1	90	90	CD
cord-286132-ag2l1xa7	130	2	s.c	s.c	NNP
cord-286132-ag2l1xa7	130	3	A	A	NNP
cord-286132-ag2l1xa7	130	4	phase	phase	NN
cord-286132-ag2l1xa7	130	5	III	iii	CD
cord-286132-ag2l1xa7	130	6	,	,	,
cord-286132-ag2l1xa7	130	7	randomized	randomized	JJ
cord-286132-ag2l1xa7	130	8	mAb	mab	NN
cord-286132-ag2l1xa7	130	9	briakinumab	briakinumab	NNS
cord-286132-ag2l1xa7	130	10	in	in	IN
cord-286132-ag2l1xa7	130	11	moderate	moderate	JJ
cord-286132-ag2l1xa7	130	12	-	-	HYPH
cord-286132-ag2l1xa7	130	13	to	to	IN
cord-286132-ag2l1xa7	130	14	-	-	HYPH
cord-286132-ag2l1xa7	130	15	severe	severe	JJ
cord-286132-ag2l1xa7	130	16	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	130	17	Briakinumab	Briakinumab	NNP
cord-286132-ag2l1xa7	130	18	for	for	IN
cord-286132-ag2l1xa7	130	19	treatment	treatment	NN
cord-286132-ag2l1xa7	130	20	of	of	IN
cord-286132-ag2l1xa7	130	21	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	130	22	's	's	POS
cord-286132-ag2l1xa7	130	23	disease	disease	NN
cord-286132-ag2l1xa7	130	24	:	:	:
cord-286132-ag2l1xa7	130	25	results	result	NNS
cord-286132-ag2l1xa7	130	26	of	of	IN
cord-286132-ag2l1xa7	130	27	a	a	DT
cord-286132-ag2l1xa7	130	28	randomized	randomized	JJ
cord-286132-ag2l1xa7	130	29	trial	trial	NN
cord-286132-ag2l1xa7	130	30	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	130	31	and	and	CC
cord-286132-ag2l1xa7	130	32	safety	safety	NN
cord-286132-ag2l1xa7	130	33	of	of	IN
cord-286132-ag2l1xa7	130	34	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	130	35	,	,	,
cord-286132-ag2l1xa7	130	36	a	a	DT
cord-286132-ag2l1xa7	130	37	human	human	JJ
cord-286132-ag2l1xa7	130	38	interleukin-12/23	interleukin-12/23	NNP
cord-286132-ag2l1xa7	130	39	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	130	40	antibody	antibody	NN
cord-286132-ag2l1xa7	130	41	,	,	,
cord-286132-ag2l1xa7	130	42	in	in	IN
cord-286132-ag2l1xa7	130	43	patients	patient	NNS
cord-286132-ag2l1xa7	130	44	with	with	IN
cord-286132-ag2l1xa7	130	45	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	130	46	:	:	:
cord-286132-ag2l1xa7	130	47	52-week	52-week	CD
cord-286132-ag2l1xa7	130	48	results	result	NNS
cord-286132-ag2l1xa7	130	49	from	from	IN
cord-286132-ag2l1xa7	130	50	a	a	DT
cord-286132-ag2l1xa7	130	51	randomised	randomised	JJ
cord-286132-ag2l1xa7	130	52	,	,	,
cord-286132-ag2l1xa7	130	53	double	double	JJ
cord-286132-ag2l1xa7	130	54	-	-	HYPH
cord-286132-ag2l1xa7	130	55	blind	blind	JJ
cord-286132-ag2l1xa7	130	56	,	,	,
cord-286132-ag2l1xa7	130	57	placebo	placebo	NN
cord-286132-ag2l1xa7	130	58	-	-	HYPH
cord-286132-ag2l1xa7	130	59	controlled	control	VBN
cord-286132-ag2l1xa7	130	60	trial	trial	NN
cord-286132-ag2l1xa7	130	61	(	(	-LRB-
cord-286132-ag2l1xa7	130	62	PHOENIX	PHOENIX	NNP
cord-286132-ag2l1xa7	130	63	2	2	CD
cord-286132-ag2l1xa7	130	64	)	)	-RRB-
cord-286132-ag2l1xa7	130	65	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	130	66	induction	induction	NN
cord-286132-ag2l1xa7	130	67	and	and	CC
cord-286132-ag2l1xa7	130	68	maintenance	maintenance	NN
cord-286132-ag2l1xa7	130	69	therapy	therapy	NN
cord-286132-ag2l1xa7	130	70	in	in	IN
cord-286132-ag2l1xa7	130	71	refractory	refractory	JJ
cord-286132-ag2l1xa7	130	72	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	130	73	's	's	POS
cord-286132-ag2l1xa7	130	74	disease	disease	NN
cord-286132-ag2l1xa7	130	75	Tildrakizumab	Tildrakizumab	NNP
cord-286132-ag2l1xa7	130	76	versus	versus	IN
cord-286132-ag2l1xa7	130	77	placebo	placebo	NN
cord-286132-ag2l1xa7	130	78	or	or	CC
cord-286132-ag2l1xa7	130	79	etanercept	etanercept	VBN
cord-286132-ag2l1xa7	130	80	for	for	IN
cord-286132-ag2l1xa7	130	81	chronic	chronic	JJ
cord-286132-ag2l1xa7	130	82	plaque	plaque	NN
cord-286132-ag2l1xa7	130	83	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	131	1	(	(	-LRB-
cord-286132-ag2l1xa7	131	2	reSURFACE	reSURFACE	NNP
cord-286132-ag2l1xa7	131	3	1	1	CD
cord-286132-ag2l1xa7	131	4	and	and	CC
cord-286132-ag2l1xa7	131	5	reSURFACE	reSURFACE	NNP
cord-286132-ag2l1xa7	131	6	2	2	CD
cord-286132-ag2l1xa7	131	7	)	)	-RRB-
cord-286132-ag2l1xa7	132	1	:	:	:
cord-286132-ag2l1xa7	132	2	results	result	NNS
cord-286132-ag2l1xa7	132	3	from	from	IN
cord-286132-ag2l1xa7	132	4	two	two	CD
cord-286132-ag2l1xa7	132	5	randomised	randomised	JJ
cord-286132-ag2l1xa7	132	6	controlled	control	VBN
cord-286132-ag2l1xa7	132	7	,	,	,
cord-286132-ag2l1xa7	132	8	phase	phase	NN
cord-286132-ag2l1xa7	132	9	3	3	CD
cord-286132-ag2l1xa7	132	10	trials	trial	NNS
cord-286132-ag2l1xa7	132	11	MK-3222	MK-3222	NNP
cord-286132-ag2l1xa7	132	12	)	)	-RRB-
cord-286132-ag2l1xa7	132	13	,	,	,
cord-286132-ag2l1xa7	132	14	an	an	DT
cord-286132-ag2l1xa7	132	15	anti	anti	NN
cord-286132-ag2l1xa7	132	16	-	-	JJ
cord-286132-ag2l1xa7	132	17	interleukin-23p19	interleukin-23p19	JJ
cord-286132-ag2l1xa7	132	18	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	132	19	antibody	antibody	NN
cord-286132-ag2l1xa7	132	20	,	,	,
cord-286132-ag2l1xa7	132	21	improves	improve	VBZ
cord-286132-ag2l1xa7	132	22	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	132	23	in	in	IN
cord-286132-ag2l1xa7	132	24	a	a	DT
cord-286132-ag2l1xa7	132	25	phase	phase	NN
cord-286132-ag2l1xa7	133	1	IIb	IIb	NNP
cord-286132-ag2l1xa7	133	2	randomized	randomize	VBD
cord-286132-ag2l1xa7	133	3	placebo	placebo	NN
cord-286132-ag2l1xa7	133	4	-	-	HYPH
cord-286132-ag2l1xa7	133	5	controlled	control	VBN
cord-286132-ag2l1xa7	133	6	trial	trial	NN
cord-286132-ag2l1xa7	133	7	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	133	8	and	and	CC
cord-286132-ag2l1xa7	133	9	safety	safety	NN
cord-286132-ag2l1xa7	133	10	of	of	IN
cord-286132-ag2l1xa7	133	11	risankizumab	risankizumab	NNS
cord-286132-ag2l1xa7	133	12	in	in	IN
cord-286132-ag2l1xa7	133	13	moderate	moderate	JJ
cord-286132-ag2l1xa7	133	14	-	-	HYPH
cord-286132-ag2l1xa7	133	15	to	to	IN
cord-286132-ag2l1xa7	133	16	-	-	HYPH
cord-286132-ag2l1xa7	133	17	severe	severe	JJ
cord-286132-ag2l1xa7	133	18	plaque	plaque	NN
cord-286132-ag2l1xa7	133	19	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	133	20	(	(	-LRB-
cord-286132-ag2l1xa7	133	21	UltIMMa-1	ultimma-1	NN
cord-286132-ag2l1xa7	133	22	and	and	CC
cord-286132-ag2l1xa7	133	23	UltIMMa-2	ultimma-2	NN
cord-286132-ag2l1xa7	133	24	)	)	-RRB-
cord-286132-ag2l1xa7	134	1	:	:	:
cord-286132-ag2l1xa7	134	2	results	result	NNS
cord-286132-ag2l1xa7	134	3	from	from	IN
cord-286132-ag2l1xa7	134	4	two	two	CD
cord-286132-ag2l1xa7	134	5	double	double	JJ
cord-286132-ag2l1xa7	134	6	-	-	HYPH
cord-286132-ag2l1xa7	134	7	blind	blind	JJ
cord-286132-ag2l1xa7	134	8	,	,	,
cord-286132-ag2l1xa7	134	9	randomised	randomised	JJ
cord-286132-ag2l1xa7	134	10	,	,	,
cord-286132-ag2l1xa7	134	11	placebo	placebo	NN
cord-286132-ag2l1xa7	134	12	-	-	HYPH
cord-286132-ag2l1xa7	134	13	controlled	control	VBN
cord-286132-ag2l1xa7	134	14	and	and	CC
cord-286132-ag2l1xa7	134	15	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	134	16	-	-	HYPH
cord-286132-ag2l1xa7	134	17	controlled	control	VBN
cord-286132-ag2l1xa7	134	18	phase	phase	NN
cord-286132-ag2l1xa7	134	19	3	3	CD
cord-286132-ag2l1xa7	134	20	trials	trial	NNS
cord-286132-ag2l1xa7	135	1	Induction	induction	NN
cord-286132-ag2l1xa7	135	2	therapy	therapy	NN
cord-286132-ag2l1xa7	135	3	with	with	IN
cord-286132-ag2l1xa7	135	4	the	the	DT
cord-286132-ag2l1xa7	135	5	selective	selective	JJ
cord-286132-ag2l1xa7	135	6	interleukin-23	interleukin-23	NN
cord-286132-ag2l1xa7	135	7	inhibitor	inhibitor	NN
cord-286132-ag2l1xa7	135	8	risankizumab	risankizumab	NNS
cord-286132-ag2l1xa7	135	9	in	in	IN
cord-286132-ag2l1xa7	135	10	patients	patient	NNS
cord-286132-ag2l1xa7	135	11	with	with	IN
cord-286132-ag2l1xa7	135	12	moderate	moderate	JJ
cord-286132-ag2l1xa7	135	13	-	-	HYPH
cord-286132-ag2l1xa7	135	14	to	to	IN
cord-286132-ag2l1xa7	135	15	-	-	HYPH
cord-286132-ag2l1xa7	135	16	severe	severe	JJ
cord-286132-ag2l1xa7	135	17	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	135	18	's	's	POS
cord-286132-ag2l1xa7	135	19	disease	disease	NN
cord-286132-ag2l1xa7	135	20	:	:	:
cord-286132-ag2l1xa7	135	21	a	a	DT
cord-286132-ag2l1xa7	135	22	randomised	randomised	JJ
cord-286132-ag2l1xa7	135	23	,	,	,
cord-286132-ag2l1xa7	135	24	double	double	JJ
cord-286132-ag2l1xa7	135	25	-	-	HYPH
cord-286132-ag2l1xa7	135	26	blind	blind	JJ
cord-286132-ag2l1xa7	135	27	,	,	,
cord-286132-ag2l1xa7	135	28	placebo	placebo	NN
cord-286132-ag2l1xa7	135	29	-	-	HYPH
cord-286132-ag2l1xa7	135	30	controlled	control	VBN
cord-286132-ag2l1xa7	135	31	phase	phase	NN
cord-286132-ag2l1xa7	135	32	2	2	CD
cord-286132-ag2l1xa7	135	33	study	study	NN
cord-286132-ag2l1xa7	136	1	A	a	DT
cord-286132-ag2l1xa7	136	2	Phase	phase	NN
cord-286132-ag2l1xa7	136	3	2	2	CD
cord-286132-ag2l1xa7	136	4	Trial	trial	NN
cord-286132-ag2l1xa7	136	5	of	of	IN
cord-286132-ag2l1xa7	136	6	Guselkumab	Guselkumab	NNP
cord-286132-ag2l1xa7	136	7	versus	versus	IN
cord-286132-ag2l1xa7	136	8	Adalimumab	Adalimumab	NNP
cord-286132-ag2l1xa7	136	9	for	for	IN
cord-286132-ag2l1xa7	136	10	Plaque	Plaque	NNP
cord-286132-ag2l1xa7	136	11	Psoriasis	Psoriasis	NNP
cord-286132-ag2l1xa7	136	12	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	136	13	and	and	CC
cord-286132-ag2l1xa7	136	14	safety	safety	NN
cord-286132-ag2l1xa7	136	15	of	of	IN
cord-286132-ag2l1xa7	136	16	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	136	17	,	,	,
cord-286132-ag2l1xa7	136	18	an	an	DT
cord-286132-ag2l1xa7	136	19	anti	anti	JJ
cord-286132-ag2l1xa7	136	20	-	-	JJ
cord-286132-ag2l1xa7	136	21	interleukin-23	interleukin-23	JJ
cord-286132-ag2l1xa7	136	22	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	136	23	antibody	antibody	NN
cord-286132-ag2l1xa7	136	24	,	,	,
cord-286132-ag2l1xa7	136	25	compared	compare	VBN
cord-286132-ag2l1xa7	136	26	with	with	IN
cord-286132-ag2l1xa7	136	27	adalimumab	adalimumab	NNS
cord-286132-ag2l1xa7	136	28	for	for	IN
cord-286132-ag2l1xa7	136	29	the	the	DT
cord-286132-ag2l1xa7	136	30	treatment	treatment	NN
cord-286132-ag2l1xa7	136	31	of	of	IN
cord-286132-ag2l1xa7	136	32	patients	patient	NNS
cord-286132-ag2l1xa7	136	33	with	with	IN
cord-286132-ag2l1xa7	136	34	moderate	moderate	JJ
cord-286132-ag2l1xa7	136	35	to	to	IN
cord-286132-ag2l1xa7	136	36	severe	severe	JJ
cord-286132-ag2l1xa7	136	37	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	136	38	with	with	IN
cord-286132-ag2l1xa7	136	39	randomized	randomized	JJ
cord-286132-ag2l1xa7	136	40	withdrawal	withdrawal	NN
cord-286132-ag2l1xa7	136	41	and	and	CC
cord-286132-ag2l1xa7	136	42	retreatment	retreatment	NN
cord-286132-ag2l1xa7	136	43	:	:	:
cord-286132-ag2l1xa7	136	44	Results	result	NNS
cord-286132-ag2l1xa7	136	45	from	from	IN
cord-286132-ag2l1xa7	136	46	the	the	DT
cord-286132-ag2l1xa7	136	47	phase	phase	NN
cord-286132-ag2l1xa7	136	48	III	iii	CD
cord-286132-ag2l1xa7	136	49	,	,	,
cord-286132-ag2l1xa7	136	50	double	double	JJ
cord-286132-ag2l1xa7	136	51	-	-	HYPH
cord-286132-ag2l1xa7	136	52	blind	blind	JJ
cord-286132-ag2l1xa7	136	53	,	,	,
cord-286132-ag2l1xa7	136	54	placebo	placebo	NN
cord-286132-ag2l1xa7	136	55	-	-	HYPH
cord-286132-ag2l1xa7	136	56	and	and	CC
cord-286132-ag2l1xa7	136	57	active	active	JJ
cord-286132-ag2l1xa7	136	58	comparator	comparator	NN
cord-286132-ag2l1xa7	136	59	-	-	HYPH
cord-286132-ag2l1xa7	136	60	controlled	control	VBN
cord-286132-ag2l1xa7	136	61	VOYAGE	voyage	NN
cord-286132-ag2l1xa7	136	62	2	2	CD
cord-286132-ag2l1xa7	136	63	trial	trial	NN
cord-286132-ag2l1xa7	136	64	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	136	65	and	and	CC
cord-286132-ag2l1xa7	136	66	Safety	Safety	NNP
cord-286132-ag2l1xa7	136	67	of	of	IN
cord-286132-ag2l1xa7	136	68	MEDI2070	MEDI2070	NNP
cord-286132-ag2l1xa7	136	69	,	,	,
cord-286132-ag2l1xa7	136	70	an	an	DT
cord-286132-ag2l1xa7	136	71	Patients	patient	NNS
cord-286132-ag2l1xa7	136	72	With	with	IN
cord-286132-ag2l1xa7	136	73	Moderate	moderate	JJ
cord-286132-ag2l1xa7	136	74	to	to	IN
cord-286132-ag2l1xa7	136	75	Severe	severe	JJ
cord-286132-ag2l1xa7	136	76	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	136	77	's	's	POS
cord-286132-ag2l1xa7	136	78	Disease	Disease	NNP
cord-286132-ag2l1xa7	136	79	:	:	:
cord-286132-ag2l1xa7	137	1	A	a	DT
cord-286132-ag2l1xa7	137	2	Phase	Phase	NNP
cord-286132-ag2l1xa7	137	3	2a	2a	CD
cord-286132-ag2l1xa7	137	4	Study	Study	NNP
cord-286132-ag2l1xa7	137	5	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	137	6	's	's	POS
cord-286132-ag2l1xa7	137	7	disease	disease	NN
cord-286132-ag2l1xa7	137	8	Disease	Disease	NNP
cord-286132-ag2l1xa7	137	9	Coverage	Coverage	NNP
cord-286132-ag2l1xa7	138	1	The	the	DT
cord-286132-ag2l1xa7	138	2	safety	safety	NN
cord-286132-ag2l1xa7	138	3	of	of	IN
cord-286132-ag2l1xa7	138	4	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	138	5	for	for	IN
cord-286132-ag2l1xa7	138	6	the	the	DT
cord-286132-ag2l1xa7	138	7	treatment	treatment	NN
cord-286132-ag2l1xa7	138	8	of	of	IN
cord-286132-ag2l1xa7	138	9	psoriatic	psoriatic	JJ
cord-286132-ag2l1xa7	138	10	arthritis	arthritis	NN
cord-286132-ag2l1xa7	138	11	Association	Association	NNP
cord-286132-ag2l1xa7	138	12	of	of	IN
cord-286132-ag2l1xa7	138	13	Noninfectious	Noninfectious	NNP
cord-286132-ag2l1xa7	138	14	Pneumonia	Pneumonia	NNP
cord-286132-ag2l1xa7	138	15	With	with	IN
cord-286132-ag2l1xa7	138	16	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	138	17	Use	Use	NNP
cord-286132-ag2l1xa7	138	18	Editorial	editorial	NN
cord-286132-ag2l1xa7	138	19	:	:	:
cord-286132-ag2l1xa7	138	20	The	the	DT
cord-286132-ag2l1xa7	138	21	explosive	explosive	JJ
cord-286132-ag2l1xa7	138	22	epidemic	epidemic	NN
cord-286132-ag2l1xa7	138	23	outbreak	outbreak	NN
cord-286132-ag2l1xa7	138	24	of	of	IN
cord-286132-ag2l1xa7	138	25	novel	novel	JJ
cord-286132-ag2l1xa7	138	26	coronavirus	coronavirus	NN
cord-286132-ag2l1xa7	138	27	disease	disease	NN
cord-286132-ag2l1xa7	138	28	COVID-19	COVID-19	NNP
cord-286132-ag2l1xa7	138	29	)	)	-RRB-
cord-286132-ag2l1xa7	138	30	and	and	CC
cord-286132-ag2l1xa7	138	31	the	the	DT
cord-286132-ag2l1xa7	138	32	persistent	persistent	JJ
cord-286132-ag2l1xa7	138	33	threat	threat	NN
cord-286132-ag2l1xa7	138	34	of	of	IN
cord-286132-ag2l1xa7	138	35	respiratory	respiratory	JJ
cord-286132-ag2l1xa7	138	36	tract	tract	NN
cord-286132-ag2l1xa7	138	37	infectious	infectious	JJ
cord-286132-ag2l1xa7	138	38	diseases	disease	NNS
cord-286132-ag2l1xa7	138	39	to	to	IN
cord-286132-ag2l1xa7	138	40	global	global	JJ
cord-286132-ag2l1xa7	138	41	health	health	NN
cord-286132-ag2l1xa7	138	42	security	security	NN
cord-286132-ag2l1xa7	138	43	Should	Should	MD
cord-286132-ag2l1xa7	138	44	biologics	biologic	NNS
cord-286132-ag2l1xa7	138	45	for	for	IN
cord-286132-ag2l1xa7	138	46	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	138	47	be	be	VB
cord-286132-ag2l1xa7	138	48	interrupted	interrupt	VBN
cord-286132-ag2l1xa7	138	49	in	in	IN
cord-286132-ag2l1xa7	138	50	the	the	DT
cord-286132-ag2l1xa7	138	51	era	era	NN
cord-286132-ag2l1xa7	138	52	of	of	IN
cord-286132-ag2l1xa7	138	53	COVID-19	COVID-19	NNP
cord-286132-ag2l1xa7	138	54	?	?	.
cord-286132-ag2l1xa7	139	1	Are	be	VBP
cord-286132-ag2l1xa7	139	2	patients	patient	NNS
cord-286132-ag2l1xa7	139	3	with	with	IN
cord-286132-ag2l1xa7	139	4	inflammatory	inflammatory	JJ
cord-286132-ag2l1xa7	139	5	bowel	bowel	NN
cord-286132-ag2l1xa7	139	6	disease	disease	NN
cord-286132-ag2l1xa7	139	7	at	at	IN
cord-286132-ag2l1xa7	139	8	increased	increase	VBN
cord-286132-ag2l1xa7	139	9	risk	risk	NN
cord-286132-ag2l1xa7	139	10	for	for	IN
cord-286132-ag2l1xa7	139	11	Covid-19	covid-19	NN
cord-286132-ag2l1xa7	139	12	infection	infection	NN
cord-286132-ag2l1xa7	139	13	?	?	.
cord-286132-ag2l1xa7	140	1	Preferred	preferred	JJ
cord-286132-ag2l1xa7	140	2	reporting	reporting	NN
cord-286132-ag2l1xa7	140	3	items	item	NNS
cord-286132-ag2l1xa7	140	4	for	for	IN
cord-286132-ag2l1xa7	140	5	systematic	systematic	JJ
cord-286132-ag2l1xa7	140	6	reviews	review	NNS
cord-286132-ag2l1xa7	140	7	and	and	CC
cord-286132-ag2l1xa7	140	8	meta	meta	NNP
cord-286132-ag2l1xa7	140	9	-	-	HYPH
cord-286132-ag2l1xa7	140	10	analyses	analysis	NNS
cord-286132-ag2l1xa7	140	11	:	:	:
cord-286132-ag2l1xa7	141	1	the	the	DT
cord-286132-ag2l1xa7	141	2	PRISMA	PRISMA	NNP
cord-286132-ag2l1xa7	141	3	statement	statement	NN
cord-286132-ag2l1xa7	141	4	PROSPERO	PROSPERO	NNP
cord-286132-ag2l1xa7	141	5	's	's	POS
cord-286132-ag2l1xa7	141	6	progress	progress	NN
cord-286132-ag2l1xa7	141	7	and	and	CC
cord-286132-ag2l1xa7	141	8	activities	activity	NNS
cord-286132-ag2l1xa7	141	9	2012/13	2012/13	CD
cord-286132-ag2l1xa7	141	10	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	141	11	and	and	CC
cord-286132-ag2l1xa7	141	12	safety	safety	NN
cord-286132-ag2l1xa7	141	13	of	of	IN
cord-286132-ag2l1xa7	141	14	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	141	15	,	,	,
cord-286132-ag2l1xa7	141	16	administered	administer	VBN
cord-286132-ag2l1xa7	141	17	with	with	IN
cord-286132-ag2l1xa7	141	18	a	a	DT
cord-286132-ag2l1xa7	141	19	novel	novel	JJ
cord-286132-ag2l1xa7	141	20	patient	patient	NN
cord-286132-ag2l1xa7	141	21	-	-	HYPH
cord-286132-ag2l1xa7	141	22	controlled	control	VBN
cord-286132-ag2l1xa7	141	23	injector	injector	NN
cord-286132-ag2l1xa7	141	24	(	(	-LRB-
cord-286132-ag2l1xa7	141	25	One	one	CD
cord-286132-ag2l1xa7	141	26	-	-	HYPH
cord-286132-ag2l1xa7	141	27	Press	Press	NNP
cord-286132-ag2l1xa7	141	28	)	)	-RRB-
cord-286132-ag2l1xa7	141	29	,	,	,
cord-286132-ag2l1xa7	141	30	for	for	IN
cord-286132-ag2l1xa7	141	31	moderate	moderate	JJ
cord-286132-ag2l1xa7	141	32	-	-	HYPH
cord-286132-ag2l1xa7	141	33	to	to	IN
cord-286132-ag2l1xa7	141	34	-	-	HYPH
cord-286132-ag2l1xa7	141	35	severe	severe	JJ
cord-286132-ag2l1xa7	141	36	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	141	37	:	:	:
cord-286132-ag2l1xa7	141	38	results	result	NNS
cord-286132-ag2l1xa7	141	39	from	from	IN
cord-286132-ag2l1xa7	141	40	the	the	DT
cord-286132-ag2l1xa7	141	41	phase	phase	NN
cord-286132-ag2l1xa7	141	42	3	3	CD
cord-286132-ag2l1xa7	141	43	ORION	ORION	NNP
cord-286132-ag2l1xa7	141	44	study	study	NN
cord-286132-ag2l1xa7	142	1	In	in	IN
cord-286132-ag2l1xa7	143	1	vivo	vivo	NNP
cord-286132-ag2l1xa7	143	2	IL-12	IL-12	NNP
cord-286132-ag2l1xa7	143	3	/	/	SYM
cord-286132-ag2l1xa7	143	4	IL-23p40	il-23p40	CD
cord-286132-ag2l1xa7	143	5	neutralization	neutralization	NN
cord-286132-ag2l1xa7	143	6	blocks	block	NNS
cord-286132-ag2l1xa7	144	1	Th1	Th1	NNP
cord-286132-ag2l1xa7	144	2	/	/	SYM
cord-286132-ag2l1xa7	144	3	Th17	th17	CD
cord-286132-ag2l1xa7	144	4	response	response	NN
cord-286132-ag2l1xa7	144	5	after	after	IN
cord-286132-ag2l1xa7	144	6	allogeneic	allogeneic	JJ
cord-286132-ag2l1xa7	144	7	hematopoietic	hematopoietic	JJ
cord-286132-ag2l1xa7	144	8	cell	cell	NN
cord-286132-ag2l1xa7	144	9	transplantation	transplantation	NN
cord-286132-ag2l1xa7	144	10	Assessing	assess	VBG
cord-286132-ag2l1xa7	144	11	the	the	DT
cord-286132-ag2l1xa7	144	12	quality	quality	NN
cord-286132-ag2l1xa7	144	13	of	of	IN
cord-286132-ag2l1xa7	144	14	reports	report	NNS
cord-286132-ag2l1xa7	144	15	of	of	IN
cord-286132-ag2l1xa7	144	16	randomized	randomized	JJ
cord-286132-ag2l1xa7	144	17	clinical	clinical	JJ
cord-286132-ag2l1xa7	144	18	trials	trial	NNS
cord-286132-ag2l1xa7	144	19	:	:	:
cord-286132-ag2l1xa7	144	20	is	be	VBZ
cord-286132-ag2l1xa7	144	21	blinding	blind	VBG
cord-286132-ag2l1xa7	144	22	necessary	necessary	JJ
cord-286132-ag2l1xa7	144	23	?	?	.
cord-286132-ag2l1xa7	145	1	The	the	DT
cord-286132-ag2l1xa7	145	2	Cochrane	Cochrane	NNP
cord-286132-ag2l1xa7	145	3	Collaboration	Collaboration	NNP
cord-286132-ag2l1xa7	145	4	's	's	POS
cord-286132-ag2l1xa7	145	5	tool	tool	NN
cord-286132-ag2l1xa7	145	6	for	for	IN
cord-286132-ag2l1xa7	145	7	assessing	assess	VBG
cord-286132-ag2l1xa7	145	8	risk	risk	NN
cord-286132-ag2l1xa7	145	9	of	of	IN
cord-286132-ag2l1xa7	145	10	bias	bias	NN
cord-286132-ag2l1xa7	145	11	in	in	IN
cord-286132-ag2l1xa7	145	12	randomised	randomised	JJ
cord-286132-ag2l1xa7	145	13	trials	trial	NNS
cord-286132-ag2l1xa7	145	14	GRADE	grade	NN
cord-286132-ag2l1xa7	145	15	guidelines	guideline	NNS
cord-286132-ag2l1xa7	145	16	:	:	:
cord-286132-ag2l1xa7	145	17	4	4	CD
cord-286132-ag2l1xa7	145	18	.	.	.
cord-286132-ag2l1xa7	146	1	Rating	rate	VBG
cord-286132-ag2l1xa7	146	2	the	the	DT
cord-286132-ag2l1xa7	146	3	quality	quality	NN
cord-286132-ag2l1xa7	146	4	of	of	IN
cord-286132-ag2l1xa7	146	5	evidence	evidence	NN
cord-286132-ag2l1xa7	146	6	--	--	:
cord-286132-ag2l1xa7	146	7	study	study	NN
cord-286132-ag2l1xa7	146	8	limitations	limitation	NNS
cord-286132-ag2l1xa7	146	9	(	(	-LRB-
cord-286132-ag2l1xa7	146	10	risk	risk	NN
cord-286132-ag2l1xa7	146	11	of	of	IN
cord-286132-ag2l1xa7	146	12	bias	bias	NN
cord-286132-ag2l1xa7	146	13	)	)	-RRB-
cord-286132-ag2l1xa7	147	1	Inclusion	inclusion	NN
cord-286132-ag2l1xa7	147	2	of	of	IN
cord-286132-ag2l1xa7	147	3	zero	zero	CD
cord-286132-ag2l1xa7	147	4	total	total	JJ
cord-286132-ag2l1xa7	147	5	event	event	NN
cord-286132-ag2l1xa7	147	6	trials	trial	NNS
cord-286132-ag2l1xa7	147	7	in	in	IN
cord-286132-ag2l1xa7	147	8	meta	meta	NNP
cord-286132-ag2l1xa7	147	9	-	-	HYPH
cord-286132-ag2l1xa7	147	10	analyses	analysis	NNS
cord-286132-ag2l1xa7	147	11	maintains	maintain	VBZ
cord-286132-ag2l1xa7	147	12	analytic	analytic	JJ
cord-286132-ag2l1xa7	147	13	consistency	consistency	NN
cord-286132-ag2l1xa7	147	14	and	and	CC
cord-286132-ag2l1xa7	147	15	incorporates	incorporate	VBZ
cord-286132-ag2l1xa7	147	16	all	all	DT
cord-286132-ag2l1xa7	147	17	available	available	JJ
cord-286132-ag2l1xa7	147	18	data	datum	NNS
cord-286132-ag2l1xa7	147	19	The	the	DT
cord-286132-ag2l1xa7	147	20	Peto	Peto	NNP
cord-286132-ag2l1xa7	147	21	odds	odd	NNS
cord-286132-ag2l1xa7	147	22	ratio	ratio	NN
cord-286132-ag2l1xa7	147	23	viewed	view	VBN
cord-286132-ag2l1xa7	147	24	as	as	IN
cord-286132-ag2l1xa7	147	25	a	a	DT
cord-286132-ag2l1xa7	147	26	new	new	JJ
cord-286132-ag2l1xa7	147	27	effect	effect	NN
cord-286132-ag2l1xa7	147	28	measure	measure	NN
cord-286132-ag2l1xa7	147	29	Methods	method	NNS
cord-286132-ag2l1xa7	147	30	for	for	IN
cord-286132-ag2l1xa7	147	31	pooled	pool	VBN
cord-286132-ag2l1xa7	147	32	analyses	analysis	NNS
cord-286132-ag2l1xa7	147	33	of	of	IN
cord-286132-ag2l1xa7	147	34	epidemiologic	epidemiologic	JJ
cord-286132-ag2l1xa7	147	35	studies	study	NNS
cord-286132-ag2l1xa7	147	36	Anti	Anti	NNP
cord-286132-ag2l1xa7	147	37	-	-	NNP
cord-286132-ag2l1xa7	147	38	TNF	TNF	NNP
cord-286132-ag2l1xa7	147	39	antibody	antibody	NN
cord-286132-ag2l1xa7	147	40	therapy	therapy	NN
cord-286132-ag2l1xa7	147	41	in	in	IN
cord-286132-ag2l1xa7	147	42	rheumatoid	rheumatoid	JJ
cord-286132-ag2l1xa7	147	43	arthritis	arthritis	NN
cord-286132-ag2l1xa7	147	44	and	and	CC
cord-286132-ag2l1xa7	147	45	the	the	DT
cord-286132-ag2l1xa7	147	46	risk	risk	NN
cord-286132-ag2l1xa7	147	47	of	of	IN
cord-286132-ag2l1xa7	147	48	serious	serious	JJ
cord-286132-ag2l1xa7	147	49	infections	infection	NNS
cord-286132-ag2l1xa7	147	50	and	and	CC
cord-286132-ag2l1xa7	147	51	malignancies	malignancy	NNS
cord-286132-ag2l1xa7	147	52	:	:	:
cord-286132-ag2l1xa7	147	53	systematic	systematic	JJ
cord-286132-ag2l1xa7	147	54	review	review	NN
cord-286132-ag2l1xa7	147	55	and	and	CC
cord-286132-ag2l1xa7	147	56	meta	meta	NNP
cord-286132-ag2l1xa7	147	57	-	-	HYPH
cord-286132-ag2l1xa7	147	58	analysis	analysis	NN
cord-286132-ag2l1xa7	147	59	of	of	IN
cord-286132-ag2l1xa7	147	60	rare	rare	JJ
cord-286132-ag2l1xa7	147	61	harmful	harmful	JJ
cord-286132-ag2l1xa7	147	62	effects	effect	NNS
cord-286132-ag2l1xa7	147	63	in	in	IN
cord-286132-ag2l1xa7	147	64	randomized	randomized	JJ
cord-286132-ag2l1xa7	147	65	controlled	control	VBN
cord-286132-ag2l1xa7	147	66	trials	trial	NNS
cord-286132-ag2l1xa7	148	1	Measuring	measure	VBG
cord-286132-ag2l1xa7	148	2	inconsistency	inconsistency	NN
cord-286132-ag2l1xa7	148	3	in	in	IN
cord-286132-ag2l1xa7	148	4	meta	meta	NNP
cord-286132-ag2l1xa7	148	5	-	-	HYPH
cord-286132-ag2l1xa7	148	6	analyses	analysis	NNS
cord-286132-ag2l1xa7	148	7	Cochrane	Cochrane	NNP
cord-286132-ag2l1xa7	148	8	Handbook	Handbook	NNP
cord-286132-ag2l1xa7	148	9	for	for	IN
cord-286132-ag2l1xa7	148	10	Systematic	Systematic	NNP
cord-286132-ag2l1xa7	148	11	Reviews	Reviews	NNPS
cord-286132-ag2l1xa7	148	12	of	of	IN
cord-286132-ag2l1xa7	148	13	Interventions	Interventions	NNPS
cord-286132-ag2l1xa7	148	14	,	,	,
cord-286132-ag2l1xa7	148	15	Version	Version	NNP
cord-286132-ag2l1xa7	148	16	5.1	5.1	CD
cord-286132-ag2l1xa7	148	17	.	.	.
cord-286132-ag2l1xa7	148	18	0	0	NFP
cord-286132-ag2l1xa7	148	19	.	.	.
cord-286132-ag2l1xa7	149	1	London	London	NNP
cord-286132-ag2l1xa7	149	2	The	the	DT
cord-286132-ag2l1xa7	149	3	Cochrane	Cochrane	NNP
cord-286132-ag2l1xa7	149	4	Collaboration	Collaboration	NNP
cord-286132-ag2l1xa7	149	5	Operating	Operating	NNP
cord-286132-ag2l1xa7	149	6	characteristics	characteristic	NNS
cord-286132-ag2l1xa7	149	7	of	of	IN
cord-286132-ag2l1xa7	149	8	a	a	DT
cord-286132-ag2l1xa7	149	9	rank	rank	NN
cord-286132-ag2l1xa7	149	10	correlation	correlation	NN
cord-286132-ag2l1xa7	149	11	test	test	NN
cord-286132-ag2l1xa7	149	12	for	for	IN
cord-286132-ag2l1xa7	149	13	publication	publication	NN
cord-286132-ag2l1xa7	149	14	bias	bias	NN
cord-286132-ag2l1xa7	149	15	Bias	Bias	NNP
cord-286132-ag2l1xa7	149	16	in	in	IN
cord-286132-ag2l1xa7	149	17	meta	meta	NNP
cord-286132-ag2l1xa7	149	18	-	-	HYPH
cord-286132-ag2l1xa7	149	19	analysis	analysis	NN
cord-286132-ag2l1xa7	149	20	detected	detect	VBN
cord-286132-ag2l1xa7	149	21	by	by	IN
cord-286132-ag2l1xa7	149	22	a	a	DT
cord-286132-ag2l1xa7	149	23	simple	simple	JJ
cord-286132-ag2l1xa7	149	24	,	,	,
cord-286132-ag2l1xa7	149	25	graphical	graphical	JJ
cord-286132-ag2l1xa7	149	26	test	test	NN
cord-286132-ag2l1xa7	149	27	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	149	28	and	and	CC
cord-286132-ag2l1xa7	149	29	safety	safety	NN
cord-286132-ag2l1xa7	149	30	of	of	IN
cord-286132-ag2l1xa7	149	31	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	149	32	in	in	IN
cord-286132-ag2l1xa7	149	33	Japanese	japanese	JJ
cord-286132-ag2l1xa7	149	34	patients	patient	NNS
cord-286132-ag2l1xa7	149	35	with	with	IN
cord-286132-ag2l1xa7	149	36	moderate	moderate	JJ
cord-286132-ag2l1xa7	149	37	-	-	HYPH
cord-286132-ag2l1xa7	149	38	to	to	IN
cord-286132-ag2l1xa7	149	39	-	-	HYPH
cord-286132-ag2l1xa7	149	40	severe	severe	JJ
cord-286132-ag2l1xa7	149	41	plaque	plaque	NN
cord-286132-ag2l1xa7	149	42	-	-	HYPH
cord-286132-ag2l1xa7	149	43	type	type	NN
cord-286132-ag2l1xa7	149	44	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	149	45	:	:	:
cord-286132-ag2l1xa7	149	46	long	long	JJ
cord-286132-ag2l1xa7	149	47	-	-	HYPH
cord-286132-ag2l1xa7	149	48	term	term	NN
cord-286132-ag2l1xa7	149	49	results	result	NNS
cord-286132-ag2l1xa7	149	50	from	from	IN
cord-286132-ag2l1xa7	149	51	a	a	DT
cord-286132-ag2l1xa7	149	52	phase	phase	NN
cord-286132-ag2l1xa7	149	53	2/3	2/3	CD
cord-286132-ag2l1xa7	149	54	clinical	clinical	JJ
cord-286132-ag2l1xa7	149	55	trial	trial	NN
cord-286132-ag2l1xa7	149	56	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	149	57	and	and	CC
cord-286132-ag2l1xa7	149	58	safety	safety	NN
cord-286132-ag2l1xa7	149	59	of	of	IN
cord-286132-ag2l1xa7	149	60	the	the	DT
cord-286132-ag2l1xa7	149	61	anti	anti	JJ
cord-286132-ag2l1xa7	149	62	-	-	JJ
cord-286132-ag2l1xa7	149	63	IL-12/23	il-12/23	JJ
cord-286132-ag2l1xa7	149	64	p40	p40	CD
cord-286132-ag2l1xa7	149	65	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	149	66	antibody	antibody	NN
cord-286132-ag2l1xa7	149	67	,	,	,
cord-286132-ag2l1xa7	149	68	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	149	69	,	,	,
cord-286132-ag2l1xa7	149	70	in	in	IN
cord-286132-ag2l1xa7	149	71	patients	patient	NNS
cord-286132-ag2l1xa7	149	72	with	with	IN
cord-286132-ag2l1xa7	149	73	active	active	JJ
cord-286132-ag2l1xa7	149	74	psoriatic	psoriatic	JJ
cord-286132-ag2l1xa7	149	75	arthritis	arthritis	NN
cord-286132-ag2l1xa7	149	76	despite	despite	IN
cord-286132-ag2l1xa7	149	77	conventional	conventional	JJ
cord-286132-ag2l1xa7	149	78	non	non	JJ
cord-286132-ag2l1xa7	149	79	-	-	JJ
cord-286132-ag2l1xa7	149	80	biological	biological	JJ
cord-286132-ag2l1xa7	149	81	and	and	CC
cord-286132-ag2l1xa7	149	82	biological	biological	JJ
cord-286132-ag2l1xa7	149	83	anti	anti	JJ
cord-286132-ag2l1xa7	149	84	-	-	JJ
cord-286132-ag2l1xa7	149	85	tumour	tumour	JJ
cord-286132-ag2l1xa7	149	86	necrosis	necrosis	NN
cord-286132-ag2l1xa7	149	87	factor	factor	NN
cord-286132-ag2l1xa7	149	88	therapy	therapy	NN
cord-286132-ag2l1xa7	149	89	:	:	:
cord-286132-ag2l1xa7	149	90	6-month	6-month	CD
cord-286132-ag2l1xa7	149	91	and	and	CC
cord-286132-ag2l1xa7	149	92	1-year	1-year	CD
cord-286132-ag2l1xa7	149	93	results	result	NNS
cord-286132-ag2l1xa7	149	94	of	of	IN
cord-286132-ag2l1xa7	149	95	the	the	DT
cord-286132-ag2l1xa7	149	96	phase	phase	NN
cord-286132-ag2l1xa7	149	97	3	3	CD
cord-286132-ag2l1xa7	149	98	,	,	,
cord-286132-ag2l1xa7	149	99	multicentre	multicentre	NNP
cord-286132-ag2l1xa7	149	100	,	,	,
cord-286132-ag2l1xa7	149	101	double	double	JJ
cord-286132-ag2l1xa7	149	102	-	-	HYPH
cord-286132-ag2l1xa7	149	103	blind	blind	JJ
cord-286132-ag2l1xa7	149	104	,	,	,
cord-286132-ag2l1xa7	149	105	placebo	placebo	NN
cord-286132-ag2l1xa7	149	106	-	-	HYPH
cord-286132-ag2l1xa7	149	107	controlled	control	VBN
cord-286132-ag2l1xa7	149	108	,	,	,
cord-286132-ag2l1xa7	149	109	randomised	randomised	JJ
cord-286132-ag2l1xa7	149	110	PSUMMIT	PSUMMIT	NNP
cord-286132-ag2l1xa7	149	111	2	2	CD
cord-286132-ag2l1xa7	149	112	trial	trial	NN
cord-286132-ag2l1xa7	149	113	Safety	safety	NN
cord-286132-ag2l1xa7	149	114	and	and	CC
cord-286132-ag2l1xa7	149	115	efficacy	efficacy	NN
cord-286132-ag2l1xa7	149	116	of	of	IN
cord-286132-ag2l1xa7	149	117	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	149	118	or	or	CC
cord-286132-ag2l1xa7	149	119	golimumab	golimumab	NNP
cord-286132-ag2l1xa7	149	120	in	in	IN
cord-286132-ag2l1xa7	149	121	patients	patient	NNS
cord-286132-ag2l1xa7	149	122	with	with	IN
cord-286132-ag2l1xa7	149	123	chronic	chronic	JJ
cord-286132-ag2l1xa7	149	124	sarcoidosis	sarcoidosis	NN
cord-286132-ag2l1xa7	149	125	Risankizumab	Risankizumab	NNP
cord-286132-ag2l1xa7	149	126	,	,	,
cord-286132-ag2l1xa7	149	127	an	an	DT
cord-286132-ag2l1xa7	149	128	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	149	129	inhibitor	inhibitor	NN
cord-286132-ag2l1xa7	149	130	,	,	,
cord-286132-ag2l1xa7	149	131	for	for	IN
cord-286132-ag2l1xa7	149	132	ankylosing	ankylosing	NN
cord-286132-ag2l1xa7	149	133	spondylitis	spondylitis	NN
cord-286132-ag2l1xa7	149	134	:	:	:
cord-286132-ag2l1xa7	149	135	results	result	NNS
cord-286132-ag2l1xa7	149	136	of	of	IN
cord-286132-ag2l1xa7	149	137	a	a	DT
cord-286132-ag2l1xa7	149	138	randomised	randomised	JJ
cord-286132-ag2l1xa7	149	139	,	,	,
cord-286132-ag2l1xa7	149	140	double	double	JJ
cord-286132-ag2l1xa7	149	141	-	-	HYPH
cord-286132-ag2l1xa7	149	142	blind	blind	JJ
cord-286132-ag2l1xa7	149	143	,	,	,
cord-286132-ag2l1xa7	149	144	placebo	placebo	NN
cord-286132-ag2l1xa7	149	145	-	-	HYPH
cord-286132-ag2l1xa7	149	146	controlled	control	VBN
cord-286132-ag2l1xa7	149	147	,	,	,
cord-286132-ag2l1xa7	149	148	proof	proof	NN
cord-286132-ag2l1xa7	149	149	-	-	HYPH
cord-286132-ag2l1xa7	149	150	of	of	IN
cord-286132-ag2l1xa7	149	151	-	-	HYPH
cord-286132-ag2l1xa7	149	152	concept	concept	NN
cord-286132-ag2l1xa7	149	153	,	,	,
cord-286132-ag2l1xa7	149	154	dose	dose	NN
cord-286132-ag2l1xa7	149	155	-	-	HYPH
cord-286132-ag2l1xa7	149	156	finding	find	VBG
cord-286132-ag2l1xa7	149	157	phase	phase	NN
cord-286132-ag2l1xa7	149	158	2	2	CD
cord-286132-ag2l1xa7	149	159	study	study	NN
cord-286132-ag2l1xa7	149	160	Vaccination	vaccination	NN
cord-286132-ag2l1xa7	149	161	recommendations	recommendation	NNS
cord-286132-ag2l1xa7	149	162	for	for	IN
cord-286132-ag2l1xa7	149	163	the	the	DT
cord-286132-ag2l1xa7	149	164	adult	adult	NN
cord-286132-ag2l1xa7	149	165	immunosuppressed	immunosuppressed	JJ
cord-286132-ag2l1xa7	149	166	patient	patient	NN
cord-286132-ag2l1xa7	149	167	:	:	:
cord-286132-ag2l1xa7	149	168	A	a	DT
cord-286132-ag2l1xa7	149	169	systematic	systematic	JJ
cord-286132-ag2l1xa7	149	170	review	review	NN
cord-286132-ag2l1xa7	149	171	and	and	CC
cord-286132-ag2l1xa7	149	172	comprehensive	comprehensive	JJ
cord-286132-ag2l1xa7	149	173	field	field	NN
cord-286132-ag2l1xa7	149	174	synopsis	synopsis	NN
cord-286132-ag2l1xa7	149	175	Interstitial	Interstitial	NNP
cord-286132-ag2l1xa7	149	176	Pneumonia	Pneumonia	NNP
cord-286132-ag2l1xa7	149	177	in	in	IN
cord-286132-ag2l1xa7	149	178	Psoriasis	Psoriasis	NNP
cord-286132-ag2l1xa7	149	179	Management	Management	NNP
cord-286132-ag2l1xa7	149	180	of	of	IN
cord-286132-ag2l1xa7	149	181	interstitial	interstitial	JJ
cord-286132-ag2l1xa7	149	182	lung	lung	NN
cord-286132-ag2l1xa7	149	183	disease	disease	NN
cord-286132-ag2l1xa7	149	184	associated	associate	VBN
cord-286132-ag2l1xa7	149	185	with	with	IN
cord-286132-ag2l1xa7	149	186	connective	connective	JJ
cord-286132-ag2l1xa7	149	187	tissue	tissue	NN
cord-286132-ag2l1xa7	149	188	disease	disease	NN
cord-286132-ag2l1xa7	149	189	Thoracic	thoracic	JJ
cord-286132-ag2l1xa7	149	190	manifestations	manifestation	NNS
cord-286132-ag2l1xa7	149	191	of	of	IN
cord-286132-ag2l1xa7	149	192	inflammatory	inflammatory	JJ
cord-286132-ag2l1xa7	149	193	bowel	bowel	NN
cord-286132-ag2l1xa7	149	194	disease	disease	NN
cord-286132-ag2l1xa7	150	1	Distinct	distinct	JJ
cord-286132-ag2l1xa7	150	2	immune	immune	JJ
cord-286132-ag2l1xa7	150	3	response	response	NN
cord-286132-ag2l1xa7	150	4	in	in	IN
cord-286132-ag2l1xa7	150	5	two	two	CD
cord-286132-ag2l1xa7	150	6	MERS	MERS	NNP
cord-286132-ag2l1xa7	150	7	-	-	HYPH
cord-286132-ag2l1xa7	150	8	CoV	cov	NN
cord-286132-ag2l1xa7	150	9	-	-	HYPH
cord-286132-ag2l1xa7	150	10	infected	infect	VBN
cord-286132-ag2l1xa7	150	11	patients	patient	NNS
cord-286132-ag2l1xa7	150	12	:	:	:
cord-286132-ag2l1xa7	150	13	can	can	MD
cord-286132-ag2l1xa7	150	14	we	-PRON-	PRP
cord-286132-ag2l1xa7	150	15	go	go	VB
cord-286132-ag2l1xa7	150	16	from	from	IN
cord-286132-ag2l1xa7	150	17	bench	bench	NN
cord-286132-ag2l1xa7	150	18	to	to	IN
cord-286132-ag2l1xa7	150	19	bedside	bedside	NN
cord-286132-ag2l1xa7	150	20	?	?	.
cord-286132-ag2l1xa7	151	1	Immunology	Immunology	NNP
cord-286132-ag2l1xa7	151	2	taught	teach	VBD
cord-286132-ag2l1xa7	151	3	by	by	IN
cord-286132-ag2l1xa7	151	4	human	human	JJ
cord-286132-ag2l1xa7	151	5	genetics	genetic	NNS
cord-286132-ag2l1xa7	151	6	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	151	7	is	be	VBZ
cord-286132-ag2l1xa7	151	8	essential	essential	JJ
cord-286132-ag2l1xa7	151	9	for	for	IN
cord-286132-ag2l1xa7	151	10	T	T	NNP
cord-286132-ag2l1xa7	151	11	cell	cell	NN
cord-286132-ag2l1xa7	151	12	-	-	HYPH
cord-286132-ag2l1xa7	151	13	mediated	mediate	VBN
cord-286132-ag2l1xa7	151	14	colitis	colitis	NN
cord-286132-ag2l1xa7	151	15	and	and	CC
cord-286132-ag2l1xa7	151	16	promotes	promote	VBZ
cord-286132-ag2l1xa7	151	17	inflammation	inflammation	NN
cord-286132-ag2l1xa7	151	18	via	via	IN
cord-286132-ag2l1xa7	151	19	IL-17	IL-17	NNP
cord-286132-ag2l1xa7	151	20	and	and	CC
cord-286132-ag2l1xa7	151	21	IL-6	IL-6	NNP
cord-286132-ag2l1xa7	151	22	IL-12	IL-12	NNP
cord-286132-ag2l1xa7	151	23	and	and	CC
cord-286132-ag2l1xa7	151	24	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	151	25	cytokines	cytokine	NNS
cord-286132-ag2l1xa7	151	26	:	:	:
cord-286132-ag2l1xa7	151	27	from	from	IN
cord-286132-ag2l1xa7	151	28	discovery	discovery	NN
cord-286132-ag2l1xa7	151	29	to	to	IN
cord-286132-ag2l1xa7	151	30	targeted	target	VBN
cord-286132-ag2l1xa7	151	31	therapies	therapy	NNS
cord-286132-ag2l1xa7	151	32	for	for	IN
cord-286132-ag2l1xa7	151	33	immune	immune	NN
cord-286132-ag2l1xa7	151	34	-	-	HYPH
cord-286132-ag2l1xa7	151	35	mediated	mediate	VBN
cord-286132-ag2l1xa7	151	36	inflammatory	inflammatory	JJ
cord-286132-ag2l1xa7	151	37	diseases	disease	NNS
cord-286132-ag2l1xa7	151	38	Critical	critical	JJ
cord-286132-ag2l1xa7	151	39	role	role	NN
cord-286132-ag2l1xa7	151	40	of	of	IN
cord-286132-ag2l1xa7	151	41	IL-17RA	il-17ra	NN
cord-286132-ag2l1xa7	151	42	in	in	IN
cord-286132-ag2l1xa7	151	43	immunopathology	immunopathology	NN
cord-286132-ag2l1xa7	151	44	of	of	IN
cord-286132-ag2l1xa7	151	45	influenza	influenza	NN
cord-286132-ag2l1xa7	151	46	infection	infection	NN
cord-286132-ag2l1xa7	151	47	What	what	WP
cord-286132-ag2l1xa7	151	48	to	to	TO
cord-286132-ag2l1xa7	151	49	add	add	VB
cord-286132-ag2l1xa7	151	50	to	to	IN
cord-286132-ag2l1xa7	151	51	nothing	nothing	NN
cord-286132-ag2l1xa7	151	52	?	?	.
cord-286132-ag2l1xa7	152	1	Use	use	VB
cord-286132-ag2l1xa7	152	2	and	and	CC
cord-286132-ag2l1xa7	152	3	avoidance	avoidance	NN
cord-286132-ag2l1xa7	152	4	of	of	IN
cord-286132-ag2l1xa7	152	5	continuity	continuity	NN
cord-286132-ag2l1xa7	152	6	corrections	correction	NNS
cord-286132-ag2l1xa7	152	7	in	in	IN
cord-286132-ag2l1xa7	152	8	meta	meta	NNP
cord-286132-ag2l1xa7	152	9	-	-	HYPH
cord-286132-ag2l1xa7	152	10	analysis	analysis	NN
cord-286132-ag2l1xa7	152	11	of	of	IN
cord-286132-ag2l1xa7	152	12	sparse	sparse	JJ
cord-286132-ag2l1xa7	152	13	data	datum	NNS
cord-286132-ag2l1xa7	152	14	an	an	DT
cord-286132-ag2l1xa7	152	15	anti	anti	JJ
cord-286132-ag2l1xa7	152	16	-	-	JJ
cord-286132-ag2l1xa7	152	17	interleukin-23	interleukin-23	JJ
cord-286132-ag2l1xa7	152	18	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	152	19	antibody	antibody	NN
cord-286132-ag2l1xa7	152	20	,	,	,
cord-286132-ag2l1xa7	152	21	for	for	IN
cord-286132-ag2l1xa7	152	22	the	the	DT
cord-286132-ag2l1xa7	152	23	treatment	treatment	NN
cord-286132-ag2l1xa7	152	24	of	of	IN
cord-286132-ag2l1xa7	152	25	moderate	moderate	JJ
cord-286132-ag2l1xa7	152	26	to	to	IN
cord-286132-ag2l1xa7	152	27	severe	severe	JJ
cord-286132-ag2l1xa7	152	28	plaque	plaque	NN
cord-286132-ag2l1xa7	152	29	-	-	HYPH
cord-286132-ag2l1xa7	152	30	type	type	NN
cord-286132-ag2l1xa7	152	31	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	152	32	in	in	IN
cord-286132-ag2l1xa7	152	33	Japanese	japanese	JJ
cord-286132-ag2l1xa7	152	34	patients	patient	NNS
cord-286132-ag2l1xa7	152	35	:	:	:
cord-286132-ag2l1xa7	153	1	Efficacy	efficacy	NN
cord-286132-ag2l1xa7	153	2	and	and	CC
cord-286132-ag2l1xa7	153	3	safety	safety	NN
cord-286132-ag2l1xa7	153	4	results	result	NNS
cord-286132-ag2l1xa7	153	5	from	from	IN
cord-286132-ag2l1xa7	153	6	a	a	DT
cord-286132-ag2l1xa7	153	7	phase	phase	NN
cord-286132-ag2l1xa7	153	8	3	3	CD
cord-286132-ag2l1xa7	153	9	,	,	,
cord-286132-ag2l1xa7	153	10	randomized	randomized	JJ
cord-286132-ag2l1xa7	153	11	,	,	,
cord-286132-ag2l1xa7	153	12	double	double	JJ
cord-286132-ag2l1xa7	153	13	-	-	HYPH
cord-286132-ag2l1xa7	153	14	blind	blind	JJ
cord-286132-ag2l1xa7	153	15	,	,	,
cord-286132-ag2l1xa7	153	16	placebo	placebo	NN
cord-286132-ag2l1xa7	153	17	-	-	HYPH
cord-286132-ag2l1xa7	153	18	controlled	control	VBN
cord-286132-ag2l1xa7	153	19	study	study	NN
cord-286132-ag2l1xa7	153	20	Safety	safety	NN
cord-286132-ag2l1xa7	153	21	and	and	CC
cord-286132-ag2l1xa7	153	22	efficacy	efficacy	NN
cord-286132-ag2l1xa7	153	23	of	of	IN
cord-286132-ag2l1xa7	153	24	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	153	25	in	in	IN
cord-286132-ag2l1xa7	153	26	Japanese	japanese	JJ
cord-286132-ag2l1xa7	153	27	patients	patient	NNS
cord-286132-ag2l1xa7	153	28	with	with	IN
cord-286132-ag2l1xa7	153	29	moderate	moderate	JJ
cord-286132-ag2l1xa7	153	30	-	-	HYPH
cord-286132-ag2l1xa7	153	31	to	to	IN
cord-286132-ag2l1xa7	153	32	-	-	HYPH
cord-286132-ag2l1xa7	153	33	severe	severe	JJ
cord-286132-ag2l1xa7	153	34	plaque	plaque	NN
cord-286132-ag2l1xa7	153	35	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	153	36	:	:	:
cord-286132-ag2l1xa7	153	37	a	a	DT
cord-286132-ag2l1xa7	153	38	randomized	randomized	JJ
cord-286132-ag2l1xa7	153	39	,	,	,
cord-286132-ag2l1xa7	153	40	placebo	placebo	NN
cord-286132-ag2l1xa7	153	41	-	-	HYPH
cord-286132-ag2l1xa7	153	42	controlled	control	VBN
cord-286132-ag2l1xa7	153	43	,	,	,
cord-286132-ag2l1xa7	153	44	ascending	ascend	VBG
cord-286132-ag2l1xa7	153	45	-	-	HYPH
cord-286132-ag2l1xa7	153	46	dose	dose	NN
cord-286132-ag2l1xa7	153	47	study	study	NN
cord-286132-ag2l1xa7	153	48	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	153	49	and	and	CC
cord-286132-ag2l1xa7	153	50	safety	safety	NN
cord-286132-ag2l1xa7	153	51	of	of	IN
cord-286132-ag2l1xa7	153	52	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	153	53	,	,	,
cord-286132-ag2l1xa7	153	54	an	an	DT
cord-286132-ag2l1xa7	153	55	anti	anti	JJ
cord-286132-ag2l1xa7	153	56	-	-	JJ
cord-286132-ag2l1xa7	153	57	interleukin-23	interleukin-23	JJ
cord-286132-ag2l1xa7	153	58	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	153	59	antibody	antibody	NN
cord-286132-ag2l1xa7	153	60	,	,	,
cord-286132-ag2l1xa7	153	61	compared	compare	VBN
cord-286132-ag2l1xa7	153	62	with	with	IN
cord-286132-ag2l1xa7	153	63	adalimumab	adalimumab	NNS
cord-286132-ag2l1xa7	153	64	for	for	IN
cord-286132-ag2l1xa7	153	65	the	the	DT
cord-286132-ag2l1xa7	153	66	continuous	continuous	JJ
cord-286132-ag2l1xa7	153	67	treatment	treatment	NN
cord-286132-ag2l1xa7	153	68	of	of	IN
cord-286132-ag2l1xa7	153	69	patients	patient	NNS
cord-286132-ag2l1xa7	153	70	with	with	IN
cord-286132-ag2l1xa7	153	71	moderate	moderate	JJ
cord-286132-ag2l1xa7	153	72	to	to	IN
cord-286132-ag2l1xa7	153	73	severe	severe	JJ
cord-286132-ag2l1xa7	153	74	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	154	1	:	:	:
cord-286132-ag2l1xa7	154	2	Results	result	NNS
cord-286132-ag2l1xa7	154	3	from	from	IN
cord-286132-ag2l1xa7	154	4	the	the	DT
cord-286132-ag2l1xa7	154	5	phase	phase	NN
cord-286132-ag2l1xa7	154	6	III	iii	CD
cord-286132-ag2l1xa7	154	7	,	,	,
cord-286132-ag2l1xa7	154	8	double	double	RB
cord-286132-ag2l1xa7	154	9	-	-	HYPH
cord-286132-ag2l1xa7	154	10	blinded	blinded	JJ
cord-286132-ag2l1xa7	154	11	,	,	,
cord-286132-ag2l1xa7	154	12	placebo	placebo	NN
cord-286132-ag2l1xa7	154	13	-	-	HYPH
cord-286132-ag2l1xa7	154	14	and	and	CC
cord-286132-ag2l1xa7	154	15	active	active	JJ
cord-286132-ag2l1xa7	154	16	comparator	comparator	NN
cord-286132-ag2l1xa7	154	17	-	-	HYPH
cord-286132-ag2l1xa7	154	18	controlled	control	VBN
cord-286132-ag2l1xa7	154	19	VOYAGE	voyage	NN
cord-286132-ag2l1xa7	154	20	1	1	CD
cord-286132-ag2l1xa7	154	21	trial	trial	NN
cord-286132-ag2l1xa7	154	22	Guselkumab	Guselkumab	NNP
cord-286132-ag2l1xa7	154	23	(	(	-LRB-
cord-286132-ag2l1xa7	154	24	an	an	DT
cord-286132-ag2l1xa7	154	25	IL-23-specific	IL-23-specific	NNP
cord-286132-ag2l1xa7	154	26	mAb	mab	NN
cord-286132-ag2l1xa7	154	27	)	)	-RRB-
cord-286132-ag2l1xa7	154	28	demonstrates	demonstrate	VBZ
cord-286132-ag2l1xa7	154	29	clinical	clinical	JJ
cord-286132-ag2l1xa7	154	30	and	and	CC
cord-286132-ag2l1xa7	154	31	molecular	molecular	JJ
cord-286132-ag2l1xa7	154	32	response	response	NN
cord-286132-ag2l1xa7	154	33	in	in	IN
cord-286132-ag2l1xa7	154	34	patients	patient	NNS
cord-286132-ag2l1xa7	154	35	with	with	IN
cord-286132-ag2l1xa7	154	36	moderate	moderate	JJ
cord-286132-ag2l1xa7	154	37	-	-	HYPH
cord-286132-ag2l1xa7	154	38	to	to	IN
cord-286132-ag2l1xa7	154	39	-	-	HYPH
cord-286132-ag2l1xa7	154	40	severe	severe	JJ
cord-286132-ag2l1xa7	154	41	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	154	42	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	154	43	and	and	CC
cord-286132-ag2l1xa7	154	44	Safety	Safety	NNP
cord-286132-ag2l1xa7	154	45	of	of	IN
cord-286132-ag2l1xa7	154	46	Guselkumab	Guselkumab	NNP
cord-286132-ag2l1xa7	154	47	,	,	,
cord-286132-ag2l1xa7	154	48	an	an	DT
cord-286132-ag2l1xa7	154	49	Anti	anti	JJ
cord-286132-ag2l1xa7	154	50	-	-	JJ
cord-286132-ag2l1xa7	154	51	interleukin	interleukin	JJ
cord-286132-ag2l1xa7	154	52	23	23	CD
cord-286132-ag2l1xa7	154	53	Monoclonal	Monoclonal	NNP
cord-286132-ag2l1xa7	154	54	Antibody	Antibody	NNP
cord-286132-ag2l1xa7	154	55	,	,	,
cord-286132-ag2l1xa7	154	56	for	for	IN
cord-286132-ag2l1xa7	154	57	Palmoplantar	Palmoplantar	NNP
cord-286132-ag2l1xa7	154	58	Pustulosis	Pustulosis	NNP
cord-286132-ag2l1xa7	154	59	:	:	:
cord-286132-ag2l1xa7	155	1	A	a	DT
cord-286132-ag2l1xa7	155	2	Randomized	Randomized	NNP
cord-286132-ag2l1xa7	155	3	Clinical	Clinical	NNP
cord-286132-ag2l1xa7	155	4	Trial	Trial	NNP
cord-286132-ag2l1xa7	155	5	First	first	JJ
cord-286132-ag2l1xa7	155	6	-	-	HYPH
cord-286132-ag2l1xa7	155	7	in	in	IN
cord-286132-ag2l1xa7	155	8	-	-	HYPH
cord-286132-ag2l1xa7	155	9	human	human	JJ
cord-286132-ag2l1xa7	155	10	study	study	NN
cord-286132-ag2l1xa7	155	11	to	to	TO
cord-286132-ag2l1xa7	155	12	assess	assess	VB
cord-286132-ag2l1xa7	155	13	guselkumab	guselkumab	NNS
cord-286132-ag2l1xa7	155	14	(	(	-LRB-
cord-286132-ag2l1xa7	155	15	anti	anti	JJ
cord-286132-ag2l1xa7	155	16	-	-	JJ
cord-286132-ag2l1xa7	155	17	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	155	18	mAb	mAb	NNP
cord-286132-ag2l1xa7	155	19	)	)	-RRB-
cord-286132-ag2l1xa7	155	20	pharmacokinetics	pharmacokinetic	NNS
cord-286132-ag2l1xa7	155	21	/	/	SYM
cord-286132-ag2l1xa7	155	22	safety	safety	NN
cord-286132-ag2l1xa7	155	23	in	in	IN
cord-286132-ag2l1xa7	155	24	healthy	healthy	JJ
cord-286132-ag2l1xa7	155	25	subjects	subject	NNS
cord-286132-ag2l1xa7	155	26	and	and	CC
cord-286132-ag2l1xa7	155	27	patients	patient	NNS
cord-286132-ag2l1xa7	155	28	with	with	IN
cord-286132-ag2l1xa7	155	29	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	30	-	-	HYPH
cord-286132-ag2l1xa7	155	31	to	to	IN
cord-286132-ag2l1xa7	155	32	-	-	HYPH
cord-286132-ag2l1xa7	155	33	severe	severe	JJ
cord-286132-ag2l1xa7	155	34	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	35	Anti	anti	NN
cord-286132-ag2l1xa7	155	36	-	-	NNP
cord-286132-ag2l1xa7	155	37	IL-23A	IL-23A	NNP
cord-286132-ag2l1xa7	155	38	mAb	mAb	HYPH
cord-286132-ag2l1xa7	155	39	BI	BI	NNP
cord-286132-ag2l1xa7	155	40	655066	655066	CD
cord-286132-ag2l1xa7	155	41	for	for	IN
cord-286132-ag2l1xa7	155	42	treatment	treatment	NN
cord-286132-ag2l1xa7	155	43	of	of	IN
cord-286132-ag2l1xa7	155	44	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	45	-	-	HYPH
cord-286132-ag2l1xa7	155	46	to	to	IN
cord-286132-ag2l1xa7	155	47	-	-	HYPH
cord-286132-ag2l1xa7	155	48	severe	severe	JJ
cord-286132-ag2l1xa7	155	49	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	50	:	:	:
cord-286132-ag2l1xa7	155	51	Safety	safety	NN
cord-286132-ag2l1xa7	155	52	,	,	,
cord-286132-ag2l1xa7	155	53	efficacy	efficacy	NN
cord-286132-ag2l1xa7	155	54	,	,	,
cord-286132-ag2l1xa7	155	55	pharmacokinetics	pharmacokinetic	NNS
cord-286132-ag2l1xa7	155	56	,	,	,
cord-286132-ag2l1xa7	155	57	and	and	CC
cord-286132-ag2l1xa7	155	58	biomarker	biomarker	NN
cord-286132-ag2l1xa7	155	59	results	result	NNS
cord-286132-ag2l1xa7	155	60	of	of	IN
cord-286132-ag2l1xa7	155	61	a	a	DT
cord-286132-ag2l1xa7	155	62	single	single	RB
cord-286132-ag2l1xa7	155	63	-	-	HYPH
cord-286132-ag2l1xa7	155	64	rising	rise	VBG
cord-286132-ag2l1xa7	155	65	-	-	HYPH
cord-286132-ag2l1xa7	155	66	dose	dose	NN
cord-286132-ag2l1xa7	155	67	,	,	,
cord-286132-ag2l1xa7	155	68	randomized	randomized	JJ
cord-286132-ag2l1xa7	155	69	,	,	,
cord-286132-ag2l1xa7	155	70	double	double	JJ
cord-286132-ag2l1xa7	155	71	-	-	HYPH
cord-286132-ag2l1xa7	155	72	blind	blind	JJ
cord-286132-ag2l1xa7	155	73	,	,	,
cord-286132-ag2l1xa7	155	74	placebo	placebo	NN
cord-286132-ag2l1xa7	155	75	-	-	HYPH
cord-286132-ag2l1xa7	155	76	controlled	control	VBN
cord-286132-ag2l1xa7	155	77	trial	trial	NN
cord-286132-ag2l1xa7	155	78	Pharmacokinetics	Pharmacokinetics	NNP
cord-286132-ag2l1xa7	155	79	of	of	IN
cord-286132-ag2l1xa7	155	80	Tildrakizumab	Tildrakizumab	NNP
cord-286132-ag2l1xa7	155	81	(	(	-LRB-
cord-286132-ag2l1xa7	155	82	MK-3222	MK-3222	NNP
cord-286132-ag2l1xa7	155	83	)	)	-RRB-
cord-286132-ag2l1xa7	155	84	,	,	,
cord-286132-ag2l1xa7	155	85	an	an	DT
cord-286132-ag2l1xa7	155	86	Anti	Anti	NNP
cord-286132-ag2l1xa7	155	87	-	-	NNP
cord-286132-ag2l1xa7	155	88	IL-23	IL-23	NNP
cord-286132-ag2l1xa7	155	89	Monoclonal	Monoclonal	NNP
cord-286132-ag2l1xa7	155	90	After	after	IN
cord-286132-ag2l1xa7	155	91	Intravenous	Intravenous	NNP
cord-286132-ag2l1xa7	155	92	or	or	CC
cord-286132-ag2l1xa7	155	93	Subcutaneous	Subcutaneous	NNP
cord-286132-ag2l1xa7	155	94	Administration	Administration	NNP
cord-286132-ag2l1xa7	155	95	in	in	IN
cord-286132-ag2l1xa7	155	96	Healthy	Healthy	NNP
cord-286132-ag2l1xa7	155	97	Subjects	Subjects	NNPS
cord-286132-ag2l1xa7	155	98	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	155	99	and	and	CC
cord-286132-ag2l1xa7	155	100	safety	safety	NN
cord-286132-ag2l1xa7	155	101	of	of	IN
cord-286132-ag2l1xa7	155	102	briakinumab	briakinumab	NNP
cord-286132-ag2l1xa7	155	103	vs.	vs.	FW
cord-286132-ag2l1xa7	155	104	etanercept	etanercept	NNP
cord-286132-ag2l1xa7	155	105	and	and	CC
cord-286132-ag2l1xa7	155	106	placebo	placebo	NN
cord-286132-ag2l1xa7	155	107	in	in	IN
cord-286132-ag2l1xa7	155	108	patients	patient	NNS
cord-286132-ag2l1xa7	155	109	with	with	IN
cord-286132-ag2l1xa7	155	110	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	111	to	to	IN
cord-286132-ag2l1xa7	155	112	severe	severe	JJ
cord-286132-ag2l1xa7	155	113	chronic	chronic	JJ
cord-286132-ag2l1xa7	155	114	plaque	plaque	NN
cord-286132-ag2l1xa7	155	115	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	116	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	155	117	and	and	CC
cord-286132-ag2l1xa7	155	118	safety	safety	NN
cord-286132-ag2l1xa7	155	119	results	result	NNS
cord-286132-ag2l1xa7	155	120	from	from	IN
cord-286132-ag2l1xa7	155	121	a	a	DT
cord-286132-ag2l1xa7	155	122	phase	phase	NN
cord-286132-ag2l1xa7	155	123	III	iii	CD
cord-286132-ag2l1xa7	155	124	,	,	,
cord-286132-ag2l1xa7	155	125	randomized	randomize	VBN
cord-286132-ag2l1xa7	155	126	controlled	control	VBN
cord-286132-ag2l1xa7	155	127	trial	trial	NN
cord-286132-ag2l1xa7	155	128	comparing	compare	VBG
cord-286132-ag2l1xa7	155	129	the	the	DT
cord-286132-ag2l1xa7	155	130	safety	safety	NN
cord-286132-ag2l1xa7	155	131	and	and	CC
cord-286132-ag2l1xa7	155	132	efficacy	efficacy	NN
cord-286132-ag2l1xa7	155	133	of	of	IN
cord-286132-ag2l1xa7	155	134	briakinumab	briakinumab	NNP
cord-286132-ag2l1xa7	155	135	with	with	IN
cord-286132-ag2l1xa7	155	136	etanercept	etanercept	NNP
cord-286132-ag2l1xa7	155	137	and	and	CC
cord-286132-ag2l1xa7	155	138	placebo	placebo	NN
cord-286132-ag2l1xa7	155	139	in	in	IN
cord-286132-ag2l1xa7	155	140	patients	patient	NNS
cord-286132-ag2l1xa7	155	141	with	with	IN
cord-286132-ag2l1xa7	155	142	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	143	to	to	IN
cord-286132-ag2l1xa7	155	144	severe	severe	JJ
cord-286132-ag2l1xa7	155	145	chronic	chronic	JJ
cord-286132-ag2l1xa7	155	146	plaque	plaque	NN
cord-286132-ag2l1xa7	155	147	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	148	Safety	safety	NN
cord-286132-ag2l1xa7	155	149	and	and	CC
cord-286132-ag2l1xa7	155	150	efficacy	efficacy	NN
cord-286132-ag2l1xa7	155	151	of	of	IN
cord-286132-ag2l1xa7	155	152	ABT-874	abt-874	DT
cord-286132-ag2l1xa7	155	153	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	155	154	antibody	antibody	NN
cord-286132-ag2l1xa7	155	155	,	,	,
cord-286132-ag2l1xa7	155	156	in	in	IN
cord-286132-ag2l1xa7	155	157	the	the	DT
cord-286132-ag2l1xa7	155	158	treatment	treatment	NN
cord-286132-ag2l1xa7	155	159	of	of	IN
cord-286132-ag2l1xa7	155	160	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	161	to	to	IN
cord-286132-ag2l1xa7	155	162	severe	severe	JJ
cord-286132-ag2l1xa7	155	163	chronic	chronic	JJ
cord-286132-ag2l1xa7	155	164	plaque	plaque	NN
cord-286132-ag2l1xa7	155	165	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	166	:	:	:
cord-286132-ag2l1xa7	155	167	results	result	NNS
cord-286132-ag2l1xa7	155	168	of	of	IN
cord-286132-ag2l1xa7	155	169	a	a	DT
cord-286132-ag2l1xa7	155	170	randomized	randomized	JJ
cord-286132-ag2l1xa7	155	171	,	,	,
cord-286132-ag2l1xa7	155	172	placebo	placebo	NN
cord-286132-ag2l1xa7	155	173	-	-	HYPH
cord-286132-ag2l1xa7	155	174	controlled	control	VBN
cord-286132-ag2l1xa7	155	175	,	,	,
cord-286132-ag2l1xa7	155	176	phase	phase	NN
cord-286132-ag2l1xa7	155	177	2	2	CD
cord-286132-ag2l1xa7	155	178	trial	trial	NN
cord-286132-ag2l1xa7	155	179	Anti	Anti	NNP
cord-286132-ag2l1xa7	155	180	-	-	JJ
cord-286132-ag2l1xa7	155	181	interleukin-12	interleukin-12	JJ
cord-286132-ag2l1xa7	155	182	antibody	antibody	NN
cord-286132-ag2l1xa7	155	183	for	for	IN
cord-286132-ag2l1xa7	155	184	active	active	JJ
cord-286132-ag2l1xa7	155	185	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	155	186	's	's	POS
cord-286132-ag2l1xa7	155	187	disease	disease	NN
cord-286132-ag2l1xa7	155	188	A	a	DT
cord-286132-ag2l1xa7	155	189	phase	phase	NN
cord-286132-ag2l1xa7	155	190	2	2	CD
cord-286132-ag2l1xa7	155	191	,	,	,
cord-286132-ag2l1xa7	155	192	24-week	24-week	JJ
cord-286132-ag2l1xa7	155	193	,	,	,
cord-286132-ag2l1xa7	155	194	randomized	randomized	JJ
cord-286132-ag2l1xa7	155	195	,	,	,
cord-286132-ag2l1xa7	155	196	placebo	placebo	NN
cord-286132-ag2l1xa7	155	197	-	-	HYPH
cord-286132-ag2l1xa7	155	198	controlled	control	VBN
cord-286132-ag2l1xa7	155	199	,	,	,
cord-286132-ag2l1xa7	155	200	double	double	JJ
cord-286132-ag2l1xa7	155	201	-	-	HYPH
cord-286132-ag2l1xa7	155	202	blind	blind	JJ
cord-286132-ag2l1xa7	155	203	study	study	NN
cord-286132-ag2l1xa7	155	204	examining	examine	VBG
cord-286132-ag2l1xa7	155	205	the	the	DT
cord-286132-ag2l1xa7	155	206	efficacy	efficacy	NN
cord-286132-ag2l1xa7	155	207	and	and	CC
cord-286132-ag2l1xa7	155	208	safety	safety	NN
cord-286132-ag2l1xa7	155	209	of	of	IN
cord-286132-ag2l1xa7	155	210	an	an	DT
cord-286132-ag2l1xa7	155	211	anti	anti	JJ
cord-286132-ag2l1xa7	155	212	-	-	JJ
cord-286132-ag2l1xa7	155	213	interleukin-12	interleukin-12	JJ
cord-286132-ag2l1xa7	155	214	and	and	CC
cord-286132-ag2l1xa7	155	215	-23	-23	NN
cord-286132-ag2l1xa7	155	216	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	155	217	antibody	antibody	NN
cord-286132-ag2l1xa7	155	218	in	in	IN
cord-286132-ag2l1xa7	155	219	patients	patient	NNS
cord-286132-ag2l1xa7	155	220	with	with	IN
cord-286132-ag2l1xa7	155	221	relapsing	relapse	VBG
cord-286132-ag2l1xa7	155	222	-	-	HYPH
cord-286132-ag2l1xa7	155	223	remitting	remit	VBG
cord-286132-ag2l1xa7	155	224	or	or	CC
cord-286132-ag2l1xa7	155	225	secondary	secondary	JJ
cord-286132-ag2l1xa7	155	226	progressive	progressive	JJ
cord-286132-ag2l1xa7	155	227	multiple	multiple	JJ
cord-286132-ag2l1xa7	155	228	sclerosis	sclerosis	NN
cord-286132-ag2l1xa7	155	229	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	155	230	in	in	IN
cord-286132-ag2l1xa7	155	231	adolescent	adolescent	JJ
cord-286132-ag2l1xa7	155	232	patients	patient	NNS
cord-286132-ag2l1xa7	155	233	age	age	NN
cord-286132-ag2l1xa7	155	234	12	12	CD
cord-286132-ag2l1xa7	155	235	to	to	TO
cord-286132-ag2l1xa7	155	236	17	17	CD
cord-286132-ag2l1xa7	155	237	years	year	NNS
cord-286132-ag2l1xa7	155	238	with	with	IN
cord-286132-ag2l1xa7	155	239	moderate	moderate	JJ
cord-286132-ag2l1xa7	155	240	-	-	HYPH
cord-286132-ag2l1xa7	155	241	to	to	IN
cord-286132-ag2l1xa7	155	242	-	-	HYPH
cord-286132-ag2l1xa7	155	243	severe	severe	JJ
cord-286132-ag2l1xa7	155	244	plaque	plaque	NN
cord-286132-ag2l1xa7	155	245	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	155	246	:	:	:
cord-286132-ag2l1xa7	155	247	results	result	NNS
cord-286132-ag2l1xa7	155	248	of	of	IN
cord-286132-ag2l1xa7	155	249	the	the	DT
cord-286132-ag2l1xa7	155	250	randomized	randomized	JJ
cord-286132-ag2l1xa7	155	251	phase	phase	NN
cord-286132-ag2l1xa7	155	252	3	3	CD
cord-286132-ag2l1xa7	155	253	CADMUS	CADMUS	NNP
cord-286132-ag2l1xa7	155	254	study	study	NN
cord-286132-ag2l1xa7	155	255	Phase	Phase	NNP
cord-286132-ag2l1xa7	156	1	3	3	LS
cord-286132-ag2l1xa7	156	2	Studies	study	NNS
cord-286132-ag2l1xa7	156	3	Comparing	compare	VBG
cord-286132-ag2l1xa7	156	4	Brodalumab	Brodalumab	NNP
cord-286132-ag2l1xa7	156	5	with	with	IN
cord-286132-ag2l1xa7	156	6	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	156	7	in	in	IN
cord-286132-ag2l1xa7	156	8	Psoriasis	Psoriasis	NNP
cord-286132-ag2l1xa7	156	9	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	156	10	and	and	CC
cord-286132-ag2l1xa7	156	11	safety	safety	NN
cord-286132-ag2l1xa7	156	12	of	of	IN
cord-286132-ag2l1xa7	156	13	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	156	14	in	in	IN
cord-286132-ag2l1xa7	156	15	Chinese	chinese	JJ
cord-286132-ag2l1xa7	156	16	patients	patient	NNS
cord-286132-ag2l1xa7	156	17	with	with	IN
cord-286132-ag2l1xa7	156	18	moderate	moderate	JJ
cord-286132-ag2l1xa7	156	19	to	to	IN
cord-286132-ag2l1xa7	156	20	severe	severe	JJ
cord-286132-ag2l1xa7	156	21	plaque	plaque	NN
cord-286132-ag2l1xa7	156	22	-	-	HYPH
cord-286132-ag2l1xa7	156	23	type	type	NN
cord-286132-ag2l1xa7	156	24	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	156	25	:	:	:
cord-286132-ag2l1xa7	156	26	results	result	NNS
cord-286132-ag2l1xa7	156	27	from	from	IN
cord-286132-ag2l1xa7	156	28	a	a	DT
cord-286132-ag2l1xa7	156	29	phase	phase	NN
cord-286132-ag2l1xa7	156	30	3	3	CD
cord-286132-ag2l1xa7	156	31	clinical	clinical	JJ
cord-286132-ag2l1xa7	156	32	trial	trial	NN
cord-286132-ag2l1xa7	156	33	(	(	-LRB-
cord-286132-ag2l1xa7	156	34	LOTUS	LOTUS	NNP
cord-286132-ag2l1xa7	156	35	)	)	-RRB-
cord-286132-ag2l1xa7	156	36	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	156	37	and	and	CC
cord-286132-ag2l1xa7	156	38	safety	safety	NN
cord-286132-ag2l1xa7	156	39	of	of	IN
cord-286132-ag2l1xa7	156	40	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	156	41	for	for	IN
cord-286132-ag2l1xa7	156	42	the	the	DT
cord-286132-ag2l1xa7	156	43	treatment	treatment	NN
cord-286132-ag2l1xa7	156	44	of	of	IN
cord-286132-ag2l1xa7	156	45	moderate	moderate	JJ
cord-286132-ag2l1xa7	156	46	-	-	HYPH
cord-286132-ag2l1xa7	156	47	to	to	IN
cord-286132-ag2l1xa7	156	48	-	-	HYPH
cord-286132-ag2l1xa7	156	49	severe	severe	JJ
cord-286132-ag2l1xa7	156	50	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	156	51	:	:	:
cord-286132-ag2l1xa7	156	52	a	a	DT
cord-286132-ag2l1xa7	156	53	phase	phase	NN
cord-286132-ag2l1xa7	156	54	III	iii	CD
cord-286132-ag2l1xa7	156	55	,	,	,
cord-286132-ag2l1xa7	156	56	randomized	randomized	JJ
cord-286132-ag2l1xa7	156	57	,	,	,
cord-286132-ag2l1xa7	156	58	placebo	placebo	NN
cord-286132-ag2l1xa7	156	59	-	-	HYPH
cord-286132-ag2l1xa7	156	60	controlled	control	VBN
cord-286132-ag2l1xa7	156	61	trial	trial	NN
cord-286132-ag2l1xa7	156	62	in	in	IN
cord-286132-ag2l1xa7	156	63	Taiwanese	taiwanese	JJ
cord-286132-ag2l1xa7	156	64	and	and	CC
cord-286132-ag2l1xa7	156	65	Korean	korean	JJ
cord-286132-ag2l1xa7	156	66	patients	patient	NNS
cord-286132-ag2l1xa7	156	67	(	(	-LRB-
cord-286132-ag2l1xa7	156	68	PEARL	PEARL	NNP
cord-286132-ag2l1xa7	156	69	)	)	-RRB-
cord-286132-ag2l1xa7	156	70	Efficacy	efficacy	NN
cord-286132-ag2l1xa7	156	71	and	and	CC
cord-286132-ag2l1xa7	156	72	safety	safety	NN
cord-286132-ag2l1xa7	156	73	of	of	IN
cord-286132-ag2l1xa7	156	74	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	156	75	,	,	,
cord-286132-ag2l1xa7	156	76	a	a	DT
cord-286132-ag2l1xa7	156	77	human	human	JJ
cord-286132-ag2l1xa7	156	78	interleukin-12/23	interleukin-12/23	NNP
cord-286132-ag2l1xa7	156	79	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	156	80	antibody	antibody	NN
cord-286132-ag2l1xa7	156	81	,	,	,
cord-286132-ag2l1xa7	156	82	in	in	IN
cord-286132-ag2l1xa7	156	83	patients	patient	NNS
cord-286132-ag2l1xa7	156	84	with	with	IN
cord-286132-ag2l1xa7	156	85	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	156	86	:	:	:
cord-286132-ag2l1xa7	156	87	76-week	76-week	CD
cord-286132-ag2l1xa7	156	88	results	result	NNS
cord-286132-ag2l1xa7	156	89	from	from	IN
cord-286132-ag2l1xa7	156	90	a	a	DT
cord-286132-ag2l1xa7	156	91	randomised	randomised	JJ
cord-286132-ag2l1xa7	156	92	,	,	,
cord-286132-ag2l1xa7	156	93	double	double	JJ
cord-286132-ag2l1xa7	156	94	-	-	HYPH
cord-286132-ag2l1xa7	156	95	blind	blind	JJ
cord-286132-ag2l1xa7	156	96	,	,	,
cord-286132-ag2l1xa7	156	97	placebo	placebo	NN
cord-286132-ag2l1xa7	156	98	-	-	HYPH
cord-286132-ag2l1xa7	156	99	controlled	control	VBN
cord-286132-ag2l1xa7	156	100	trial	trial	NN
cord-286132-ag2l1xa7	156	101	(	(	-LRB-
cord-286132-ag2l1xa7	156	102	PHOENIX	PHOENIX	NNP
cord-286132-ag2l1xa7	156	103	1	1	CD
cord-286132-ag2l1xa7	156	104	)	)	-RRB-
cord-286132-ag2l1xa7	157	1	A	a	DT
cord-286132-ag2l1xa7	157	2	human	human	JJ
cord-286132-ag2l1xa7	157	3	interleukin-12/23	interleukin-12/23	NNP
cord-286132-ag2l1xa7	157	4	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	157	5	antibody	antibody	NN
cord-286132-ag2l1xa7	157	6	for	for	IN
cord-286132-ag2l1xa7	157	7	the	the	DT
cord-286132-ag2l1xa7	157	8	treatment	treatment	NN
cord-286132-ag2l1xa7	157	9	of	of	IN
cord-286132-ag2l1xa7	157	10	psoriasis	psoriasis	NN
cord-286132-ag2l1xa7	157	11	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	157	12	and	and	CC
cord-286132-ag2l1xa7	157	13	safety	safety	NN
cord-286132-ag2l1xa7	157	14	of	of	IN
cord-286132-ag2l1xa7	157	15	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	157	16	in	in	IN
cord-286132-ag2l1xa7	157	17	patients	patient	NNS
cord-286132-ag2l1xa7	157	18	with	with	IN
cord-286132-ag2l1xa7	157	19	active	active	JJ
cord-286132-ag2l1xa7	157	20	psoriatic	psoriatic	JJ
cord-286132-ag2l1xa7	157	21	arthritis	arthritis	NN
cord-286132-ag2l1xa7	157	22	:	:	:
cord-286132-ag2l1xa7	157	23	1	1	CD
cord-286132-ag2l1xa7	157	24	year	year	NN
cord-286132-ag2l1xa7	157	25	results	result	NNS
cord-286132-ag2l1xa7	157	26	of	of	IN
cord-286132-ag2l1xa7	157	27	the	the	DT
cord-286132-ag2l1xa7	157	28	phase	phase	NN
cord-286132-ag2l1xa7	157	29	3	3	CD
cord-286132-ag2l1xa7	157	30	,	,	,
cord-286132-ag2l1xa7	157	31	multicentre	multicentre	NNP
cord-286132-ag2l1xa7	157	32	,	,	,
cord-286132-ag2l1xa7	157	33	double	double	JJ
cord-286132-ag2l1xa7	157	34	-	-	HYPH
cord-286132-ag2l1xa7	157	35	blind	blind	JJ
cord-286132-ag2l1xa7	157	36	,	,	,
cord-286132-ag2l1xa7	157	37	placebo	placebo	NN
cord-286132-ag2l1xa7	157	38	-	-	HYPH
cord-286132-ag2l1xa7	157	39	controlled	control	VBN
cord-286132-ag2l1xa7	157	40	PSUMMIT	PSUMMIT	NNP
cord-286132-ag2l1xa7	157	41	1	1	CD
cord-286132-ag2l1xa7	157	42	trial	trial	NN
cord-286132-ag2l1xa7	157	43	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	157	44	,	,	,
cord-286132-ag2l1xa7	157	45	a	a	DT
cord-286132-ag2l1xa7	157	46	human	human	JJ
cord-286132-ag2l1xa7	157	47	interleukin	interleukin	NN
cord-286132-ag2l1xa7	157	48	12/23	12/23	CD
cord-286132-ag2l1xa7	157	49	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	157	50	antibody	antibody	NN
cord-286132-ag2l1xa7	157	51	,	,	,
cord-286132-ag2l1xa7	157	52	for	for	IN
cord-286132-ag2l1xa7	157	53	psoriatic	psoriatic	JJ
cord-286132-ag2l1xa7	157	54	arthritis	arthritis	NN
cord-286132-ag2l1xa7	157	55	:	:	:
cord-286132-ag2l1xa7	157	56	randomised	randomised	JJ
cord-286132-ag2l1xa7	157	57	,	,	,
cord-286132-ag2l1xa7	157	58	double	double	JJ
cord-286132-ag2l1xa7	157	59	-	-	HYPH
cord-286132-ag2l1xa7	157	60	blind	blind	JJ
cord-286132-ag2l1xa7	157	61	,	,	,
cord-286132-ag2l1xa7	157	62	placebo	placebo	NN
cord-286132-ag2l1xa7	157	63	-	-	HYPH
cord-286132-ag2l1xa7	157	64	controlled	control	VBN
cord-286132-ag2l1xa7	157	65	,	,	,
cord-286132-ag2l1xa7	157	66	crossover	crossover	NN
cord-286132-ag2l1xa7	157	67	trial	trial	NN
cord-286132-ag2l1xa7	157	68	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	157	69	as	as	IN
cord-286132-ag2l1xa7	157	70	Induction	Induction	NNP
cord-286132-ag2l1xa7	157	71	and	and	CC
cord-286132-ag2l1xa7	157	72	Maintenance	Maintenance	NNP
cord-286132-ag2l1xa7	157	73	Therapy	Therapy	NNP
cord-286132-ag2l1xa7	157	74	for	for	IN
cord-286132-ag2l1xa7	157	75	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	157	76	's	's	POS
cord-286132-ag2l1xa7	157	77	Disease	Disease	NNP
cord-286132-ag2l1xa7	157	78	A	A	NNP
cord-286132-ag2l1xa7	157	79	randomized	randomized	JJ
cord-286132-ag2l1xa7	157	80	trial	trial	NN
cord-286132-ag2l1xa7	157	81	of	of	IN
cord-286132-ag2l1xa7	157	82	Ustekinumab	Ustekinumab	NNP
cord-286132-ag2l1xa7	157	83	monoclonal	monoclonal	JJ
cord-286132-ag2l1xa7	157	84	antibody	antibody	NN
cord-286132-ag2l1xa7	157	85	,	,	,
cord-286132-ag2l1xa7	157	86	in	in	IN
cord-286132-ag2l1xa7	157	87	patients	patient	NNS
cord-286132-ag2l1xa7	157	88	with	with	IN
cord-286132-ag2l1xa7	157	89	moderate	moderate	JJ
cord-286132-ag2l1xa7	157	90	-	-	HYPH
cord-286132-ag2l1xa7	157	91	to	to	IN
cord-286132-ag2l1xa7	157	92	-	-	HYPH
cord-286132-ag2l1xa7	157	93	severe	severe	JJ
cord-286132-ag2l1xa7	157	94	Crohn	Crohn	NNP
cord-286132-ag2l1xa7	157	95	's	's	POS
cord-286132-ag2l1xa7	157	96	disease	disease	NN
cord-286132-ag2l1xa7	157	97	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	157	98	and	and	CC
cord-286132-ag2l1xa7	157	99	safety	safety	NN
cord-286132-ag2l1xa7	157	100	of	of	IN
cord-286132-ag2l1xa7	157	101	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	157	102	treatment	treatment	NN
cord-286132-ag2l1xa7	157	103	in	in	IN
cord-286132-ag2l1xa7	157	104	adults	adult	NNS
cord-286132-ag2l1xa7	157	105	with	with	IN
cord-286132-ag2l1xa7	157	106	moderate	moderate	JJ
cord-286132-ag2l1xa7	157	107	-	-	HYPH
cord-286132-ag2l1xa7	157	108	to	to	IN
cord-286132-ag2l1xa7	157	109	-	-	HYPH
cord-286132-ag2l1xa7	157	110	severe	severe	JJ
cord-286132-ag2l1xa7	157	111	atopic	atopic	JJ
cord-286132-ag2l1xa7	157	112	dermatitis	dermatitis	NN
cord-286132-ag2l1xa7	157	113	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	157	114	and	and	CC
cord-286132-ag2l1xa7	157	115	safety	safety	NN
cord-286132-ag2l1xa7	157	116	of	of	IN
cord-286132-ag2l1xa7	157	117	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	157	118	in	in	IN
cord-286132-ag2l1xa7	157	119	Japanese	japanese	JJ
cord-286132-ag2l1xa7	157	120	patients	patient	NNS
cord-286132-ag2l1xa7	157	121	with	with	IN
cord-286132-ag2l1xa7	157	122	severe	severe	JJ
cord-286132-ag2l1xa7	157	123	atopic	atopic	JJ
cord-286132-ag2l1xa7	157	124	dermatitis	dermatitis	NN
cord-286132-ag2l1xa7	157	125	:	:	:
cord-286132-ag2l1xa7	157	126	a	a	DT
cord-286132-ag2l1xa7	157	127	randomized	randomized	JJ
cord-286132-ag2l1xa7	157	128	,	,	,
cord-286132-ag2l1xa7	157	129	double	double	JJ
cord-286132-ag2l1xa7	157	130	-	-	HYPH
cord-286132-ag2l1xa7	157	131	blind	blind	JJ
cord-286132-ag2l1xa7	157	132	,	,	,
cord-286132-ag2l1xa7	157	133	placebo	placebo	NN
cord-286132-ag2l1xa7	157	134	-	-	HYPH
cord-286132-ag2l1xa7	157	135	controlled	control	VBN
cord-286132-ag2l1xa7	157	136	,	,	,
cord-286132-ag2l1xa7	157	137	phase	phase	NN
cord-286132-ag2l1xa7	157	138	II	ii	CD
cord-286132-ag2l1xa7	157	139	study	study	NN
cord-286132-ag2l1xa7	157	140	Efficacy	Efficacy	NNP
cord-286132-ag2l1xa7	157	141	and	and	CC
cord-286132-ag2l1xa7	157	142	safety	safety	NN
cord-286132-ag2l1xa7	157	143	of	of	IN
cord-286132-ag2l1xa7	157	144	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	157	145	inhibitor	inhibitor	NN
cord-286132-ag2l1xa7	157	146	,	,	,
cord-286132-ag2l1xa7	157	147	in	in	IN
cord-286132-ag2l1xa7	157	148	patients	patient	NNS
cord-286132-ag2l1xa7	157	149	with	with	IN
cord-286132-ag2l1xa7	157	150	active	active	JJ
cord-286132-ag2l1xa7	157	151	systemic	systemic	JJ
cord-286132-ag2l1xa7	157	152	lupus	lupus	NN
cord-286132-ag2l1xa7	157	153	erythematosus	erythematosus	NN
cord-286132-ag2l1xa7	157	154	:	:	:
cord-286132-ag2l1xa7	157	155	results	result	NNS
cord-286132-ag2l1xa7	157	156	of	of	IN
cord-286132-ag2l1xa7	157	157	a	a	DT
cord-286132-ag2l1xa7	157	158	multicentre	multicentre	NN
cord-286132-ag2l1xa7	157	159	,	,	,
cord-286132-ag2l1xa7	158	1	double	double	JJ
cord-286132-ag2l1xa7	158	2	-	-	HYPH
cord-286132-ag2l1xa7	158	3	blind	blind	JJ
cord-286132-ag2l1xa7	158	4	,	,	,
cord-286132-ag2l1xa7	158	5	phase	phase	NN
cord-286132-ag2l1xa7	158	6	2	2	CD
cord-286132-ag2l1xa7	158	7	,	,	,
cord-286132-ag2l1xa7	158	8	randomised	randomised	JJ
cord-286132-ag2l1xa7	158	9	,	,	,
cord-286132-ag2l1xa7	158	10	controlled	controlled	JJ
cord-286132-ag2l1xa7	158	11	study	study	NN
cord-286132-ag2l1xa7	158	12	Repeated	repeat	VBD
cord-286132-ag2l1xa7	158	13	subcutaneous	subcutaneous	JJ
cord-286132-ag2l1xa7	158	14	injections	injection	NNS
cord-286132-ag2l1xa7	158	15	of	of	IN
cord-286132-ag2l1xa7	158	16	IL12/23	il12/23	CD
cord-286132-ag2l1xa7	158	17	p40	p40	CD
cord-286132-ag2l1xa7	158	18	neutralising	neutralise	VBG
cord-286132-ag2l1xa7	158	19	antibody	antibody	NN
cord-286132-ag2l1xa7	158	20	,	,	,
cord-286132-ag2l1xa7	158	21	ustekinumab	ustekinumab	NN
cord-286132-ag2l1xa7	158	22	,	,	,
cord-286132-ag2l1xa7	158	23	in	in	IN
cord-286132-ag2l1xa7	158	24	patients	patient	NNS
cord-286132-ag2l1xa7	158	25	with	with	IN
cord-286132-ag2l1xa7	158	26	relapsing	relapse	VBG
cord-286132-ag2l1xa7	158	27	-	-	HYPH
cord-286132-ag2l1xa7	158	28	remitting	remit	VBG
cord-286132-ag2l1xa7	158	29	multiple	multiple	JJ
cord-286132-ag2l1xa7	158	30	sclerosis	sclerosis	NN
cord-286132-ag2l1xa7	158	31	:	:	:
cord-286132-ag2l1xa7	158	32	a	a	DT
cord-286132-ag2l1xa7	158	33	phase	phase	NN
cord-286132-ag2l1xa7	158	34	II	ii	CD
cord-286132-ag2l1xa7	158	35	,	,	,
cord-286132-ag2l1xa7	158	36	double	double	JJ
cord-286132-ag2l1xa7	158	37	-	-	HYPH
cord-286132-ag2l1xa7	158	38	blind	blind	JJ
cord-286132-ag2l1xa7	158	39	,	,	,
cord-286132-ag2l1xa7	158	40	placebo	placebo	NN
cord-286132-ag2l1xa7	158	41	-	-	HYPH
cord-286132-ag2l1xa7	158	42	controlled	control	VBN
cord-286132-ag2l1xa7	158	43	,	,	,
cord-286132-ag2l1xa7	158	44	randomised	randomised	JJ
cord-286132-ag2l1xa7	158	45	,	,	,
cord-286132-ag2l1xa7	158	46	dose	dose	NN
cord-286132-ag2l1xa7	158	47	-	-	HYPH
cord-286132-ag2l1xa7	158	48	ranging	range	VBG
cord-286132-ag2l1xa7	158	49	study	study	NN